INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39001, 'Dexamethasone', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', NULL, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', NULL, 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39057/', '[1] "Product Information. Xcopri (cenobamate)." SK Life Science, Inc., Paramus, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39002, 'Dexamethasone', 'Ceritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib.', NULL, 'Patients receiving ceritinib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to ceritinib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39058/', '[1] "Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39003, 'Dexamethasone', 'Certolizumab pegol', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39059/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm." ([2011 Sept 7]):[2] "Product Information. Cimzia (certolizumab)." UCB Pharma Inc, Smyrna, GA.[3] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[4] "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[6] "Product Information. Humira (adalimumab)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39004, 'Dexamethasone', 'Cevimeline', 'Minor', 'Coadministration with inducers of CYP450 3A4 may theoretically decrease the plasma concentrations of cevimeline, which is a substrate of the isoenzyme. However, the clinical relevance has not been established, since cevimeline is also metabolized by CYP450 2D6, which is not inducible to any significant extent.', NULL, '-', NULL, '-', 'Metabolism', 'Bethanechol', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39060/', '[1] "Product Information. Evoxac (cevimeline)" Daiichi Pharmaceuticals, Fort lee, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39005, 'Dexamethasone', 'Chlorothiazide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39061/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39006, 'Dexamethasone', 'Chlorpropamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39062/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39007, 'Dexamethasone', 'Chlorthalidone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39063/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39008, 'Dexamethasone', 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39064/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39009, 'Dexamethasone', 'Vibrio cholerae CVD 103-HgR strain live antigen (live)', 'Moderate', 'There are no data regarding the use of live, attenuated cholera vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.', NULL, 'The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.', NULL, 'The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39065/', '[1] "Product Information. Vaxchora (cholera vaccine, live)." PaxVax, Miami, FL.[2] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.[3] "Product Information. Vaxchora (cholera vaccine, live)." PaxVax, Miami, FL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39010, 'Dexamethasone', 'Cholestyramine', 'Moderate', 'INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.', NULL, 'Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.', NULL, 'Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.', 'Absorption', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Ipratropium, Cromoglicic acid, More', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, Alirocumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39066/', '[1] Johansson C, Adamsson U, Stierner U, Lindsten T "Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract." Acta Med Scand 204 (1978): 509-12[2] "Product Information. Colestid (colestipol HCI)." Pharmacia and Upjohn, Kalamazoo, MI.[3] Nekl KE, Aron DC "Hydrocortisone-colestipol interaction." Ann Pharmacother 27 (1993): 980-1[4] "Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc, Chestnut Ridge, NY.[5] "Product Information. Welchol (colesevelam)" Daiichi Sankyo, Inc., Parsippany, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39011, 'Dexamethasone', 'Choline salicylate', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', NULL, 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', NULL, 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Excretion', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Ziconotide, Methoxyflurane', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39067/', '[1] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[2] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34[3] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L "Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis." Ther Drug Monit 9 (1987): 177-9[4] Edelman J, Potter JM, Hackett LP "The effect of intra-articular steroids on plasma salicylate concentrations." Br J Clin Pharmacol 21 (1986): 301-7[5] Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39012, 'Dexamethasone', 'Cinoxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39068/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39013, 'Dexamethasone', 'Ciprofloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Tinidazole, Cefixime, Secnidazole, Polymyxin B, Polymyxin B, Rifamycin, Miconazole, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, More', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39069/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39014, 'Dexamethasone', 'Cisplatin', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39070/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39015, 'Dexamethasone', 'Cladribine', 'Major', 'The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.', NULL, 'Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39071/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[3] "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39016, 'Dexamethasone', 'Clarithromycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Tinidazole, Bismuth subcitrate potassium, Dexlansoprazole, Esomeprazole, Lincomycin, Dirithromycin', 'Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, Fluorometholone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39072/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39017, 'Dexamethasone', 'Clevidipine', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Nimodipine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39073/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39018, 'Dexamethasone', 'Clonidine', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Acetylcholine, Physostigmine, Apraclonidine, Levobunolol, Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Naratriptan, Galcanezumab, Zolmitriptan, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39074/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39019, 'Dexamethasone', 'Cobicistat', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39075/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39020, 'Dexamethasone', 'Cobimetinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of cobimetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of cobimetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39076/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Cotellic (cobimetinib)." Genentech, South San Francisco, CA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Cotellic (cobimetinib)." Genentech, South San Francisco, CA.[5] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[6] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[7] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[8] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Cotellic (cobimetinib)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39021, 'Dexamethasone', 'Coccidioides immitis spherule', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39077/', '[1] "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc, Wallingford, CT.[2] "Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative)." Connaught Laboratories Ltd, Toronto, ON.[3] "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc, San Diego, CA.[4] "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals, Swiftwater, PA.[6] "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc, Wallingford, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39022, 'Dexamethasone', 'Colesevelam', 'Moderate', 'INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.', NULL, 'Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.', NULL, 'Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.', 'Absorption', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, Alirocumab', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39078/', '[1] Johansson C, Adamsson U, Stierner U, Lindsten T "Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract." Acta Med Scand 204 (1978): 509-12[2] "Product Information. Colestid (colestipol HCI)." Pharmacia and Upjohn, Kalamazoo, MI.[3] Nekl KE, Aron DC "Hydrocortisone-colestipol interaction." Ann Pharmacother 27 (1993): 980-1[4] "Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc, Chestnut Ridge, NY.[5] "Product Information. Welchol (colesevelam)" Daiichi Sankyo, Inc., Parsippany, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39023, 'Dexamethasone', 'Colestipol', 'Moderate', 'INTERVAL: Concurrent administration of bile acid sequestrants may delay and/or decrease the absorption of oral corticosteroids. Bile acid sequestrants can bind certain drugs in the intestine to form an insoluble complex that is excreted in the feces. Reduced bioavailability of hydrocortisone has been reported during concomitant administration with cholestyramine and colestipol. It is not known whether the interaction occurs with other bile acid binding resins such as colesevelam or with corticosteroids other than hydrocortisone, but the possibility should be considered.', NULL, 'Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.', NULL, 'Oral corticosteroids should be administered at least 1 hour before or 4 to 6 hours after a cholestyramine or colestipol dose, and at least 4 hours before a colesevelam dose.', 'Absorption', 'Fenofibric acid, Mipomersen, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Clofibrate, Cerivastatin, Lomitapide, Alirocumab', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39079/', '[1] Johansson C, Adamsson U, Stierner U, Lindsten T "Interaction by cholestyramine on the uptake of hydrocortisone in the gastrointestinal tract." Acta Med Scand 204 (1978): 509-12[2] "Product Information. Colestid (colestipol HCI)." Pharmacia and Upjohn, Kalamazoo, MI.[3] Nekl KE, Aron DC "Hydrocortisone-colestipol interaction." Ann Pharmacother 27 (1993): 980-1[4] "Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc, Chestnut Ridge, NY.[5] "Product Information. Welchol (colesevelam)" Daiichi Sankyo, Inc., Parsippany, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39024, 'Dexamethasone', 'Conivaptan', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39080/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39025, 'Dexamethasone', 'Conjugated estrogens', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Bazedoxifene', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39081/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39026, 'Dexamethasone', 'Conjugated estrogens (topical)', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Bazedoxifene', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39082/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39027, 'Dexamethasone', 'Copanlisib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'The potential for diminished pharmacologic effects of copanlisib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', NULL, 'The potential for diminished pharmacologic effects of copanlisib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39083/', '[1] "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39028, 'Dexamethasone', 'Crizotinib', 'Moderate', 'Coadministration with CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution and clinical monitoring should be considered if CYP450 3A4 inducers such as efavirenz are used with crizotinib.', NULL, 'Caution and clinical monitoring should be considered if CYP450 3A4 inducers such as efavirenz are used with crizotinib.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39084/', '[1] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[10] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39029, 'Dexamethasone', 'Cyclosporine', 'Moderate', 'Coadministration of cyclosporine with a corticosteroid may result in altered (usually elevated) plasma concentrations of one or both drugs. Cyclosporine and corticosteroids undergo metabolism primarily by CYP450 3A4, thus competitive inhibition of metabolic clearance may occur during concomitant use.', NULL, 'Caution is advised during concomitant therapy with cyclosporine and corticosteroids.', NULL, 'Caution is advised during concomitant therapy with cyclosporine and corticosteroids. Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever one or the other agent is added to or withdrawn from therapy in patients stabilized on their existing therapeutic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39085/', '[1] Klintmalm G, Sawe J "High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients." Lancet 1 (1984): 731[2] Durrant S, Chipping PM, Palmer S, Gordon-Smith EC "Cyclosporin A, methylprednisolone, and convulsions." Lancet 2 (1982): 829-30[3] Ost L "Effects of cyclosporin on prednisolone metabolism." Lancet 1 (1984): 451[4] Langhoff E, Madsen S, Flachs H, et al "Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients." Transplantation 39 (1985): 107-9[5] Ducharme MP, Warbasse LH, Edwards DJ "Disposition of intravenous and oral cyclosporine after administration with grapefruit juice." Clin Pharmacol Ther 57 (1995): 485-91[6] Min DI, Ku YM, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG "Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients." Transplantation 62 (1996): 123-5[7] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[8] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[9] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[10] Honcharik N, Yatscoff RW, Jeffery JR, Rush DN "The effect of meal composition on cyclosporine absorption." Transplantation 52 (1991): 1087-9[11] Tsunoda SM, Harris RZ, Christians U, et al. "Red wine decreases cyclosporine bioavailability." Clin Pharmacol Ther 70 (2001): 462-7[12] Yee GC, Stanley DL, Pessa LJ, et al. "Effect of grrapefruit juice on blood cyclosporin concentration." Lancet 345 (1995): 955-6[13] Ioannidesdemos LL, Christophidis N, Ryan P, Angelis P, Liolios L, Mclean AJ "Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases." J Rheumatol 24 (1997): 49-54[14] Oliveira-Freitas VL, Dalla Costa T, Manfro RC, Cruz LB, Schwartsmann G "Influence of purple grape juice in cyclosporine availability." J Ren Nutr 20 (2010): 309-13[15] Tan KKC, Trull AK, Uttridge JA, Metcalfe S, Heyes CS, Facey S, Evans DB "Effect of dietary fat on the pharmacokinetics and pharmacodynamics of cyclosporine in kidney transplant recipients." Clin Pharmacol Ther 57 (1995): 425-33[16] Hollander AAMJ, Vanrooij J, Lentjes EGWM, Arbouw F, Vanbree JB, Schoemaker RC, Vanes LA, Vanderwoude FJ, Cohen AF "The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients." Clin Pharmacol Ther 57 (1995): 318-24[17] Ducharme MP, Provenzano R, Dehoornesmith M, Edwards DJ "Trough concentrations of cyclosporine in blood following administration with grapefruit juice." Br J Clin Pharmacol 36 (1993): 457-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39030, 'Dexamethasone', 'Dabrafenib', 'Moderate', 'Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9. Dabrafenib has been found in vitro to be an inducer of these isoenzymes.', NULL, 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9.', NULL, 'Caution is advised when dabrafenib is prescribed with drugs that undergo metabolism by CYP450 3A4 and/or 2C9. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dabrafenib is added to or withdrawn from therapy. Significantly reduced plasma concentrations and loss of efficacy may occur with sensitive substrates of CYP450 3A4 or 2C9 such as hormonal contraceptives, immunosuppressants (cyclosporine, everolimus, sirolimus, tacrolimus), ivacaftor, and warfarin-type anticoagulants. Alternatives to these medications should be considered if possible.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39086/', '[1] "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline, Research Triangle Park, NC.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[5] "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39031, 'Dexamethasone', 'Daclatasvir', 'Major', 'Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, an increase in the dosage of daclatasvir to 90 mg once daily is recommended when used with moderate CYP450 3A4 inducers.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39087/', '[1] "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39032, 'Dexamethasone', 'Dapagliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39088/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39033, 'Dexamethasone', 'Dapsone (topical)', 'Minor', 'Theoretically, coadministration of dapsone with inducers of CYP450 3A4 such as rifamycins, anticonvulsants, barbiturates, and St. John''s wort may increase the formation of dapsone hydroxylamine, a metabolite associated with hemolysis. Dose-related hemolysis is the most common adverse event associated with oral dapsone in both patients with or without glucose-6-phosphate dehydrogenase (G6PD) deficiency.', NULL, '-', NULL, '-', 'Metabolism', 'Minocycline, Vitamin A, Dexamethasone, Fluorometholone, Dapsone, Azelaic acid, Adapalene, Dapsone, Clofazimine', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Nedocromil, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39089/', '[1] "Product Information. Aczone (dapsone topical)." QLT USA, Inc, Fort Collins, CO.[2] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[3] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[4] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39034, 'Dexamethasone', 'Darifenacin', 'Moderate', 'Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of darifenacin, which has been shown to be a substrate of the isoenzyme.', NULL, 'Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.', NULL, 'Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.', 'Metabolism', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Hydrocortisone, Vitamin A, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39090/', '[1] "Product Information. Enablex (darifenacin)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[4] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39035, 'Dexamethasone', 'Darolutamide', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Reduced efficacy of darolutamide may occur.', NULL, 'Concomitant use of darolutamide with dual P-gp and potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of darolutamide with dual P-gp and potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Degarelix, Abarelix, Nilutamide, Abiraterone', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39091/', '[1] "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.[2] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[3] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[4] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[6] "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39036, 'Dexamethasone', 'Darunavir', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39092/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39037, 'Dexamethasone', 'Dasatinib', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of dasatinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of dasatinib with potent CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of dasatinib with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible during treatment with dasatinib. If coadministration is required, a dosage increase for dasatinib may be necessary depending on patient tolerability. Close monitoring for toxicities (e.g., myelosuppression, bleeding complications, fluid retention, QT prolongation) is recommended if the dosage of dasatinib is increased. The dosage should be reduced to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39093/', '[1] "Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb, Princeton, NJ.[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[9] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[10] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[11] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39038, 'Dexamethasone', 'Deferasirox', 'Major', 'Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of deferasirox. Fatal gastrointestinal hemorrhages have been reported during deferasirox therapy, especially in elderly patients with advanced hematologic malignancies and/or low platelet counts.', NULL, 'Caution is advised if deferasirox is prescribed with drugs that have known ulcerogenic or hemorrhagic potential, including but not limited to NSAIDs, salicylates, corticosteroids, oral bisphosphonates, platelet inhibitors, anticoagulants, thrombolytic agents, or agents that commonly cause thrombocytopenia.', NULL, 'Caution is advised if deferasirox is prescribed with drugs that have known ulcerogenic or hemorrhagic potential, including but not limited to NSAIDs, salicylates, corticosteroids, oral bisphosphonates, platelet inhibitors, anticoagulants, thrombolytic agents, or agents that commonly cause thrombocytopenia. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, hematemesis, anorexia, and/or black, tarry stools.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Levoleucovorin, Arginine, Methionine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39094/', '[1] "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.[3] "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39039, 'Dexamethasone', 'Deflazacort', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.', NULL, 'Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of deflazacort with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Cortisone, Fludrocortisone, Betamethasone, Dexamethasone', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39095/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[4] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[6] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39040, 'Dexamethasone', 'Delafloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39096/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39041, 'Dexamethasone', 'Delavirdine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of delavirdine, which is primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised when delavirdine is used with CYP450 3A4 inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised when delavirdine is used with CYP450 3A4 inducers. Pharmacologic response to the antiretroviral regimen should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral dosage(s) adjusted as necessary.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39097/', '[1] Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53[2] "Product Information. Rescriptor (delavirdine)." Pharmacia and Upjohn, Kalamazoo, MI.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39042, 'Dexamethasone', 'Denosumab', 'Moderate', 'Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.', NULL, 'Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.', NULL, 'Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tiludronic acid, Vosoritide, Etidronic acid, Cholecalciferol, Burosumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39098/', '[1] "Product Information. Prolia (denosumab)." Amgen USA, Thousand Oaks, CA.[2] "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc., Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39043, 'Dexamethasone', 'Deserpidine', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39099/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39044, 'Dexamethasone', 'Desirudin', 'Major', 'Drugs that can affect hemostasis such as dextrans, systemic glucocorticoids, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of desirudin. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during desirudin therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'During prophylaxis of venous thromboembolism, concomitant treatment with heparins or dextrans is not recommended.', NULL, 'During prophylaxis of venous thromboembolism, concomitant treatment with heparins or dextrans is not recommended. The effects of desirudin and unfractionated heparins on prolongation of activated partial thromboplastin time (aPTT) are additive. In general, any agent which may enhance the risk of hemorrhage should be discontinued prior to initiation of desirudin therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Betrixaban, Cilostazol, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Streptokinase, Eptifibatide, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39100/', '[1] "Product Information. Ipravask (desirudin)." Aventis Pharmaceuticals, Swiftwater, PA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[21] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39045, 'Dexamethasone', 'Desmopressin', 'Major', 'Coadministration of desmopressin with loop diuretics or systemic or inhaled corticosteroids may increase the risk of severe hyponatremia. Loop diuretics and corticosteroids can potentiate the antidiuretic response to desmopressin by causing loss of sodium and water retention, respectively, thus coadministration may increase the risk of water intoxication and hyponatremia. Elderly patients may be particularly susceptible.', NULL, 'Concomitant use of certain desmopressin products with loop diuretics or systemic or inhaled corticosteroids is considered contraindicated.', NULL, 'Concomitant use of certain desmopressin products with loop diuretics or systemic or inhaled corticosteroids is considered contraindicated. Please consult individual product labeling for specific recommendations. Caution is advised when coadministration is required. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly and as often as clinically appropriate based on individual risk factors. Patients should be advised to seek medical attention if they develop signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, unsteadiness (which may lead to falls), anuria, and weight gain. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated; therefore, early treatment is important to help prevent progression to seizures, coma, respiratory arrest, and death.', 'Synergism', 'Terlipressin, Oxytocin', 'Mupirocin, Mometasone furoate, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39101/', '[1] "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Nocdurna (desmopressin)." Ferring Inc, North York, ON.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Noctiva (desmopressin)." Avadel Pharmaceuticals, Chesterfield, MO.[6] "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA.[9] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39046, 'Diazepam', 'Dexamethasone', 'Minor', 'Certain corticosteroids may decrease the plasma concentration of some benzodiazepines. The mechanism is related to induction of hepatic cytochrome P450 enzymes responsible for benzodiazepine metabolism. The clinical significance may depend on the dosage and duration of corticosteroid therapy and be of greater importance with oral administration of benzodiazepines.', NULL, '-', NULL, '-', 'Others', 'Halazepam, Clorazepic acid, Clobazam', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39102/', '[1] Villikka K, Kivisto KT, Neuvonen PJ "The effect of dexamethasone on the pharmacokinetics of triazolam." Pharmacol Toxicol 83 (1998): 135-8[2] Nakajima M, Suzuki T, Sasaki T, Yokoi T, Hosoyamada A, Yamamoto T, Kuroiwa Y "Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans." Ther Drug Monit 21 (1999): 507-13[3] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[7] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[8] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[9] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39047, 'Diazoxide', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39103/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39048, 'Diclofenamide', 'Dexamethasone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39104/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39049, 'Diclofenac', 'Dexamethasone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Fludrocortisone, Betamethasone, Fluorometholone, Dexamethasone, Cortisone, Betamethasone, Fluorometholone, Dexamethasone, Chondroitin sulfate, Esomeprazole, Glucosamine, More', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39105/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39050, 'Dicoumarol', 'Dexamethasone', 'Moderate', 'Corticosteroids and adrenocorticotropic agents may alter the pharmacologic effects of oral anticoagulants. Both increased anticoagulant dosage requirements as well as bleeding and increased anticoagulant sensitivity have been reported during concomitant corticosteroid therapy. Proposed mechanisms include blood hypercoagulability or diminished vascular integrity induced by corticosteroids.', NULL, 'Close monitoring for clinical and laboratory evidence of altered anticoagulant response is recommended during concurrent treatment with corticosteroids or adrenocorticotropic agents.', NULL, 'Close monitoring for clinical and laboratory evidence of altered anticoagulant response is recommended during concurrent treatment with corticosteroids or adrenocorticotropic agents. Patients should be advised to promptly report any signs and symptoms of bleeding or blood clots.', 'Others', 'Betrixaban, Cilostazol, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Streptokinase, Eptifibatide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39106/', '[1] Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970): 300-6[2] Stading JA "Effects of prednisone on the International Normalized Ratio." Am J Health Syst Pharm 63 (2006): 2354-2356[3] Brozovic M, Gurd LJ "Prothrombin during warfarin treatment." Br J Haematol 24 (1973): 579-88[4] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34[5] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58[6] Wadman B, Werner I "Thromboembolic complications during corticosteroid treatment of temporal arteritis." Lancet 1 (1972): 907[7] Hamblin TJ "Interaction between warfarin and phenformin." Lancet 2 (1971): 1323[8] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (first of two parts)." N Engl J Med 285 (1971): 487-98[9] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[10] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[11] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[12] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[13] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[14] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[15] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[16] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[17] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[18] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[19] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[20] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[21] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[22] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[23] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[24] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[25] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[26] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[27] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[28] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[30] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[31] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70[32] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[33] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[34] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[36] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[37] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[38] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[39] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[40] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[41] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[42] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[43] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[44] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[45] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39051, 'Dienestrol (topical)', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39107/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39052, 'Diethylstilbestrol', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Megestrol acetate, Triptorelin, Histrelin, Leuprolide, Bazedoxifene', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39108/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39053, 'Diflunisal', 'Dexamethasone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Ziconotide, Methoxyflurane', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39109/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39054, 'Digitoxin', 'Dexamethasone', 'Moderate', 'Systemically administered corticosteroids may induce hypokalemia and possibly increase the risk of digoxin toxicity. In addition, corticosteroid-induced sodium and water retention can result in edema leading to heart failure. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) which have greater mineralocorticoid activity.', NULL, 'Electrolyte levels should be monitored carefully in patients who must receive concomitant therapy.', NULL, 'Electrolyte levels should be monitored carefully in patients who must receive concomitant therapy.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39110/', '[1] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[2] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39055, 'Digoxin', 'Dexamethasone', 'Moderate', 'Systemically administered corticosteroids may induce hypokalemia and possibly increase the risk of digoxin toxicity. In addition, corticosteroid-induced sodium and water retention can result in edema leading to heart failure. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) which have greater mineralocorticoid activity.', NULL, 'Electrolyte levels should be monitored carefully in patients who must receive concomitant therapy.', NULL, 'Electrolyte levels should be monitored carefully in patients who must receive concomitant therapy.', 'Others', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Olopatadine, Ipratropium, Hyaluronic acid, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, Vitamin A, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39111/', '[1] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[2] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39056, 'Dihydroergotamine', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 'Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39112/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39057, 'Diltiazem', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Tetracaine, Procaine, Betamethasone, Fluorometholone, Dexamethasone', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39113/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39058, 'Dimethyl fumarate', 'Dexamethasone', 'Moderate', 'The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', NULL, 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.', NULL, 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39114/', '[1] "Product Information. Vumerity (diroximel fumarate)." Alkermes, Inc, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39059, 'Dinutuximab', 'Dexamethasone', 'Major', 'Coadministration of dinutuximab or dinutuximab beta with corticosteroids may potentiate the risk of infections due to additive immunosuppressive activity. Infections, including sepsis, pneumonia, herpes virus infection, myelitis, and encephalomyelitis as well as hematologic toxicities, including thrombocytopenia and neutropenia, have been reported with both dinutuximab and dinutuximab beta therapy.', NULL, 'The manufacturer of dinutuximab beta recommends that, except for life threatening conditions, concomitant use of dinutuximab beta and corticosteroids should be avoided for 2 weeks prior to the first course of dinutuximab beta and for 1 week after the last course (UK).', NULL, 'The manufacturer of dinutuximab beta recommends that, except for life threatening conditions, concomitant use of dinutuximab beta and corticosteroids should be avoided for 2 weeks prior to the first course of dinutuximab beta and for 1 week after the last course (UK). If concomitant use is required, close clinical and laboratory monitoring for the development of systemic infections and severe hematologic adverse effects is recommended both during and after discontinuation of therapy.', 'Synergism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39115/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39060, 'Diroximel fumarate', 'Dexamethasone', 'Moderate', 'The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', NULL, 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.', NULL, 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39116/', '[1] "Product Information. Vumerity (diroximel fumarate)." Alkermes, Inc, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39061, 'Disopyramide', 'Dexamethasone', 'Moderate', 'Disopyramide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', NULL, 'Coadministration of disopyramide with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', NULL, 'Coadministration of disopyramide with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with disopyramide. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Propafenone, Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39117/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Multum Information Services, Inc. Expert Review Panel"[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39062, 'Docetaxel', 'Dexamethasone', 'Minor', 'Although docetaxel is a substrate of CYP450 3A4, no significant interaction has been reported with dexamethasone or prednisone, both of which are inducers of the isoenzyme.', NULL, '-', NULL, '-', 'Others', 'Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Betamethasone, More', 'Teniposide, Cabazitaxel', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39118/', '[1] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[2] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[3] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[4] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9[8] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[9] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[10] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[11] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[12] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39063, 'Dofetilide', 'Dexamethasone', 'Minor', 'Dofetilide is metabolized to a small extent by CYP450 3A4 microsomal enzymes in the liver. The clinician should be aware of the potential for an interaction when dofetilide is used in combination with another medication that induces CYP450 3A4.', NULL, '-', NULL, '-', 'Metabolism', 'Propafenone, Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39119/', '[1] "Product Information. Tikosyn (dofetilide)" Pfizer US Pharmaceuticals, Atlanta, GA.[2] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[4] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[12] "Product Information. Tikosyn (dofetilide)" Pfizer US Pharmaceuticals, Atlanta, GA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39064, 'Donepezil', 'Dexamethasone', 'Moderate', 'Coadministration with drugs that are inducers of the CYP450 3A4 and/or 2D6 enzymatic pathways may decrease the plasma concentrations of donepezil. The mechanism is accelerated clearance of donepezil due to enhanced CYP450 activities.', NULL, 'While clinical data are lacking, the possibility of a diminished therapeutic response to donepezil should be considered in patients receiving concomitant inducer agents.', NULL, 'While clinical data are lacking, the possibility of a diminished therapeutic response to donepezil should be considered in patients receiving concomitant inducer agents.', 'Metabolism', 'Rivastigmine, Galantamine, Aducanumab, Ginkgo biloba, Tacrine', 'Mupirocin, Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39120/', '[1] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[2] Tiseo PJ, Perdomo CA, Friedhoff LT "Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses." Br J Clin Pharmacol 46 (1998): 30-4[3] "Product Information. Aricept (donepezil)." Pfizer US Pharmaceuticals, New York, NY.[4] Rojas-Fernandez C, Fisher C "Drug interactions and donepezil." J Am Geriat Soc 40 (2000): 597-8[5] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[6] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[7] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[8] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39065, 'Doravirine', 'Dexamethasone', 'Major', 'Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of doravirine with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is necessary, some authorities recommend that the doravirine dose be increased to 100 mg twice daily (approximately 12 hours apart).', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39121/', '[1] "Product Information. Pifeltro (doravirine)." Merck & Company Inc, Whitehouse Station, NJ.[2] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39066, 'Doxacurium', 'Dexamethasone', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Botulinum toxin type A', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39122/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39067, 'Doxazosin', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39123/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39068, 'Doxorubicin', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.', 'Metabolism', 'Idarubicin, Valrubicin, Plicamycin, Daunorubicin, Epirubicin', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Betamethasone, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39124/', '[1] "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.[2] Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR "Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects." Clin Pharmacol Ther 31 (1982): 263[3] "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39069, 'Doxorubicin (liposomal)', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of doxorubicin, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, 'Concomitant use of doxorubicin with CYP450 3A4 inducers should generally be avoided, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. Close monitoring for potentially reduced efficacy of doxorubicin is recommended if coadministration is required.', 'Metabolism', 'Idarubicin, Valrubicin, Plicamycin, Daunorubicin, Epirubicin', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39125/', '[1] "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.[2] Riggs CE Jr, Engel S, Wesley M, Wiernik PH, Bachur NR "Doxorubicin pharmacokinetics: prochlorperazine and barbiturate effects." Clin Pharmacol Ther 31 (1982): 263[3] "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39070, 'Dronedarone', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of dronedarone, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of dronedarone with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, 'Concomitant use of dronedarone with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort should generally be avoided. The extent to which other, less potent CYP450 3A4 inducers may interact with dronedarone is unknown. Caution is advised if they are used with dronedarone.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Propafenone, Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39126/', '[1] "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ.[2] "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39071, 'Dulaglutide', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39127/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39072, 'Durvalumab', 'Dexamethasone', 'Moderate', 'INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39128/', '[1] Jove M, Vilarino N, Nadal E "Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer." Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. "Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer." J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center." J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al "Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors." ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc "ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp." O 0 (2015):[8] Scott SC, Pennell NA "Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab." J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39073, 'Duvelisib', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of duvelisib should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of duvelisib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39129/', '[1] "Product Information. Copiktra (duvelisib)." Verastem, Inc., Needham, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39074, 'Echinacea', 'Dexamethasone', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', NULL, '-', NULL, '-', 'Antagonism', 'Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39130/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[3] Pepping J "Echinacea." Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39075, 'Edrophonium', 'Dexamethasone', 'Moderate', 'Corticosteroids and adrenocorticotropic agents may diminish the therapeutic effects of acetylcholinesterase inhibitors in myasthenia gravis. The mechanism of interaction is unknown. Marked deterioration in muscle strength has been reported in patients with myasthenia gravis shortly after the initiation of corticosteroid therapy, particularly when high dosages were used.', NULL, 'Corticosteroid therapy should be instituted at relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and in a controlled setting in patients with myasthenia gravis.', NULL, 'Corticosteroid therapy should be instituted at relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and in a controlled setting in patients with myasthenia gravis. Respiratory support should be available, and the dosage should be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached). Dose reductions of the acetylcholinesterase inhibitor may be required as symptoms improve, which often may be delayed and gradual.', 'Antagonism', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Vitamin A, Caffeine, Metyrapone, Histamine, Indocyanine green, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39131/', '[1] Patten BM, Oliver KL, Engel WK "Adverse interaction between steroid hormones and anticholinesterase drugs." Neurology 24 (1974): 442-9[2] Brunner NG, Namba T, Grob D "Corticosteroids in management of severe, generalized myasthenia gravis." Neurology 22 (1972): 603-10[3] Namba T "Corticotropin therapy in patients with myasthenia gravis." Arch Neurol 26 (1972): 144-50[4] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[5] Millikan CH, Eaton LM "Clinical evaluation of ACTH and cortisone in myasthenia gravis." Neurology 1 (1951): 145-52', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39076, 'Efalizumab', 'Dexamethasone', 'Moderate', 'The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.', NULL, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39132/', '[1] "Product Information. Raptiva (efalizumab)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39077, 'Efavirenz', 'Dexamethasone', 'Moderate', 'Coadministration of efavirenz with a drug that is both a substrate as well as inducer of CYP450 3A4 may result in altered plasma concentrations of both drugs. Efavirenz itself is also a substrate and inducer of CYP450 3A4. Theoretically, metabolism of efavirenz and the coadministered drug may be mutually induced when used in combination. Alternatively, competitive inhibition of CYP450 3A4 may occur, which can lead to increased plasma drug levels of one or both drugs. The interaction has not been specifically studied.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if efavirenz is prescribed in combination with a drug that is an inducer of CYP450 3A4.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if efavirenz is prescribed in combination with a drug that is an inducer of CYP450 3A4. Close clinical and laboratory monitoring of antiretroviral response is recommended. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 3A4.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39133/', '[1] "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.[2] "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39078, 'Elagolix', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the metabolic isoenzyme and efflux transporter.', NULL, 'The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', NULL, 'The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments or a dose adjustment of elagolix may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Norethisterone, Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39134/', '[1] "Product Information. Orilissa (elagolix)." AbbVie US LLC, North Chicago, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39079, 'Eliglustat', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat is also a substrate of P-gp efflux transporter.', NULL, 'Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat.', NULL, 'Patients receiving eliglustat with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to eliglustat. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Metreleptin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39135/', '[1] "Product Information. Cerdelga (eliglustat)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Cerdelga (eliglustat)." Genzyme Corporation, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39080, 'Elvitegravir', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 isoenzymes may reduce the plasma concentrations of elvitegravir, which is primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, the manufacturers of elvitegravir single-ingredient and combination products recommend avoiding concomitant use. Alternative treatment combinations that do not include metabolic inducers should be considered whenever possible.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39136/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Vitekta (elvitegravir)." Gilead Sciences, Foster City, CA.[4] "Product Information. Vitekta (elvitegravir)." Gilead Sciences, Foster City, CA.[5] "Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov)." Gilead Sciences, Foster City, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39081, 'Empagliflozin', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39137/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39082, 'Enalapril', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39138/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39083, 'Encorafenib', 'Dexamethasone', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may decrease the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. The extent to which CYP450 3A4 inducers may affect encorafenib exposure has not been studied.', NULL, 'Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', NULL, 'Concomitant use of encorafenib with potent and moderate CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39139/', '[1] "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO.[2] "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO.[3] "Product Information. Braftovi (encorafenib)." Array BioPharma Inc., Boulder, CO.[4] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[6] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[7] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39084, 'Enoxacin', 'Dexamethasone', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39140/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39085, 'Entrectinib', 'Dexamethasone', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme.', NULL, 'Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of entrectinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39141/', '[1] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[4] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39086, 'Enzalutamide', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.', NULL, 'Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, 'Concomitant use of enzalutamide with potent CYP450 2C8 and/or 3A4 inducers such as carbamazepine, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort should generally be avoided. Moderate inducers such as bosentan, efavirenz, etravirine, modafinil, nafcillin, and nevirapine should also be avoided if possible. The extent to which other, less potent CYP450 3A4 inducers may interact with enzalutamide is unknown. Caution is advised if they are used with enzalutamide.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Degarelix, Abarelix, Nilutamide, Abiraterone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39142/', '[1] "Product Information. Xtandi (enzalutamide)." Astellas Pharma US, Inc, Deerfield, IL.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39087, 'Ephedrine', 'Dexamethasone', 'Minor', 'In one study, after treatment with ephedrine, a 36% decrease in mean dexamethasone half-life and a 42% increase in the clearance of plasma dexamethasone has been reported. The mechanism of this interaction has not been reported. The authors of the study recommend caution when prescribing ephedrine for asthmatics requiring long term therapy with dexamethasone. The authors of the study further suggest that since ephedrine accelerates labeled dexamethasone clearance while theophylline did not, theophylline may be a more appropriate bronchodilator to use in this patient population.', NULL, '-', NULL, '-', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Homatropine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ipratropium, Hyaluronic acid, Betamethasone, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39143/', '[1] Brooks SM, Sholiton LJ, Werk EE, Jr Altenau P "The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma." J Clin Pharmacol 17 (1977): 308-18', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39088, 'Eplerenone', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39144/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39089, 'Eprosartan', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Sacubitril', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39145/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39090, 'Erdafitinib', 'Dexamethasone', 'Major', 'Coadministration with moderate inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is induction of CYP450 2C9- or 3A4-mediated metabolism of erdafitinib, which has been shown to be metabolized by these isoenzymes.', NULL, 'According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered.', NULL, 'According to the manufacturer, if a moderate CYP450 2C9 or 3A4 inducer is coadministered at the start of erdafitinib therapy, the recommended dose of erdafitinib should be administered. If a moderate CYP450 2C9 or 3A4 inducer is coadministered after the initial dose increase period, the dose of erdafitinib may be increased up to 9 mg once daily based on serum phosphate levels and tolerability. When a moderate CYP450 2C9 or 3A4 inducer is discontinued, the current dose of erdafitinib may be continued in the absence of erdafitinib toxicity.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39146/', '[1] "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ "Comparative effect of food on absorption of ampicillin and pivampicillin." J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M "Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young." Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO "Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects." J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M "Absorption and excretion of four penicillins." N Engl J Med 263 (1960): 315-26[7] Neu HC "Antimicrobial activity and human pharmacology of amoxicillin." J Infect Dis 129 (1974): s123-31', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39091, 'Ergometrine', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Dinoprostone, Oxytocin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39147/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39092, 'Ergotamine', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 'Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39148/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39093, 'Erlotinib', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.', NULL, 'Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib.', NULL, 'Alternative treatment lacking CYP450 3A4-inducing activity is recommended in patients receiving erlotinib. If alternative treatment is unavailable and a potent inducer (e.g., carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, St. John''s wort) is to be used for more than a few days, an increase in the dosage of erlotinib should be considered as tolerated at 2-week intervals. Close clinical and laboratory monitoring for altered efficacy and safety, including renal and liver functions and serum electrolytes, is recommended.', 'Metabolism', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Hydrocortisone, Olopatadine, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39149/', '[1] "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.[2] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[13] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7[14] "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39094, 'Ertugliflozin', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39150/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39095, 'Erythromycin', 'Dexamethasone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Lincomycin, Dirithromycin, Minocycline, Vitamin A, Dexamethasone, Fluorometholone, Dapsone, Azelaic acid, Adapalene, Rifamycin, Kanamycin, More', 'Ciclesonide, Mometasone furoate, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, Mometasone furoate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39151/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39096, 'Esterified estrogens', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39152/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39097, 'Estradiol (topical)', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Norgestrel, Bazedoxifene, Prasterone, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39153/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39098, 'Estramustine', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39154/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39099, 'Estrone', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Bazedoxifene', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39155/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39100, 'Estrone sulfate', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39156/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39101, 'Estrone sulfate (topical)', 'Dexamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39157/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39102, 'Eszopiclone', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zopiclone, which is a substrate of the isoenzyme.', NULL, 'Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.', NULL, 'Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39158/', '[1] "Product Information. Lunesta (eszopiclone)." Sepracor Inc, Marlborough, MA.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Lunesta (eszopiclone)." Sepracor Inc, Marlborough, MA.[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39103, 'Etanercept', 'Dexamethasone', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39159/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm." ([2011 Sept 7]):[2] "Product Information. Cimzia (certolizumab)." UCB Pharma Inc, Smyrna, GA.[3] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[4] "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[6] "Product Information. Humira (adalimumab)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39104, 'Etacrynic acid', 'Dexamethasone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39160/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39105, 'Ethotoin', 'Dexamethasone', 'Moderate', 'Phenytoin and other hydantoins may induce the CYP450 3A4 hepatic metabolism of corticosteroids and increase their clearance and decrease their half-lives, possibly reducing their therapeutic efficacy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy. Some patients may require increased corticosteroid dosages.', 'Metabolism', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39161/', '[1] Haque N, Thrasher K, Werk EE, Jr Knowles HC, Jr Sholiton LJ "Studies on dexamethasone metabolism in man: effect of diphenylhydantoin." J Clin Endocrinol Metab 34 (1972): 44-50[2] Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB "Phenytoin-dexamethasone interaction: a previously unreported observation." Surg Neurol 16 (1981): 23-4[3] Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M "Phenytoin-dexamethasone: a possible drug-drug interaction." JAMA 254 (1985): 2062-3[4] Lackner TE "Interaction of dexamethasone with phenytoin." Pharmacotherapy 11 (1991): 344-7[5] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[6] Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[9] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[10] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12[11] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[14] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[18] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[19] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[20] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[21] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[22] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39106, 'Etodolac', 'Dexamethasone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39162/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39107, 'Etravirine', 'Dexamethasone', 'Moderate', 'Coadministration of etravirine with a drug that is both a substrate as well as inducer of CYP450 3A4 may result in decreased plasma concentrations of both drugs. Etravirine itself is also a substrate and inducer of CYP450 3A4. Theoretically, metabolism of etravirine and the coadministered drug may be mutually induced when used in combination.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if etravirine is prescribed in combination with a drug that is an inducer of CYP450 3A4.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if etravirine is prescribed in combination with a drug that is an inducer of CYP450 3A4. Close clinical and laboratory monitoring of antiretroviral response is recommended. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 3A4.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39163/', '[1] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39108, 'Everolimus', 'Dexamethasone', 'Major', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the blood concentrations and pharmacologic effects of everolimus.', NULL, 'Concomitant use of everolimus with potent CYP450 3A4 and/or P-gp inducers should generally be avoided.', NULL, 'Concomitant use of everolimus with potent CYP450 3A4 and/or P-gp inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered. Some manufacturers recommend that, if concomitant use is unavoidable, the daily everolimus dose should be doubled to achieve the recommended therapeutic range for the condition being treated. Please refer to the manufacturer''s labeling for specific dosing information. If the potent CYP450 3A4 and/or P-gp inducer is discontinued, the everolimus dosage should be returned to the dosage used before the potent inducer was commenced after a washout period of approximately 3 to 5 days. Everolimus whole blood trough levels should be closely monitored during treatment, particularly 2 weeks after a dose increase, and 2 weeks after discontinuation of the potent inducers.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39164/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.[5] "Product Information. Zortress (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39109, 'Exemestane', 'Dexamethasone', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the isoenzyme.', NULL, 'The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, 'The manufacturer recommends increasing the dosage of exemestane to 50 mg once daily when used with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. However, it has also been suggested that suppression of estrogen levels is not affected by the interaction, thus dosage adjustment of exemestane is not required. The extent to which other, less potent CYP450 3A4 inducers may interact with exemestane is unknown. Caution is advised if they are used with exemestane.', 'Metabolism', 'Degarelix, Abarelix, Nilutamide, Abiraterone', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39165/', '[1] "Product Information. Aromasin (exemestane)" Pharmacia & Upjohn, Kalamazoo, MI.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39110, 'Exenatide', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39166/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39111, 'Fedratinib', 'Dexamethasone', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of fedratinib, which is a substrate of the isoenzyme.', NULL, 'According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.', NULL, 'According to the product labeling, concomitant use of fedratinib with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39167/', '[1] "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[33] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39112, 'Felodipine', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Nimodipine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39168/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39113, 'Fenoldopam', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Droxidopa, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Dopamine, Methoxamine, Mephentermine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39169/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39114, 'Fenoprofen', 'Dexamethasone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39170/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39115, 'Fesoterodine', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.', NULL, 'Caution is advised when fesoterodine is used with CYP450 3A4 inducers.', NULL, 'Caution is advised when fesoterodine is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39171/', '[1] "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39116, 'Fingolimod', 'Dexamethasone', 'Major', 'Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.', NULL, 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', NULL, 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39172/', '[1] "Product Information. Gilenya (fingolimod)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39117, 'Flibanserin', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19.', NULL, 'The potential for diminished pharmacologic effects of flibanserin should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of flibanserin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Bremelanotide, Black cohosh, Cabergoline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39173/', '[1] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.[2] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39118, 'Fluconazole', 'Dexamethasone', 'Moderate', 'Coadministration with fluconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4-mediated metabolism by fluconazole, a moderate inhibitor of the isoenzyme.', NULL, 'Caution is advised when fluconazole is used with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when fluconazole is used with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluconazole is added to or withdrawn from therapy.', 'Metabolism', 'Tinidazole, Cefixime, Secnidazole, Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin, Thiabendazole, Miconazole, Griseofulvin, More', 'Ciclesonide, Mometasone furoate, Mometasone, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, Mometasone furoate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39174/', '[1] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[2] Assan R, Fredj G, Larger E, Feutren G, Bismuth H "FK 506/fluconazole interaction enhances FK 506 nephrotoxicity." Diabete Metab 20 (1994): 49-52[3] Ulivelli M, Rubegni P, Nuti D, Bartalini S, Giannini F, Rossi S "Clinical evidence of fluconazole-induced carbamazepine toxicity." J Neurol 251 (2004): 622-3[4] "Product Information. Diflucan (fluconazole)." Roerig Division, New York, NY.[5] Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75[6] Canafax DM, Graves NM, Hilligoss DM, et al "Interaction between cyclosporine and fluconazole in renal allograft recipients." Transplantation 51 (1991): 1014-8[7] Hilbert J, Messig M, Kuye O, Friedman H "Evaluation of interaction between fluconazole and an oral contraceptive in healthy women." Obstet Gynecol 98 (2001): 218-23[8] Finch CK, Green CA, Self TH "Fluconazole-carbamazepine interaction." South Med J 95 (2002): 1099-100[9] Torregrosa V, De la Torre M, Campistol JM, et al "Interaction of fluconazole with ciclosporin A." Nephron 60 (1992): 125-6[10] Tsouli S, Maranis S, Kyritsis AP "Fluconazole-carbamazepine interaction in a patient with bipolar disorder." Psychiatry Clin Neurosci 65 (2011): 112[11] Barbara JA, Clarkson AR, LaBrooy J, et al "Candida albicans arthritis in a renal allograft recipient with an interaction between cyclosporin and fluconazole." Nephrol Dial Transplant 8 (1993): 263-6[12] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[13] Sugar AM, Saunders C, Idelson BA, Bernard DB "Interaction of fluconazole and cyclosporine." Ann Intern Med 110 (1989): 844[14] Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR "Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients." Transplantation 61 (1996): 1268-72[15] Baciewicz AM, Baciewicz FA, Jr "Ketoconazole and fluconazole drug interactions." Arch Intern Med 153 (1993): 1970-6[16] Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75[17] Lopez-Gil JA "Fluconazole-cyclosporin interaction: a dose-dependent effect?" Ann Pharmacother 27 (1993): 427-30[18] Nair DR, Morris HH "Potential fluconazole-induced carbamazepine toxicity." Ann Pharmacother 33 (1999): 790-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39119, 'Fluoxymesterone', 'Dexamethasone', 'Moderate', 'Concomitant use of androgens with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and edema due to additive steroidal effects.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39175/', '[1] "Product Information. Oxandrin (oxandrolone)." Bio-Tech, Levittown, PA.[2] "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39120, 'Fluphenazine', 'Dexamethasone', 'Moderate', 'The risk of seizures may be increased during coadministration of fluphenazine with any substance that can reduce the seizure threshold, such as aminophylline, antidepressants, antipsychotics, opioids, carbapenems, etc. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with fluphenazine.', NULL, 'Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.', NULL, 'Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Mesoridazine, Methotrimeprazine, Asenapine, Promazine, Thiothixene, Thioridazine, Pimozide, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39176/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39121, 'Flurbiprofen', 'Dexamethasone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Tolazoline, Dimethyl sulfoxide, Chondroitin sulfate, Esomeprazole, Glucosamine, Povidone-iodine, Bacitracin, Cortisone, Betamethasone, Fluorometholone, Dexamethasone', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39177/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39122, 'Fluvoxamine', 'Dexamethasone', 'Moderate', 'Coadministration with fluvoxamine may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to competitive inhibition of CYP450 3A4 activity by fluvoxamine.', NULL, 'Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluvoxamine is added to or withdrawn from therapy.', 'Metabolism', 'Phenelzine, Desipramine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John''s Wort, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39178/', '[1] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[2] Damkier P, Hansen LL, Brosen K "Effect of fluvoxamine on the pharmacokinetics of quinidine." Eur J Clin Pharmacol 55 (1999): 451-6[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39123, 'Fosamprenavir', 'Dexamethasone', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39179/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39124, 'Fosaprepitant', 'Dexamethasone', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of some corticosteroids. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Oral dexamethasone and methylprednisolone dosage should be reduced by approximately 50% when coadministered with the aprepitant 125 mg/80 mg regimen, and intravenous methylprednisolone dosage should be reduced by approximately 25%.', NULL, 'Oral dexamethasone and methylprednisolone dosage should be reduced by approximately 50% when coadministered with the aprepitant 125 mg/80 mg regimen, and intravenous methylprednisolone dosage should be reduced by approximately 25%. The daily dosage of dexamethasone administered in clinical chemotherapy-induced nausea and vomiting studies with aprepitant was reduced to account for the drug interaction. No dosage adjustment for the corticosteroid is necessary during coadministration with aprepitant in a single 40 mg dose for prevention of postoperative nausea and vomiting. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended, as it has not been studied and the drug interaction profile may change during long-term use.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39180/', '[1] "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.[2] "Product Information. Emend for Injection (fosaprepitant)." Merck & Company Inc, West Point, PA.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[33] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39125, 'Foscarnet', 'Dexamethasone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39181/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39126, 'Fosinopril', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39182/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39127, 'Fosphenytoin', 'Dexamethasone', 'Moderate', 'Phenytoin and other hydantoins may induce the CYP450 3A4 hepatic metabolism of corticosteroids and increase their clearance and decrease their half-lives, possibly reducing their therapeutic efficacy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy. Some patients may require increased corticosteroid dosages.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39183/', '[1] Haque N, Thrasher K, Werk EE, Jr Knowles HC, Jr Sholiton LJ "Studies on dexamethasone metabolism in man: effect of diphenylhydantoin." J Clin Endocrinol Metab 34 (1972): 44-50[2] Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB "Phenytoin-dexamethasone interaction: a previously unreported observation." Surg Neurol 16 (1981): 23-4[3] Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M "Phenytoin-dexamethasone: a possible drug-drug interaction." JAMA 254 (1985): 2062-3[4] Lackner TE "Interaction of dexamethasone with phenytoin." Pharmacotherapy 11 (1991): 344-7[5] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[6] Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[9] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[10] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12[11] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[14] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[18] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[19] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[20] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[21] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[22] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39128, 'Fostamatinib', 'Dexamethasone', 'Moderate', 'Coadministration of fostamatinib with inducers of CYP450 3A4 may decrease exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9.', NULL, 'The potential for diminished pharmacologic effects of fostamatinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of fostamatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39184/', '[1] "Product Information. Tavalisse (fostamatinib)." Rigel Pharmaceuticals, South San Francisco, CA.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39129, 'Fostemsavir', 'Dexamethasone', 'Minor', 'Coadministration of fostemsavir with moderate or weak CYP450 3A4 inducers may decrease the plasma concentrations of temsavir, the active moiety of fostemsavir. According to the prescribing information, temsavir is a substrate of CYP450 3A4, esterases, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).', NULL, '-', NULL, '-', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39185/', '[1] "Product Information. Rukobia (fostemsavir)." ViiV Healthcare, Research Triangle Park, NC.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39130, 'Furosemide', 'Dexamethasone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mometasone furoate, Mometasone, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, Mometasone furoate, Fluorometholone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39186/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39131, 'Gallium chloride Ga-67', 'Dexamethasone', 'Moderate', 'The concomitant use of glucocorticoids may interfere with uptake of gallium citrate Ga-67 by brain tumors or abscesses. In addition, prednisone may cause thymic uptake of Ga-67.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', NULL, 'Clinicians should be aware of possible interference with diagnostic tests in patients who are taking these medications.', 'Distribution', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39187/', '[1] "Product Information. Gallium Citrate Ga-67 (gallium citrate 67 Ga (gallium citrate 67Ga))." Bristol-Myers Squibb, Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39132, 'Gatifloxacin', 'Dexamethasone', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39188/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39133, 'Gefitinib', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme.', NULL, 'Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', NULL, 'Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. In patients receiving potent inducers such as rifampin or phenytoin, gefitinib product labeling states that a dosage increase to 500 mg daily should be considered in the absence of severe adverse reactions, and additional dosage adjustments be made based on clinical response. Gefitinib dosage should be decreased accordingly if these agents are discontinued.', 'Metabolism', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39189/', '[1] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7[2] "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39134, 'Gemifloxacin', 'Dexamethasone', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39190/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39135, 'Gilteritinib', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.', NULL, 'The potential for diminished pharmacologic effects of gilteritinib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', NULL, 'The potential for diminished pharmacologic effects of gilteritinib should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39191/', '[1] "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39136, 'Glasdegib', 'Dexamethasone', 'Major', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of glasdegib with moderate CYP450 3A4 inducers should generally be avoided. If concomitant use cannot be avoided, the glasdegib dose should be increased as tolerated from 100 mg once a day to 200 mg once a day or from 50 mg once a day to 100 mg once a day. Once the moderate CYP450 3A4 inducer has been discontinued for 7 days, the glasdegib dose should return to the dose taken prior to initiating the moderate CYP450 3A4 inducer.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39192/', '[1] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cronk GA, Wheatley WB, Fellers GF, Albright H "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci 240 (1960): 219-25[3] Neuvonen PJ, Elonen E, Pentikainen PJ "Comparative effect of food on absorption of ampicillin and pivampicillin." J Int Med Res 5 (1977): 71-6[4] Klein JO, Sabath LD, Finland M "Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young." Am J Med Sci 245 (1963): 399-411[5] Welling PG, Huang H, Koch PA, Madsen PO "Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects." J Pharm Sci 66 (1977): 549-52[6] McCarthy CG, Finland M "Absorption and excretion of four penicillins." N Engl J Med 263 (1960): 315-26[7] Neu HC "Antimicrobial activity and human pharmacology of amoxicillin." J Infect Dis 129 (1974): s123-31[8] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39137, 'Glimepiride', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39193/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39138, 'Glipizide', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Mometasone, Vitamin A, Olopatadine, Fluticasone, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39194/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39139, 'Glyburide', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Mometasone, Vitamin A, Olopatadine, Fluticasone, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39195/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39140, 'Glycerin', 'Dexamethasone', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39196/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39141, 'Glycerol phenylbutyrate', 'Dexamethasone', 'Moderate', 'Drugs that can increase plasma ammonia levels such as corticosteroids, haloperidol, or the anticonvulsants carbamazepine, topiramate, and phenobarbital may interfere with the therapeutic effects of phenylbutyrate therapy in the management of urea cycle disorders. Corticosteroids can cause the breakdown of body protein, which may lead to increased ammonia levels. The use of haloperidol has been associated with hyperammonemia in a young child with citrullinemia, an inherited disorder of ammonia excretion.', NULL, 'Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.', NULL, 'Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Metreleptin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39197/', '[1] "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc, South San Francisco, CA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Buphenyl (sodium phenylbutyrate)." Horizon Pharma USA Inc, Northbrook, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39142, 'Golimumab', 'Dexamethasone', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39198/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm." ([2011 Sept 7]):[2] "Product Information. Cimzia (certolizumab)." UCB Pharma Inc, Smyrna, GA.[3] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[4] "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[6] "Product Information. Humira (adalimumab)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39143, 'Grepafloxacin', 'Dexamethasone', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39199/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39144, 'Guanabenz', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39200/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39145, 'Guanadrel', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39201/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39146, 'Guanethidine', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Acetylcholine, Physostigmine, Apraclonidine, Levobunolol', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39202/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39147, 'Guanfacine', 'Dexamethasone', 'Major', 'Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.', NULL, 'Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers.', NULL, 'Close monitoring and dosage adjustment should be considered when guanfacine is administered with potent and moderate CYP450 3A4 inducers. For extended-release guanfacine, some manufacturers recommend increasing the dosage up to double the recommended level when initiating therapy in patients who are already receiving a CYP450 3A4 inducer. Further dosage adjustments may be required based on patient tolerance and response. If a CYP450 3A4 inducer is added to existing guanfacine therapy, the guanfacine dosage may be increased up to double the recommended level over 1 to 2 weeks. The dosage should be decreased to the recommended level over 1 to 2 weeks following discontinuation of the CYP450 3A4 inducer.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39203/', '[1] Kiechel JR, Lavene D, Guerret M, Comoy E, Godin M, Fillastre JP "Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure." Eur J Clin Pharmacol 25 (1983): 463-6[2] "Product Information. Intuniv (guanfacine)." Shire US Inc, Florence, KY.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Product Information. Intuniv (guanfacine)." Shire US Inc, Florence, KY.[7] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39148, 'Hepatitis A Vaccine', 'Dexamethasone', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39204/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39149, 'Hepatitis B Vaccine (Recombinant)', 'Dexamethasone', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39205/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39150, 'Human papillomavirus type 11 L1 capsid protein antigen', 'Dexamethasone', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39206/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39151, 'Hyaluronidase', 'Dexamethasone', 'Minor', 'Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines. These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.', NULL, '-', NULL, '-', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39207/', '[1] "Product Information. Vitrase (hyaluronidase)." Bausch and Lomb, Rochester, NY.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[34] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[35] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39152, 'Hydralazine', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39208/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39153, 'Hydroflumethiazide', 'Dexamethasone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39209/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39154, 'Ibrutinib', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished therapeutic effects of ibrutinib should be considered when prescribed in combination with CYP450 3A4 inducers.', NULL, 'The potential for diminished therapeutic effects of ibrutinib should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of ibrutinib adjusted as necessary in accordance with product labeling.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39210/', '[1] "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA.[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39155, 'Idelalisib', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of idelalisib, which is a substrate of the isoenzyme.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib.', NULL, 'Patients receiving idelalisib with CYP450 3A4 inducers should be monitored for potentially diminished pharmacologic response to idelalisib. Concomitant use should be avoided if an interaction is suspected.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39211/', '[1] "Product Information. Zydelig (idelalisib)." Gilead Sciences, Foster City, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39156, 'Imatinib', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of imatinib, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of imatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39212/', '[1] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[6] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[7] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[17] Cerner Multum, Inc. "Australian Product Information." O 0[18] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[19] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39157, 'Indacaterol', 'Dexamethasone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Olodaterol, Beclomethasone dipropionate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39213/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39158, 'Indapamide', 'Dexamethasone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39214/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39159, 'Indinavir', 'Dexamethasone', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39215/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39160, 'Indium In-111 oxyquinoline', 'Dexamethasone', 'Moderate', 'Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.', NULL, 'Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.', NULL, 'Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.', 'Others', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39216/', '[1] "Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111)." GE Healthcare, Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39161, 'Indomethacin', 'Dexamethasone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Fludrocortisone, Betamethasone, Fluorometholone, Dexamethasone, Chondroitin sulfate, Esomeprazole, Glucosamine, Cortisone, Betamethasone, Fluorometholone, Dexamethasone, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39217/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39162, 'Infliximab', 'Dexamethasone', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', NULL, 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39218/', '[1] FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm." ([2011 Sept 7]):[2] "Product Information. Cimzia (certolizumab)." UCB Pharma Inc, Smyrna, GA.[3] "Product Information. Simponi (golimumab)." Centocor Inc, Malvern, PA.[4] "Product Information. Enbrel (etanercept)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Remicade (infliximab)." Centocor Inc, Malvern, PA.[6] "Product Information. Humira (adalimumab)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39163, 'Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)', 'Dexamethasone', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39219/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39164, 'Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)', 'Dexamethasone', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39220/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39165, 'Insulin human', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39221/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39166, 'Insulin aspart (aspart)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39222/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39167, 'Insulin aspart (aspart protamine)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39223/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39168, 'Insulin degludec', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39224/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39169, 'Insulin detemir', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39225/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39170, 'Insulin glargine', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39226/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39171, 'Insulin glulisine', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39227/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39172, 'Insulin human (inhalation, rapid acting)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Mupirocin, Vitamin A, Olopatadine, Hyaluronic acid, Azelastine, Fluorometholone, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39228/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39173, 'Insulin human (isophane)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39229/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39174, 'Insulin lispro', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39230/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39175, 'Insulin lispro (protamine)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39231/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39176, 'Insulin human (regular)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39232/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39177, 'Insulin human (zinc)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39233/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39178, 'Insulin human (zinc extended)', 'Dexamethasone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39234/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39179, 'Iohexol', 'Dexamethasone', 'Major', 'Coadministration of corticosteroids with iodinated contrast media by the intrathecal route may be associated with a high incidence of radiographic arachnoiditis. Meningitis and seizures may also occur.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39235/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.[3] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[4] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[5] Nelson DA, Landau WM "Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports." J Neurol Neurosurg Psychiatry 70 (2001): 433-43', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39180, 'Iopamidol', 'Dexamethasone', 'Major', 'Coadministration of corticosteroids with iodinated contrast media by the intrathecal route may be associated with a high incidence of radiographic arachnoiditis. Meningitis and seizures may also occur.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39236/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.[3] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[4] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[5] Nelson DA, Landau WM "Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports." J Neurol Neurosurg Psychiatry 70 (2001): 433-43', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39181, 'Ipilimumab', 'Dexamethasone', 'Moderate', 'INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39237/', '[1] Jove M, Vilarino N, Nadal E "Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer." Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. "Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer." J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center." J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al "Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors." ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc "ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp." O 0 (2015):[8] Scott SC, Pennell NA "Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab." J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39182, 'Irbesartan', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Sacubitril', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39238/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39183, 'Irinotecan', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..', NULL, 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.', NULL, 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.', 'Metabolism', 'Teniposide, Cabazitaxel', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39239/', '[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ "Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies." Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF "Clinical drugs that interact with St. John''s wort and implication in drug development." Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al "Irinotecan therapy in adults with recurrent or progressive malignant glioma." J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K "Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer." Int J Clin Oncol 9 (2004): 206-9[5] "Product Information. Onivyde (irinotecan liposomal)." Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. "A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital." Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al "Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans." Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. "Influence of phenytoin on the disposition of irinotecan: a case report." J Pediatr Hematol Oncol 24 (2002): 130-3[9] "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A "Modulation of irinotecan(CPT-11)metabolism by St. John''s wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603." ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al "Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme." Pharmacotherapy 20 (2000): 353[13] Kuhn JG "Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report." Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A "Effects of St. John''s Wort on Irinotecan Metabolism." J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al "Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma." Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[17] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[18] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[22] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[23] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[24] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39184, 'Irinotecan (liposomal)', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of the CYP450 3A4 isoenzyme may decrease the plasma concentrations of irinotecan and its pharmacologically active metabolite, SN-38. Irinotecan is partially metabolized by CYP450 3A4, and induction of this process results in less of the drug available in the plasma for conversion to SN-38 via carboxylesterases..', NULL, 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers.', NULL, 'The antitumour activity of irinotecan may be reduced in patients treated with CYP450 3A4 inducers. Pharmacologic response to irinotecan should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the irinotecan dosage adjusted as necessary.', 'Metabolism', 'Teniposide, Cabazitaxel', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39240/', '[1] Minami H, Lad TE, Nicholas MK, Vokes EE, Ratain MJ "Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies." Clin Cancer Res 5 (1999): 1325-30[2] Di YM, Li CG, Xue CC, Zhou SF "Clinical drugs that interact with St. John''s wort and implication in drug development." Curr Pharm Des 14 (2008): 1723-42[3] Friedman HS, Petros WP, Friedman AH, et al "Irinotecan therapy in adults with recurrent or progressive malignant glioma." J Clin Oncol 17 (1999): 1516-25[4] Yonemori K, Takeda Y, Toyota E, Kobayashi N, Kudo K "Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer." Int J Clin Oncol 9 (2004): 206-9[5] "Product Information. Onivyde (irinotecan liposomal)." Merrimack Pharmaceuticals, Cambridge, MA.[6] Innocenti F, Undevia SD, Ramirez J, et al. "A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital." Clin Pharmacol Ther 76 (2004): 490-502[7] Santos A, Zanetta S, Cresteil T, et al "Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans." Clin Cancer Res 6 (2000): 2012-20[8] Murry DJ, Cherrick I, Salama V, et al. "Influence of phenytoin on the disposition of irinotecan: a case report." J Pediatr Hematol Oncol 24 (2002): 130-3[9] "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.[10] Mathijssen RH, Verweij J, De Bruijn P, De Jonge MJ, Sparreboom A "Modulation of irinotecan(CPT-11)metabolism by St. John''s wort in cancer patients. Available from: URL: http:aacr02.agora.com/planner/displayabstract.asp?presentationid=2603." ([2002 Apr]):[11] Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9[12] Radomski KM, Gajjar AJ, Kirstein MN, et al "Irinotecan clearance is increased by concomitant administration of enzyme inducers in a patient with glioblastoma multiforme." Pharmacotherapy 20 (2000): 353[13] Kuhn JG "Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report." Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40[14] Mathijssen RH, Verweij J, De Bruijn P, Loos WJ, Sparreboom A "Effects of St. John''s Wort on Irinotecan Metabolism." J Natl Cancer Inst 94 (2002): 1247-9[15] Zamboni WC, Gajjar AJ, Heideman RL, et al "Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma." Clin Cancer Res 4 (1998): 783-9[16] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[17] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[18] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[20] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[21] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[22] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[23] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[24] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[25] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39185, 'Isavuconazonium', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT).', NULL, 'Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers.', NULL, 'Caution is advised during concomitant use of isavuconazonium sulfate with CYP450 3A4 inducers. The potential for decreased efficacy of isavuconazonium sulfate should be considered.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39241/', '[1] "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39186, 'Isoetharine', 'Dexamethasone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39242/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39187, 'Isoniazid', 'Dexamethasone', 'Minor', 'Plasma concentrations of isoniazid may be reduced during coadministration with corticosteroids. The mechanism of interaction has not been established, but may involve enhanced hepatic and/or renal elimination of isoniazid. Nonetheless, it may be advisable to monitor patient response to isoniazid more closely during concomitant corticosteroid therapy and adjust the isoniazid dosage if necessary.', NULL, '-', NULL, '-', 'Excretion', 'Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Aminosalicylic acid', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39243/', '[1] Sarma G, Kailasam S, Nair NG, Narayana AS, Tripathy SP "Effect of prednisonlone and refampin on isoniazid metabolism in slow and rapid inactivators of isoniazid." Antimicrob Agents Chemother 18 (1980): 661-6[2] Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, MacIntyre I, Park BK "Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity." Clin Pharmacol Ther 30 (1981): 363-7[3] Dimartini A "Isoniazid, tricyclics and the ''''cheese reaction''''." Int Clin Psychopharmacol 10 (1995): 197-8[4] "Product Information. INH (isoniazid)." Ciba Pharmaceuticals, Summit, NJ.[5] Smith CK, Durack DT "Isoniazid and reaction to cheese." Ann Intern Med 88 (1978): 520-1[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Self TH, Chrisman CR, Baciewicz AM, Bronze MS "Isoniazid drug and food interactions." Am J Med Sci 317 (1999): 304-11[8] Uragoda CG, Kottegoda SR "Adverse reactions to isoniazid on ingestion of fish with a high histamine content." Tubercle 58 (1977): 83-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39188, 'Isoprenaline', 'Dexamethasone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Droxidopa, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Dopamine, Methoxamine, More', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39244/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39189, 'Isradipine', 'Dexamethasone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Nimodipine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39245/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39190, 'Istradefylline', 'Dexamethasone', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39246/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39191, 'Itraconazole', 'Dexamethasone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39247/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39192, 'Ivabradine', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivabradine and its active N-desmethylated metabolite, both of which are primarily metabolized by the isoenzyme.', NULL, 'Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers.', NULL, 'Caution is advised during concomitant use of ivabradine with CYP450 3A4 inducers. The potential for decreased efficacy of ivabradine should be considered.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Adenosine, Regadenoson, Ubidecarenone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39248/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[3] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39193, 'Ivacaftor', 'Dexamethasone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of ivacaftor-containing medications should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Doxapram, Elexacaftor', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39249/', '[1] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[2] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[3] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[4] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[5] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[6] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[7] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[8] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39194, 'Dexamethasone', 'Ixabepilone', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme. Subtherapeutic levels of ixabepilone may result.', NULL, 'The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'The use of ixabepilone in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ixabepilone is unknown. Whenever possible, therapeutic agents with low enzyme induction potential should be considered in patients treated with ixabepilone.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Idarubicin, Valrubicin, Plicamycin, Daunorubicin, Epirubicin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39250/', '[1] "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.[2] "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39195, 'Dexamethasone', 'Ketoconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39251/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39196, 'Dexamethasone', 'Ketoprofen', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39252/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39197, 'Dexamethasone', 'Labetalol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Esmolol', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39253/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39198, 'Dexamethasone', 'Lactitol', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39254/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39199, 'Dexamethasone', 'Lactobacillus acidophilus', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39255/', '[1] Borriello SP, Hammes WP, Holzapfel W, et.al "Safety of probiotics that contain lactobacilli or bifidobacteria." Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. "Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland." Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P "Lactobacillus species as opportunistic pathogens in immunocompromised patients." Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. "Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG." Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL "Lactobacillus bacteremia and endocarditis: review of 45 cases." Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML "Probiotic use in clinical practice: what are the risks?" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al "Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin." Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. "Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG." Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al "Lactobacilli and bacteremia in southern Finland, 1989-1992" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C "Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis." J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM "Lactobacillus endocarditis caused by a probiotic organism." Clin Microbiol Infect 5 (1999): 290-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39200, 'Dexamethasone', 'Lactulose', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39256/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39201, 'Dexamethasone', 'Lapatinib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.', NULL, 'The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'The use of lapatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39257/', '[1] "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39202, 'Dexamethasone', 'Larotrectinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme as well as the efflux transporter.', NULL, 'The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers.', NULL, 'The potential for diminished pharmacologic effects of larotrectinib should be considered during coadministration with CYP450 3A4 and P-gp inducers. Some authorities advise that concomitant use of larotrectinib with moderate CYP450 3A4 and/or P-gp inducers should be avoided (UK). Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39258/', '[1] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[14] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39203, 'Dexamethasone', 'Lefamulin', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks.', NULL, 'Concomitant use of lefamulin with potent or moderate inducers of CYP450 3A4 and/or P-gp should be avoided unless the benefit outweighs the risks. Monitor for reduced efficacy of lefamulin if coadministration is necessary.', 'Metabolism', 'Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39259/', '[1] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39204, 'Dexamethasone', 'Leflunomide', 'Major', 'The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide''s active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.', NULL, 'Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.', NULL, 'Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39260/', '[1] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[2] "Product Information. Aubagio (teriflunomide)." Genzyme Corporation, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39205, 'Dexamethasone', 'Lemborexant', 'Moderate', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.', NULL, 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39261/', '[1] "Product Information. Dayvigo (lemborexant)." Eisai Inc, Woodcliff Lake, NJ.[2] "Product Information. Dayvigo (lemborexant)." Eisai Inc, Woodcliff Lake, NJ.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39206, 'Dexamethasone', 'Letermovir', 'Moderate', 'Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or organic anion transporting polypeptide protein (OATP) 1B1 and 1B3. Letermovir has been shown to be a reversible inhibitor of CYP450 2C8 in vitro, although its effect on CYP450 2C8 substrates has not been evaluated clinically. Letermovir is also a time-dependent inhibitor and inducer of CYP450 3A4 in vitro.', NULL, 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy. Moreover, clinicians should be aware that the magnitude of CYP450 3A- and OATP1B1/3-mediated drug interactions with coadministered drugs may be different when letermovir is used with cyclosporine. The combined effect of the two drugs on CYP450 3A4 may be similar to that of a strong CYP450 3A4 inhibitor, hence clinicians should refer to the prescribing information for dosing recommendations of the CYP450 3A4 substrate with a strong CYP450 3A4 inhibitor. Similarly, letermovir and cyclosporine may demonstrate some additive effects on OATP1B1 inhibition, although cyclosporine by itself is already a strong OATP1B1/3 inhibitor.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39262/', '[1] "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39207, 'Dexamethasone', 'Levosalbutamol', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39263/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39208, 'Dexamethasone', 'Levamlodipine', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Nimodipine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39264/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39209, 'Dexamethasone', 'Levobupivacaine', 'Minor', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.', NULL, '-', NULL, '-', 'Metabolism', 'Ropivacaine, Chloroprocaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39265/', '[1] "Product Information. Chirocaine (levobupivacaine)" Organon, West Orange, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39210, 'Dexamethasone', 'Levofloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Tinidazole, Bismuth subcitrate potassium, Dexlansoprazole, Esomeprazole, Tinidazole, Cefixime, Secnidazole, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39266/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39211, 'Dexamethasone', 'Levacetylmethadol', 'Major', 'Coadministration with inducers of CYP450 3A4 may increase the peak activity and/or decrease the duration of action of levomethadyl acetate, which is primarily metabolized by the isoenzyme. Induction of CYP450 3A4 also results in increased formation of the active metabolites, nor-LAAM and dinor-LAAM. High plasma levels of these metabolites may increase the risk of QT interval prolongation and serious ventricular arrhythmias such as torsade de pointes.', NULL, 'Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, 'Close monitoring is recommended if levomethadyl acetate is used with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. The dose or dosing interval may require adjustment if an interaction is suspected. A 12-lead ECG should be performed before initiating levomethadyl acetate therapy, 12 to 14 days after initiating therapy, and periodically thereafter. Patients should be advised to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', 'Diamorphine, Acamprosate, Lofexidine, Naltrexone, Disulfiram, Nalmefene', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39267/', '[1] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[2] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39212, 'Dexamethasone', 'Licorice', 'Moderate', 'Licorice may potentiate the effects of corticosteroids. Licorice use has been associated with hypertension as well as sodium and water retention. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects. Prolonged use of licorice has led to a hypermineralocorticoid (pseudohyperaldosteronism) syndrome characterized by hypertension, hypernatremia, hypokalemia, metabolic alkalosis, renin-angiotensin-aldosterone suppression, and edema. In studies and case reports, licorice toxicity has generally been completely reversible within one to several weeks of licorice discontinuation. However, renin-angiotensin-aldosterone axis may be suppressed for up to several months.', NULL, 'Patients receiving prolonged corticosteroid therapy should avoid or limit the consumption of licorice-containing products.', NULL, 'Patients receiving prolonged corticosteroid therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39268/', '[1] Bannister B, Ginsburg R, Shneerson J "Cardiac arrest due to liquorice-induced hypokalaemia." Br Med J 2 (1977): 738-9[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20[3] Edwards CR "Lessons from licorice." N Engl J Med 325 (1991): 1242-3[4] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S "Liquorice-induced rise in blood pressure: a linear dose-response relationship." J Hum Hypertens 15 (2001): 549-52[5] Epstein MT, Espiner EA, Donald RA, Hughes H "Liquorice toxicity and the renin-angiotensin-aldosterone axis in man." Br Med J 1 (1977): 209-10[6] Nielsen I, Pedersen RS "Life-threatening hypokalaemia caused by liquorice ingestion." Lancet 1 (1984): 1305[7] de Klerk GJ, Nieuwenhuis MG, Beutler JJ "Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum." BMJ 314 (1997): 731[8] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N "Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa." Int J Eating Disorder 26 (1999): 111-4[9] Cumming AM, Boddy K, Brown JJ, et al "Severe hypokalaemia with paralysis induced by small doses of liquorice." Postgrad Med J 56 (1980): 526-9[10] Rosseel M, Schoors D "Chewing gum and hypokalaemia." Lancet 341 (1993): 175[11] Cumming A "Severe reduction of serum potassium induced by licorice." Nurs Times 72 (1976): 367-70[12] Cumming AM "Metabolic effects of licorice." Br Med J 1 (1977): 906[13] Clyburn EB, DiPette DJ "Hypertension induced by drugs and other substances." Semin Nephrol 15 (1995): 72-86[14] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR "Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age." Lancet 2 (1987): 821-4[15] Epstein MT, Espiner EA, Donald RA, Hughes H "Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects." Br Med J 1 (1977): 488-90[16] Dellow EL, Unwin RJ, Honour JW "Pontefract cakes can be bad for you: refractory hypertension and liquorice excess." Nephrol Dial Transplant 14 (1999): 218-20[17] Fugh-Berman A "Herb-drug interactions." Lancet 355 (2000): 134-8[18] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R "Licorice-induced hypermineralocorticoidism." N Engl J Med 325 (1991): 1223-7[19] Holmes AM, Young J, Marrott PK, Prentice E "Pseudohyperaldosteronism induced by habitual ingestion of liquorice." Postgrad Med J 46 (1970): 625-9[20] Elinav E, Chajek-Shaul T "Licorice consumption causing severe hypokalemic paralysis." Mayo Clin Proc 78 (2003): 767-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39213, 'Dexamethasone', 'Linagliptin', 'Moderate', 'Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations of linagliptin, which is a substrate for both. The interaction may produce subtherapeutic and likely ineffective plasma concentrations of linagliptin.', NULL, 'Due to the potential for reduced efficacy of linagliptin, coadministration with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'Due to the potential for reduced efficacy of linagliptin, coadministration with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. For patients requiring use of such drugs, an alternative to linagliptin is strongly recommended. Other known inducers of CYP450 3A4 include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, modafinil, nafcillin, nevirapine, and various other anticonvulsants, although the extent to which they interact with linagliptin is unknown. If concomitant use with these agents is necessary, glycemic control should be closely monitored.', 'Metabolism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39269/', '[1] "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim, Ridgefield, CT.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39214, 'Dexamethasone', 'Liraglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39270/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39215, 'Dexamethasone', 'Lisinopril', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mometasone furoate, Mometasone, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39271/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39216, 'Dexamethasone', 'Lixisenatide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39272/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39217, 'Dexamethasone', 'Lomefloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39273/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39218, 'Dexamethasone', 'Lonafarnib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of lonafarnib. In vitro, lonafarnib has been shown to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2, 2A6, 2C8, 2C9, 2C19, and 2E1.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Metreleptin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39274/', '[1] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39219, 'Dexamethasone', 'Lorlatinib', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. In addition to the potential for diminished efficacy of lorlatinib, the risk of serious hepatotoxicity may be increased due to activation of the pregnane X receptor (PXR) by both lorlatinib and CYP450 3A4 inducers. The effect of concomitant use of moderate CYP450 3A4 inducers on lorlatinib pharmacokinetics or the risk of hepatotoxicity is unknown.', NULL, 'Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of lorlatinib with moderate CYP450 3A4 inducers should generally be avoided. If coadministration is required, monitoring of AST, ALT and bilirubin is recommended 48 hours after initiating lorlatinib and at least 3 times during the first week of treatment. Depending upon the relative importance of each drug, lorlatinib or the CYP450 3A4 inducer should be discontinued for persistent Grade 2 or higher hepatotoxicity.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39275/', '[1] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39220, 'Dexamethasone', 'Losartan', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Sacubitril', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39276/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39221, 'Dexamethasone', 'Lumateperone', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.', NULL, 'Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.', NULL, 'Coadministration of CYP450 3A4 inducers with lumateperone should be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Mesoridazine, Methotrimeprazine, Asenapine, Promazine, Thiothixene, Thioridazine, Pimozide, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39277/', '[1] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY.[2] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39222, 'Dexamethasone', 'Lurasidone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of lurasidone, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of lurasidone should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of lurasidone should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Mesoridazine, Methotrimeprazine, Asenapine, Promazine, Thiothixene, Thioridazine, Pimozide, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39278/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[7] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39223, 'Dexamethasone', 'Lurbinectedin', 'Major', 'Coadministration with a strong or moderate CYP450 3A4 inducer is predicted to decrease lurbinectedin systemic exposure, which may reduce its efficacy.', NULL, 'Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of lurbinectedin and strong or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39279/', '[1] "Product Information. Zepzelca (lurbinectedin)." Jazz Pharmaceuticals, Palo Alto, CA.[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Zepzelca (lurbinectedin)." Jazz Pharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39224, 'Dexamethasone', 'Lyme disease vaccine (recombinant OspA)', 'Moderate', 'The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.', NULL, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39280/', '[1] "Product Information. Lymerix (Lyme disease vaccine)." SmithKline Beecham, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39225, 'Dexamethasone', 'Macimorelin', 'Moderate', 'Drugs that directly affect the pituitary secretion of growth hormone (e.g., somatostatin, insulin, glucocorticoids, cyclooxygenase inhibitors such as aspirin and nonsteroidal anti-inflammatory drugs) and drugs that may transiently elevate growth hormone levels (e.g., clonidine, levodopa, insulin) may impact the accuracy of the macimorelin diagnostic test.', NULL, 'Concomitant use of macimorelin with drugs affecting growth hormone levels should generally be avoided.', NULL, 'Concomitant use of macimorelin with drugs affecting growth hormone levels should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Vitamin A, Caffeine, Metyrapone, Histamine, Indocyanine green, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39281/', '[1] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.[2] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39226, 'Dexamethasone', 'Macitentan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when macitentan is used with CYP450 3A4 inducers.', NULL, 'Caution is advised when macitentan is used with CYP450 3A4 inducers. The possibility of diminished therapeutic effects should be considered.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Ambrisentan, Metyrosine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39282/', '[1] "Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[2] Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39227, 'Dexamethasone', 'Magaldrate', 'Minor', 'Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.', NULL, '-', NULL, '-', 'Absorption', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Magnesium carbonate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39283/', '[1] Naggar VF, Khalil SA, Gouda MW "Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans." J Pharm Sci 67 (1978): 1029-30[2] Tanner AR, Caffin JA, Halliday JW, Powell LW "Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone." Br J Clin Pharmacol 7 (1979): 397-400[3] Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39228, 'Dexamethasone', 'Magnesium citrate', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Sodium chloride, Sulfamethizole, Sorbitol, Sodium citrate, Magnesium gluconate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Sodium sulfate, Magnesium chloride, Alvimopan, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39284/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39229, 'Dexamethasone', 'Magnesium hydroxide', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide, Magnesium carbonate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39285/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39230, 'Dexamethasone', 'Magnesium oxide', 'Minor', 'Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.', NULL, '-', NULL, '-', 'Absorption', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Magnesium carbonate, Magnesium gluconate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Sodium sulfate, Magnesium chloride, Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39286/', '[1] Naggar VF, Khalil SA, Gouda MW "Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans." J Pharm Sci 67 (1978): 1029-30[2] Tanner AR, Caffin JA, Halliday JW, Powell LW "Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone." Br J Clin Pharmacol 7 (1979): 397-400[3] Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39231, 'Dexamethasone', 'Magnesium sulfate', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate, Methacholine, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39287/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39232, 'Dexamethasone', 'Maraviroc', 'Moderate', 'Coadministration with inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may decrease the plasma concentrations of maraviroc, which is a substrate of both.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, caution is advised if maraviroc is used with CYP450 3A4 and/or P-glycoprotein inducers. A dosage adjustment for maraviroc may be necessary if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39288/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39233, 'Dexamethasone', 'Measles virus vaccine live attenuated', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39289/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39234, 'Dexamethasone', 'Meclofenamic acid', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39290/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39235, 'Dexamethasone', 'Medroxyprogesterone acetate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of medroxyprogesterone, which is primarily metabolized by the isoenzyme.', NULL, 'Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', NULL, 'Pharmacologic response to medroxyprogesterone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary. When administered as the depot formulation for contraception, no dosage adjustment for medroxyprogesterone is currently recommended during coadministration with CYP450 3A4 inducers.', 'Metabolism', 'Norelgestromin, Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Levonorgestrel, Desogestrel, Dienogest, Etonogestrel, Norgestrel, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39291/', '[1] Kobayashi K, Mimura N, Fujii H, et al "Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate." Clin Cancer Res 6 (2000): 3297-303[2] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE "Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer." Cancer Chemother Pharmacol 27 (1990): 101-5[3] "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.[4] "FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception." J Fam Plann Reprod Health Care 31 (2005): 139-51[5] O''Brien MD, Guillebaud J "Contraception for women with epilepsy." Epilepsia 47 (2006): 1419-22[6] Halpenny O, Bye A, Cranny A, Feely J, Daly PA "Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate." Med Oncol Tumor Pharmacother 7 (1990): 241-7[7] "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39236, 'Dexamethasone', 'Mefenamic acid', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39292/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39237, 'Dexamethasone', 'Mefloquine', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of mefloquine, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'The possibility of diminished therapeutic effects should be considered when mefloquine is used in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from mefloquine therapy, and the dosage adjusted if necessary. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with mefloquine is unknown.', 'Metabolism', 'Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, Sulfadoxine, Chloroquine', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39293/', '[1] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[2] "Product Information. Lariam (mefloquine)." Roche Laboratories, Nutley, NJ.[3] Schmidt LE, Dalhoff K "Food-drug interactions." Drugs 62 (2002): 1481-502[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39238, 'Dexamethasone', 'Meloxicam', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Ropivacaine, Chloroprocaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39294/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39239, 'Dexamethasone', 'Meningococcal polysaccharide vaccine group C', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39295/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39240, 'Dexamethasone', 'Mephenytoin', 'Moderate', 'Phenytoin and other hydantoins may induce the CYP450 3A4 hepatic metabolism of corticosteroids and increase their clearance and decrease their half-lives, possibly reducing their therapeutic efficacy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy. Some patients may require increased corticosteroid dosages.', 'Metabolism', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39296/', '[1] Haque N, Thrasher K, Werk EE, Jr Knowles HC, Jr Sholiton LJ "Studies on dexamethasone metabolism in man: effect of diphenylhydantoin." J Clin Endocrinol Metab 34 (1972): 44-50[2] Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB "Phenytoin-dexamethasone interaction: a previously unreported observation." Surg Neurol 16 (1981): 23-4[3] Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M "Phenytoin-dexamethasone: a possible drug-drug interaction." JAMA 254 (1985): 2062-3[4] Lackner TE "Interaction of dexamethasone with phenytoin." Pharmacotherapy 11 (1991): 344-7[5] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[6] Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[9] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[10] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12[11] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[14] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[18] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[19] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[20] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[21] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[22] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39241, 'Dexamethasone', 'Methylphenobarbital', 'Moderate', 'Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39297/', '[1] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[2] Sehgal VN, Srivastava G "Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy." Int J Dermatol 27 (1988): 258[3] Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8[4] Hancock KW, Levell MJ "Primidone/dexamethasone interaction." Lancet 2 (1978): 97-8[5] Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32[6] Gambertoglio JG, Holford NH, Kapusnik JE, et al "Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants." Kidney Int 25 (1984): 119-23[7] "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.[8] Young MC, Hughes IA "Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone." Acta Paediatr Scand 80 (1991): 120-4[9] Brooks PM, Buchanan WW, Grove M, Downie WW "Effects of enzyme induction on metabolism of prednisolone." Ann Rheum Dis 35 (1976): 339-43[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39242, 'Dexamethasone', 'Orciprenaline', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Olodaterol, Beclomethasone dipropionate', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39298/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39243, 'Dexamethasone', 'Methadone', 'Major', 'Coadministration with inducers of various CYP450 isoenzymes may decrease the plasma concentrations of methadone, which is metabolized by CYP450 3A4, 2B6, 2C19, 2C9, and 2D6. Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on methadone following the addition of an inducer. Conversely, discontinuation of the inducer may increase methadone plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.', NULL, 'Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers.', NULL, 'Caution is advised if methadone is prescribed with CYP450 2B6, 2C19, 2C9 and/or 3A4 inducers. Pharmacologic response to methadone should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', 'Diamorphine, Acamprosate, Lofexidine, Naltrexone, Disulfiram, Nalmefene, Naltrexone, Tapentadol, Oxymorphone, Dezocine, Opium, More', 'Flunisolide, Betamethasone, Phenylephrine, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39299/', '[1] Tong TG, Pond SM, Kreek MJ, et al "Phenytoin-induced methadone withdrawal." Ann Intern Med 94 (1981): 349-51[2] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM "Rifampin-induced methadone withdrawal." N Engl J Med 294 (1976): 1104-6[3] Raistrick D, Hay A, Wolff K "Methadone maintenance and tuberculosis treatment." BMJ 313 (1996): 925-6[4] Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9[5] Otero MJ, Fuertes A, Sanchez R, Luna G "Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert." AIDS 13 (1999): 1004-5[6] Holmes VF "Rifampin-induced methadone withdrawal in AIDS." J Clin Psychopharmacol 10 (1991): 443-4[7] Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62[8] "Product Information. Diskets (methadone)." Cebert Pharmaceuticals Inc, Birmingham, AL.[9] Bending MR, Skacel PO "Rifampicin and methadone withdrawal." Lancet 1 (1977): 1211[10] Finelli PF "Phenytoin and methadone tolerance." N Engl J Med 294 (1976): 227[11] Liu S-J, Wang RI "Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome." Am J Psychiatry 141 (1984): 1287-8[12] Pinzani V, Faucherre V, Peyriere H, Blayac JP "Methadone withdrawal symptoms with nevirapine and efavirenz." Ann Pharmacother 34 (2000): 405-7[13] Foster DJ, Somogyi AA, Bochner F "Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4." Br J Clin Pharmacol 47 (1999): 403-12[14] Benmebarek M, Devaud C, Gex-Fabry M, et al. "Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone." Clin Pharmacol Ther 76 (2004): 55-63[15] Oda Y, Kharasch ED "Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation." J Pharmacol Exp Ther 298 (2001): 1021-32[16] Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF "Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes." Chem Res Toxicol 9 (1996): 365-73[17] "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[18] "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[19] "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.[20] "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39244, 'Dexamethasone', 'Methazolamide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39300/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39245, 'Dexamethasone', 'Methotrexate', 'Moderate', 'Although they are often used together in clinical practice, limited data suggest that corticosteroids may increase the risk of methotrexate toxicity. Individual cases of severe and fatal bone marrow suppression and fatal systemic moniliasis have been reported.', NULL, 'Close monitoring for signs and symptoms of bone marrow suppression and nephrotoxicity is advisable during concomitant administration.', NULL, 'Close monitoring for signs and symptoms of bone marrow suppression and nephrotoxicity is advisable during concomitant administration. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39301/', '[1] Wolff JE, Hauch H, Kuhl J, Egeler RM, Jurgens H "Dexamethasone increases hepatotoxicity of MTX in children with brain tumors." Anticancer Res 18 (1998): 2895-900[2] Roenigk HH, Fowler-Bergfeld W, Curtis GH "Methotrexate for psoriasis in weekly oral doses." Arch Dermatol 99 (1969): 86-93[3] Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC "Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients." J Rheumatol 20 (1993): 263-7[4] Nesher G, Mates M, Zevin S "Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis." Arthritis Rheum 48 (2003): 571-572', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39246, 'Dexamethasone', 'Methyldopa', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39302/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39247, 'Dexamethasone', 'Methylergometrine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Dinoprostone, Oxytocin', 'Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39303/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39248, 'Dexamethasone', 'Methyltestosterone', 'Moderate', 'Concomitant use of androgens with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and edema due to additive steroidal effects.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Prasterone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39304/', '[1] "Product Information. Oxandrin (oxandrolone)." Bio-Tech, Levittown, PA.[2] "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39249, 'Dexamethasone', 'Methysergide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 'Flunisolide, Betamethasone, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39305/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Methergine (methylergonovine)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[36] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39250, 'Dexamethasone', 'Metocurine', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39306/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39251, 'Dexamethasone', 'Metolazone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39307/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39252, 'Dexamethasone', 'Metoprolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Esmolol', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, Fluorometholone, Minocycline, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39308/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39253, 'Dexamethasone', 'Midazolam', 'Minor', 'Certain corticosteroids may decrease the plasma concentration of some benzodiazepines. The mechanism is related to induction of hepatic cytochrome P450 enzymes responsible for benzodiazepine metabolism. The clinical significance may depend on the dosage and duration of corticosteroid therapy and be of greater importance with oral administration of benzodiazepines.', NULL, '-', NULL, '-', 'Others', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39309/', '[1] Villikka K, Kivisto KT, Neuvonen PJ "The effect of dexamethasone on the pharmacokinetics of triazolam." Pharmacol Toxicol 83 (1998): 135-8[2] Nakajima M, Suzuki T, Sasaki T, Yokoi T, Hosoyamada A, Yamamoto T, Kuroiwa Y "Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans." Ther Drug Monit 21 (1999): 507-13[3] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[7] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[8] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[9] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39254, 'Dexamethasone', 'Midostaurin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of midostaurin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39310/', '[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34[2] "Product Information. Rydapt (midostaurin)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Rydapt (midostaurin)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39255, 'Dexamethasone', 'Mifepristone', 'Major', 'Mifepristone is a potent antiglucocorticoid and may antagonize the effects of corticosteroids. Pharmacokinetically, mifepristone may increase the plasma concentrations of corticosteroids by inhibiting their metabolism via CYP450 3A4. However, the clinical impact has not been studied. Dexamethasone, specifically, may also decrease the blood levels of mifepristone by inducing its metabolism via CYP450 3A4.', NULL, 'The use of mifepristone is considered contraindicated in patients on long-term corticosteroid therapy.', NULL, 'The use of mifepristone is considered contraindicated in patients on long-term corticosteroid therapy. When intended for daily use to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, mifepristone is also contraindicated in those patients who require systemic corticosteroids for serious medical conditions or illnesses, such as immunosuppression after organ transplantation. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).', 'Metabolism, Antagonism', 'Ospemifene, Prasterone, Bazedoxifene', 'Ciclesonide, Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39311/', '[1] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[2] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.[3] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[4] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39256, 'Dexamethasone', 'Miglitol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39312/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39257, 'Dexamethasone', 'Mineral oil', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39313/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39258, 'Dexamethasone', 'Minoxidil', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Deoxycholic acid, Calcium gluconate, Glycopyrronium, Aminobenzoic acid, Caffeine, Dupilumab, Tralokinumab, Povidone-iodine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39314/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39259, 'Dexamethasone', 'Mirabegron', 'Minor', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein may decrease the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme and efflux transporter. No dosage adjustment is recommended when mirabegron is administered in combination with rifampin and probably other CYP450 3A4/P-gp inducers.', NULL, '-', NULL, '-', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39315/', '[1] "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL.[2] "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39260, 'Dexamethasone', 'Mirtazapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of mirtazapine, which is partially metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic response to mirtazapine should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The possibility of diminished therapeutic response to mirtazapine should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to mirtazapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', 'Phenelzine, Desipramine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John''s Wort, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, More', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Betamethasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39316/', '[1] Sitsen JM, Maris FA, Timmer CJ "Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects." Eur J Drug Metab Pharmacokinet 26 (2001): 109-21[2] Timmer CJ, Sitsen JMA, Delbressine LP "Clinical pharmacokinetics of mirtazapine." Clin Pharmacokinet 38 (2000): 461-74[3] Spaans E, Van Den Heuvel MW, Schnabel PG, et al. "Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects." Eur J Clin Pharmacol 58 (2002): 423-9[4] "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[10] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[11] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[12] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[14] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[15] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[16] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[17] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[18] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39261, 'Dexamethasone', 'Mivacurium', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Botulinum toxin type A', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39317/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39262, 'Dexamethasone', 'Modafinil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme.', NULL, 'Pharmacologic response to modafinil or armodafinil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', NULL, 'Pharmacologic response to modafinil or armodafinil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Dose adjustments may be required if an interaction is suspected.', 'Metabolism', 'Amphetamine, Pemoline, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39318/', '[1] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.[2] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[13] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[14] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39263, 'Dexamethasone', 'Moexipril', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39319/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39264, 'Dexamethasone', 'Monomethyl fumarate', 'Moderate', 'The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', NULL, 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.', NULL, 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39320/', '[1] "Product Information. Vumerity (diroximel fumarate)." Alkermes, Inc, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39265, 'Dexamethasone', 'Montelukast', 'Moderate', 'Coadministration with inducers of hepatic CYP450 isoenzymes may decrease the plasma concentrations of montelukast, which is metabolized by CYP450 2C8, 2C9, and 3A4 .', NULL, 'No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers.', NULL, 'No dosage adjustment for montelukast is recommended when used concomitantly with CYP450 inducers. However, clinical monitoring for potentially reduced therapeutic effects may be appropriate, especially for potent inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort.', 'Metabolism', 'Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline', 'Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, Betamethasone, Phenylephrine, Beclomethasone dipropionate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39321/', '[1] "Product Information. Singulair (montelukast)." Merck & Co, Inc, West Point, PA.[2] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[4] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[5] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[6] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39266, 'Dexamethasone', 'Moxifloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39322/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39267, 'Dexamethasone', 'Mumps virus strain B level jeryl lynn live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39323/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39268, 'Dexamethasone', 'Nabumetone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39324/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39269, 'Dexamethasone', 'Nadolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Esmolol', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39325/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39270, 'Dexamethasone', 'Naldemedine', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug.', NULL, 'Caution and monitoring for potential loss of efficacy is recommended with the concomitant use of naldemedine with moderate CYP450 3A4 inducers.', NULL, 'Caution and monitoring for potential loss of efficacy is recommended with the concomitant use of naldemedine with moderate CYP450 3A4 inducers.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39326/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Symproic (naldemedine)." Shionogi USA Inc, Florham Park, NJ.[3] McCarthy CG, Finland M "Absorption and excretion of four penicillins." N Engl J Med 263 (1960): 315-26[4] Neu HC "Antimicrobial activity and human pharmacology of amoxicillin." J Infect Dis 129 (1974): s123-31[5] Klein JO, Sabath LD, Finland M "Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young." Am J Med Sci 245 (1963): 399-411[6] Cronk GA, Wheatley WB, Fellers GF, Albright H "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci 240 (1960): 219-25[7] Neuvonen PJ, Elonen E, Pentikainen PJ "Comparative effect of food on absorption of ampicillin and pivampicillin." J Int Med Res 5 (1977): 71-6[8] Welling PG, Huang H, Koch PA, Madsen PO "Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects." J Pharm Sci 66 (1977): 549-52[9] "Product Information. Symproic (naldemedine)." Shionogi USA Inc, Florham Park, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39271, 'Dexamethasone', 'Nalidixic acid', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39327/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39272, 'Dexamethasone', 'Naloxegol', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4.', NULL, 'The potential for diminished therapeutic effects of naloxegol should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of naloxegol should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39328/', '[1] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[8] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39273, 'Dexamethasone', 'Naproxen', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Bremelanotide, Black cohosh, Cabergoline, Tolazoline, Dimethyl sulfoxide, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39329/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39274, 'Dexamethasone', 'Natalizumab', 'Major', 'Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.', NULL, 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.', NULL, 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39330/', '[1] "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39275, 'Dexamethasone', 'Nateglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39331/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39276, 'Dexamethasone', 'Nebivolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Sacubitril, Esmolol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39332/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39277, 'Dexamethasone', 'Nefazodone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Phenelzine, Desipramine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John''s Wort, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39333/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39278, 'Dexamethasone', 'Nelfinavir', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39334/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39279, 'Dexamethasone', 'Neostigmine', 'Moderate', 'Corticosteroids and adrenocorticotropic agents may diminish the therapeutic effects of acetylcholinesterase inhibitors in myasthenia gravis. The mechanism of interaction is unknown. Marked deterioration in muscle strength has been reported in patients with myasthenia gravis shortly after the initiation of corticosteroid therapy, particularly when high dosages were used.', NULL, 'Corticosteroid therapy should be instituted at relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and in a controlled setting in patients with myasthenia gravis.', NULL, 'Corticosteroid therapy should be instituted at relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and in a controlled setting in patients with myasthenia gravis. Respiratory support should be available, and the dosage should be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached). Dose reductions of the acetylcholinesterase inhibitor may be required as symptoms improve, which often may be delayed and gradual.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Bethanechol, Acetylcholine, Physostigmine, Apraclonidine, Levobunolol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39335/', '[1] Patten BM, Oliver KL, Engel WK "Adverse interaction between steroid hormones and anticholinesterase drugs." Neurology 24 (1974): 442-9[2] Brunner NG, Namba T, Grob D "Corticosteroids in management of severe, generalized myasthenia gravis." Neurology 22 (1972): 603-10[3] Namba T "Corticotropin therapy in patients with myasthenia gravis." Arch Neurol 26 (1972): 144-50[4] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[5] Millikan CH, Eaton LM "Clinical evaluation of ACTH and cortisone in myasthenia gravis." Neurology 1 (1951): 145-52', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39280, 'Dexamethasone', 'Neratinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.', NULL, 'Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided.', NULL, 'Given the potential for reduced efficacy of neratinib, concomitant use with potent or moderate inducers of CYP450 3A4 should generally be avoided. According to some authorities, if the CYP450 3A4 inducer cannot be avoided, the dose of neratinib should be increased to 320 mg once daily. The daily dose of neratinib should not exceed 320 mg. The previous dose of neratinib may be resumed following discontinuation of the CYP450 3A4 inducer.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39336/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7[5] "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA.[6] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39281, 'Dexamethasone', 'Nevirapine', 'Moderate', 'Coadministration with nevirapine may decrease the plasma concentrations and therapeutic efficacy of drugs that are substrates of CYP450 3A4. The proposed mechanism is increased clearance due to nevirapine-mediated induction of CYP450 3A4.', NULL, 'Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates.', NULL, 'Caution is advised if nevirapine is used concomitantly with drugs that are CYP450 3A4 substrates. Dosage adjustments as well as clinical and laboratory monitoring of coadministered drugs should be considered whenever nevirapine is added to or withdrawn from therapy.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39337/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Viramune (nevirapine)." Boehringer-Ingelheim, Ridgefield, CT.[3] "Product Information. Viramune XR (nevirapine)." Boehringer Ingelheim, Ridgefield, CT.[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39282, 'Dexamethasone', 'Nicardipine', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Nimodipine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39338/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39283, 'Dexamethasone', 'Nilotinib', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme. In healthy subjects receiving the potent inducer rifampin (600 mg once daily for 12 days), nilotinib systemic exposure (AUC) was decreased approximately 80%.', NULL, 'Concomitant use of nilotinib with potent CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', NULL, 'Concomitant use of nilotinib with potent CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy. If coadministration is required, a dosage increase for nilotinib may be necessary depending on patient tolerability. The dosage should be reduced to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39339/', '[1] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39284, 'Dexamethasone', 'Nintedanib', 'Major', 'Coadministration with inducers of P-glycoprotein (P-gp) and CYP450 3A4 may decrease the plasma concentrations of nintedanib, which is a substrate of the efflux transporter and a minor substrate of the isoenzyme.', NULL, 'Concomitant use of nintedanib with P-gp and CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', NULL, 'Concomitant use of nintedanib with P-gp and CYP450 3A4 inducers should generally be avoided due to the potential for reduced efficacy.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39340/', '[1] "Product Information. Ofev (nintedanib)." Boehringer Ingelheim, Ridgefield, CT.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] "Product Information. Ofev (nintedanib)." Boehringer Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39285, 'Dexamethasone', 'Nisoldipine', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Nimodipine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39341/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39286, 'Dexamethasone', 'Nitisinone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and therapeutic effects of nitisinone. The proposed mechanism is induction of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in vitro to be metabolized by this isoenzyme.', NULL, 'Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers.', NULL, 'Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inducers. Dosage adjustments as well as clinical and laboratory monitoring of nitisinone should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Metreleptin, More', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39342/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[28] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[34] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39287, 'Dexamethasone', 'Nitroprusside', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39343/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39288, 'Dexamethasone', 'Nivolumab', 'Moderate', 'INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39344/', '[1] Jove M, Vilarino N, Nadal E "Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer." Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. "Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer." J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center." J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al "Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors." ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc "ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp." O 0 (2015):[8] Scott SC, Pennell NA "Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab." J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39289, 'Dexamethasone', 'Norfloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Tinidazole, Cefixime, Secnidazole, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, Povidone-iodine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39345/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39290, 'Dexamethasone', 'Ocrelizumab', 'Moderate', 'The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.', NULL, 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.', NULL, 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39346/', '[1] "Product Information. Ocrevus (ocrelizumab)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39291, 'Dexamethasone', 'Ofloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Tinidazole, Cefixime, Secnidazole, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Sulfamethizole, Trifluridine, Benzylpenicillin, Sulfisoxazole, More', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39347/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39292, 'Dexamethasone', 'Olaparib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of olaparib with potent and moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of olaparib with potent and moderate CYP450 3A4 inducers should generally be avoided. If coadministration with a moderate CYP450 3A4 inducer such as bosentan, dexamethasone, efavirenz, etravirine, modafinil or nafcillin is required, the potential for decreased efficacy of olaparib should be considered.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39348/', '[1] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39293, 'Dexamethasone', 'Oliceridine', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.', NULL, 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', NULL, 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39349/', '[1] "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI.[2] "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[4] "Product Information. Ionsys (fentanyl)." Ortho McNeil Pharmaceutical, Raritan, NJ.[5] "Product Information. Butorphanol Tartrate (butorphanol)." Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[10] "Product Information. Zohydro ER (HYDROcodone)." Zogenix, Inc, San Diego, CA.[11] "Product Information. Olinvyk (oliceridine)." Trevena Inc, Chesterbrook, PA.[12] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39294, 'Dexamethasone', 'Olmesartan', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Sacubitril', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39350/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39295, 'Dexamethasone', 'Omacetaxine mepesuccinate', 'Moderate', 'The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.', NULL, 'Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.', 'Synergism', 'Mupirocin, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39351/', '[1] "Product Information. Synribo (omacetaxine)." Teva Pharmaceuticals USA, North Wales, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39296, 'Dexamethasone', 'Osilodrostat', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or 2B6 may decrease the plasma concentrations of osilodrostat, which is partially metabolized by these isoenzymes. According to the product labeling, multiple CYP450 isoenzymes (CYP450 3A4, 2B6, and 2D6) and UDP-glucuronosyltransferases contribute to osilodrostat metabolism, and no single pathway contributes greater than 25% to the total clearance. Some of the known CYP450 3A4 and 2B6 inducers also induce UDP-glucuronosyltransferases.', NULL, 'The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer.', NULL, 'The potential for diminished pharmacologic effects of osilodrostat should be considered during concomitant use of a CYP450 3A4 and/or 2B6 inducer. An increase in the dosage of osilodrostat may be required. Dosage adjustments should be based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations of their signs and symptoms. A reduction in dosage of osilodrostat may be required if the CYP450 3A4 and/or 2B6 inducer is discontinued during treatment with osilodrostat.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39352/', '[1] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Inc, Lebanon, NJ.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39297, 'Dexamethasone', 'Osimertinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. Reduced therapeutic efficacy of osimertinib may occur. However, no pharmacokinetic data are available from drug interaction studies.', NULL, 'The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of osimertinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39353/', '[1] "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39298, 'Dexamethasone', 'Oxandrolone', 'Moderate', 'Concomitant use of androgens with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and edema due to additive steroidal effects.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', 'Synergism', 'Prasterone', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39354/', '[1] "Product Information. Oxandrin (oxandrolone)." Bio-Tech, Levittown, PA.[2] "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39299, 'Dexamethasone', 'Oxaprozin', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39355/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39300, 'Dexamethasone', 'Oxcarbazepine', 'Moderate', 'Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.', NULL, 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.', 'Metabolism', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39356/', '[1] Rosche J, Froscher W, Abendroth D, Liebel J "Possible oxcarbazepine interaction with cyclosporine serum levels: A single case study." Clin Neuropharmacol 24 (2001): 113-6[2] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC "Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine." Ther Drug Monit 15 (1993): 39-42[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[5] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39301, 'Dexamethasone', 'Oxycodone', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone. Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer. Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.', NULL, 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', NULL, 'Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.', 'Metabolism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Betamethasone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39357/', '[1] "Product Information. Mycobutin (rifabutin)." Pharmacia and Upjohn, Kalamazoo, MI.[2] "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.[4] "Product Information. Ionsys (fentanyl)." Ortho McNeil Pharmaceutical, Raritan, NJ.[5] "Product Information. Butorphanol Tartrate (butorphanol)." Apotex Corporation, Weston, FL.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.[9] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[10] "Product Information. Zohydro ER (HYDROcodone)." Zogenix, Inc, San Diego, CA.[11] "Product Information. Olinvyk (oliceridine)." Trevena Inc, Chesterbrook, PA.[12] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39302, 'Dexamethasone', 'Oxymetholone', 'Moderate', 'Concomitant use of androgens with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and edema due to additive steroidal effects.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Prasterone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39358/', '[1] "Product Information. Oxandrin (oxandrolone)." Bio-Tech, Levittown, PA.[2] "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39303, 'Dexamethasone', 'Paclitaxel (protein-bound)', 'Moderate', 'Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is metabolized by these isoenzymes.', NULL, 'Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.', NULL, 'Clinicians should recognize the potential for interaction with drugs that induce CYP450 2C8 and/or 3A4 and monitor for evidence of reduced therapeutic response to paclitaxel during coadministration.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39359/', '[1] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[2] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[3] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[6] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[11] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[12] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[13] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39304, 'Dexamethasone', 'Palbociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of palbociclib, which is a substrate of the isoenzyme.', NULL, 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4.', NULL, 'The potential for diminished therapeutic effects of palbociclib should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of palbociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and alternative treatment considered if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39360/', '[1] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39305, 'Dexamethasone', 'Pancuronium', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Botulinum toxin type A', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39361/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39306, 'Dexamethasone', 'Panobinostat', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme. The interaction has not been evaluated clinically, but simulations using physiologically-based pharmacokinetic (PBPK) models suggest an approximately 70% decrease in panobinostat systemic exposure in the presence of potent CYP450 3A4 inducers.', NULL, 'Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers.', NULL, 'Caution is advised during concomitant use of panobinostat with CYP450 3A4 inducers. The potential for decreased efficacy of panobinostat should be considered.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39362/', '[1] "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Cerner Multum, Inc. "Australian Product Information." O 0[14] "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39307, 'Dexamethasone', 'Patiromer', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39363/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39308, 'Dexamethasone', 'Pazopanib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of pazopanib, which is primarily metabolized by the isoenzyme.', NULL, 'The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'The use of pazopanib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Alternative treatment lacking CYP450 3A4-inducing activity should be considered in patients receiving pazopanib; otherwise, pazopanib should not be used. Other known CYP450 3A4 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they may interact with pazopanib is unknown.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39364/', '[1] "Product Information. Votrient (pazopanib)." GlaxoSmithKline, Research Triangle Park, NC.[2] "Product Information. Votrient (pazopanib)." GlaxoSmithKline, Research Triangle Park, NC.[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39309, 'Dexamethasone', 'Pegaspargase', 'Moderate', 'INTERVAL: The administration of asparaginase with or immediately preceding prednisone may increase the risk of hyperglycaemia. Concomitant use of asparaginase and corticosteroids may increase the risk of thrombosis or hemorrhage. The proposed mechanism may be related to asparaginase-induced fluctuation of coagulation proteins.', NULL, 'Close monitoring for clinical and laboratory evidence of hyperglycemia and/or altered coagulation is also recommended at baseline and periodically throughout concurrent treatment with corticosteroids and asparaginase-derived products.', NULL, 'Close monitoring for clinical and laboratory evidence of hyperglycemia and/or altered coagulation is also recommended at baseline and periodically throughout concurrent treatment with corticosteroids and asparaginase-derived products. Patients should be advised to promptly report any signs and symptoms of hyperglycemia, bleeding, blood clots or bone pain.', 'Synergism', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39365/', '[1] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[2] "Product Information. Erwinaze (asparaginase Erwinia chrysanthemi)." EUSA Pharma, Newtown, PA.[3] Athale UH, Atkinson HH, Athale A, Nayiager T, Chan A "Effect of asparaginase and dexamethasone on FVIIa-at complex and F1.2 in children with acute lymphoblastic leukemia: evidence of a hypercoagulable state." Blood 126 (2015): 3522[4] Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308[5] Athale UH, Chan AK "Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy." Thromb Res 111 (2003): 199-212[6] Truelove E, Fielding AK, Hunt BJ "The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia." Leukemia 27 (2013): 553-9[7] Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R "Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia." Leukemia 21 (2007): 2377-80[8] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[9] Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Duarte X, Esteves S, Neto AM, Pereira F "Incidence and risk factors for central nervous system thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre study." Br J Haematol 174 (2016): 280-91[13] "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39310, 'Dexamethasone', 'Pembrolizumab', 'Moderate', 'INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations.', NULL, 'The manufacturers'' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39366/', '[1] Jove M, Vilarino N, Nadal E "Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer." Transl Lung Cancer Res 8 (2019): S364-8[2] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[4] Arbour KC, Mezquita L, Long N, et al. "Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer." J Clin Oncol 36 (2018): 2872-2878[5] Horvat TZ, Adel NG, Dand TO, et.al "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center." J Clin Oncol 33 (2015): 3193-8[6] Fuca G, Galli G, Poggi M, et.al "Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors." ESMO Open 4 (2019): e000457[7] Cerner Multum, Inc "ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp." O 0 (2015):[8] Scott SC, Pennell NA "Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab." J Thorac Oncol 13 (2018): 1771-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39311, 'Dexamethasone', 'Pemigatinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.', NULL, 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.', NULL, 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inducers should be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39367/', '[1] "Product Information. Pemazyre (pemigatinib)." Incyte Corporation, Wilmington, DE.[2] "Product Information. Pemazyre (pemigatinib)." Incyte Corporation, Wilmington, DE.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39312, 'Dexamethasone', 'Penbutolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Esmolol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39368/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39313, 'Dexamethasone', 'Pentobarbital', 'Moderate', 'Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39369/', '[1] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[2] Sehgal VN, Srivastava G "Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy." Int J Dermatol 27 (1988): 258[3] Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8[4] Hancock KW, Levell MJ "Primidone/dexamethasone interaction." Lancet 2 (1978): 97-8[5] Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32[6] Gambertoglio JG, Holford NH, Kapusnik JE, et al "Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants." Kidney Int 25 (1984): 119-23[7] "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.[8] Young MC, Hughes IA "Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone." Acta Paediatr Scand 80 (1991): 120-4[9] Brooks PM, Buchanan WW, Grove M, Downie WW "Effects of enzyme induction on metabolism of prednisolone." Ann Rheum Dis 35 (1976): 339-43[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39314, 'Dexamethasone', 'Perampanel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of perampanel, which is primarily metabolized by the isoenzyme. The interaction has been reported with known CYP450 3A4 inducers such as carbamazepine, oxcarbazepine, and phenytoin.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', NULL, 'According to the manufacturer, concomitant use of perampanel with strong CYP450 3A4 inducers should be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39370/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39315, 'Dexamethasone', 'Perindopril', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39371/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39316, 'Dexamethasone', 'Pexidartinib', 'Moderate', 'Coadministration of pexidartinib with moderate CYP450 3A4 inducers may decrease the plasma concentrations and therapeutic effects of pexidartinib. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of pexidartinib.', NULL, 'Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers.', NULL, 'Caution is advised if pexidartinib is used with moderate CYP450 3A4 inducers. It is unknown if pexidartinib will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inducer. Clinical and laboratory monitoring of pexidartinib should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39372/', '[1] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39317, 'Dexamethasone', 'Phenobarbital', 'Moderate', 'Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39373/', '[1] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[2] Sehgal VN, Srivastava G "Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy." Int J Dermatol 27 (1988): 258[3] Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8[4] Hancock KW, Levell MJ "Primidone/dexamethasone interaction." Lancet 2 (1978): 97-8[5] Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32[6] Gambertoglio JG, Holford NH, Kapusnik JE, et al "Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants." Kidney Int 25 (1984): 119-23[7] "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.[8] Young MC, Hughes IA "Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone." Acta Paediatr Scand 80 (1991): 120-4[9] Brooks PM, Buchanan WW, Grove M, Downie WW "Effects of enzyme induction on metabolism of prednisolone." Ann Rheum Dis 35 (1976): 339-43[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39318, 'Dexamethasone', 'Phenolphthalein', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39374/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39319, 'Dexamethasone', 'Phenylbutazone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39375/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39320, 'Dexamethasone', 'Phenytoin', 'Moderate', 'Phenytoin and other hydantoins may induce the CYP450 3A4 hepatic metabolism of corticosteroids and increase their clearance and decrease their half-lives, possibly reducing their therapeutic efficacy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy.', NULL, 'Patients should be closely monitored for clinical and laboratory evidence of reduced corticosteroid effects and changes in phenytoin concentrations during concomitant therapy. Some patients may require increased corticosteroid dosages.', 'Metabolism', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39376/', '[1] Haque N, Thrasher K, Werk EE, Jr Knowles HC, Jr Sholiton LJ "Studies on dexamethasone metabolism in man: effect of diphenylhydantoin." J Clin Endocrinol Metab 34 (1972): 44-50[2] Lawson LA, Blouin RA, Smith RB, Rapp RP, Young AB "Phenytoin-dexamethasone interaction: a previously unreported observation." Surg Neurol 16 (1981): 23-4[3] Wong DD, Longenecker RG, Liepman M, Baker S, LaVergne M "Phenytoin-dexamethasone: a possible drug-drug interaction." JAMA 254 (1985): 2062-3[4] Lackner TE "Interaction of dexamethasone with phenytoin." Pharmacotherapy 11 (1991): 344-7[5] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[6] Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[9] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[10] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12[11] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[14] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[18] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[19] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[20] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[21] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[22] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39321, 'Dexamethasone', 'Pimavanserin', 'Moderate', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme.', NULL, 'Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.', NULL, 'Coadministration of potent or moderate CYP450 3A4 inducers with pimavanserin should be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Mesoridazine, Methotrimeprazine, Asenapine, Promazine, Thiothixene, Thioridazine, Pimozide, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39377/', '[1] "Product Information. Nuplazid (pimavanserin)." Accelis Pharma, East Windsor, NJ.[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39322, 'Dexamethasone', 'Pindolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Esmolol', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39378/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39323, 'Dexamethasone', 'Pipecuronium', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Botulinum toxin type A', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39379/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39324, 'Dexamethasone', 'Pirbuterol', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mupirocin, Mometasone furoate, Vitamin A, Hyaluronic acid, Ipratropium, Nedocromil, Mometasone furoate, Fluorometholone, Minocycline, Clindamycin, Vitamin A, More', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Olodaterol, Beclomethasone dipropionate', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39380/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39325, 'Dexamethasone', 'Piroxicam', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide, Cortisone, Betamethasone, Fluorometholone, Dexamethasone', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39381/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39326, 'Dexamethasone', 'Pitolisant', 'Moderate', 'Concomitant use of pitolisant with NSAIDs and/or corticosteroids may increase the risk of gastrointestinal adverse effects such as dyspepsia, abdominal pain or discomfort, and gastritis due to potential additive irritant effects on the gastrointestinal mucosa. However, the effects were described as mostly mild to moderate in severity. Data are not available on the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if pitolisant is used in combination with NSAIDs and/or corticosteroids, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly or debilitated patients.', NULL, 'Caution is advised if pitolisant is used in combination with NSAIDs and/or corticosteroids, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly or debilitated patients. If concomitant therapy is required, patients should be advised to report signs and symptoms of adverse GI effects, including abdominal pain or discomfort, dyspepsia, gastroesophageal reflux disease, gastritis, or the appearance of black, tarry stools.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Deutetrabenazine, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39382/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39327, 'Dexamethasone', 'Poliovirus type 1 antigen (formaldehyde inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39383/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39328, 'Dexamethasone', 'Polyethylene glycol (3350)', 'Moderate', 'The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy. Corticosteroids promote the retention of sodium and water and the excretion of potassium. Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', NULL, 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39384/', '[1] Chin RL "Laxative-induced hypokalemia." Ann Emerg Med 32 (1998): 517-8[2] Blumenthal M, Goldberg A, Brinckmann J, eds. "Herbal Medicine: Expanded Commission E Monographs." Newton, MA: Integrative Medicine Communications (2000):[3] Muller-Lissner SA "Adverse effects of laxatives: fact and fiction." Pharmacology 47 (1993): 138-45[4] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[5] Swartz SL, Dluhy RG "Corticosteroids: clinical pharmacology and therapeutic use." Drugs 16 (1978): 238-55[6] Lieberman P, Patterson R, Kunske R "Complications of long-term steroid therapy for asthma." J Allergy Clin Immunol 49 (1972): 329-36[7] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39329, 'Dexamethasone', 'Polythiazide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39385/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39330, 'Dexamethasone', 'Ponatinib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.', NULL, 'Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'Coadministration of ponatinib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided unless the benefit outweighs the potential risk of ponatinib underexposure. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is required, close monitoring for signs of reduced therapeutic efficacy is advised. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, etravirine, nafcillin, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with ponatinib is unknown.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39386/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.[4] "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39331, 'Dexamethasone', 'Posaconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39387/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39332, 'Dexamethasone', 'Pralsetinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A may decrease the plasma concentrations of pralsetinib which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of pralsetinib should be considered during coadministration with moderate CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39388/', '[1] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation, Cambridge, MA.[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation, Cambridge, MA.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39333, 'Dexamethasone', 'Pramlintide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39389/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39334, 'Dexamethasone', 'Praziquantel', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of praziquantel, which is a substrate of the isoenzyme.', NULL, 'Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved.', NULL, 'Concomitant use of praziquantel with CYP450 3A4 inducers should generally be avoided, since therapeutically effective blood levels of praziquantel may not be achieved. Alternative agents for schistosomiasis should be considered whenever possible in patients receiving treatment with a CYP450 3A4 inducer. Otherwise, clinical response to praziquantel should be closely monitored.', 'Metabolism', 'Triclabendazole, Oxamniquine', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39390/', '[1] Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M "Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers." Clin Pharmacol Ther 72 (2002): 505-13[2] Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Biltricide (praziquantel)." Bayer, West Haven, CT.[5] Castro N, Medina R, Sotelo J, Jung H "Bioavailability of praziquantel increases with concomitant administration of food." Antimicrob Agents Chemother 44 (2000): 2903-4[6] Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J "Interaction between grapefruit juice and praziquantel in humans." Antimicrob Agents Chemother 46 (2002): 1614-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39335, 'Dexamethasone', 'Prazosin', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39391/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39336, 'Dexamethasone', 'Pretomanid', 'Major', 'Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme.', NULL, 'The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided.', NULL, 'The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Aminosalicylic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39392/', '[1] "Product Information. Pretomanid (pretomanid)." The Global Alliance for TB Drug Development, New York, NY.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Pretomanid (pretomanid)." The Global Alliance for TB Drug Development, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39337, 'Dexamethasone', 'Primidone', 'Moderate', 'Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39393/', '[1] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[2] Sehgal VN, Srivastava G "Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy." Int J Dermatol 27 (1988): 258[3] Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8[4] Hancock KW, Levell MJ "Primidone/dexamethasone interaction." Lancet 2 (1978): 97-8[5] Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32[6] Gambertoglio JG, Holford NH, Kapusnik JE, et al "Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants." Kidney Int 25 (1984): 119-23[7] "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.[8] Young MC, Hughes IA "Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone." Acta Paediatr Scand 80 (1991): 120-4[9] Brooks PM, Buchanan WW, Grove M, Downie WW "Effects of enzyme induction on metabolism of prednisolone." Ann Rheum Dis 35 (1976): 339-43[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39338, 'Dexamethasone', 'Propranolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Esmolol', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39394/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39339, 'Dexamethasone', 'Pyridostigmine', 'Moderate', 'Corticosteroids and adrenocorticotropic agents may diminish the therapeutic effects of acetylcholinesterase inhibitors in myasthenia gravis. The mechanism of interaction is unknown. Marked deterioration in muscle strength has been reported in patients with myasthenia gravis shortly after the initiation of corticosteroid therapy, particularly when high dosages were used.', NULL, 'Corticosteroid therapy should be instituted at relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and in a controlled setting in patients with myasthenia gravis.', NULL, 'Corticosteroid therapy should be instituted at relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and in a controlled setting in patients with myasthenia gravis. Respiratory support should be available, and the dosage should be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached). Dose reductions of the acetylcholinesterase inhibitor may be required as symptoms improve, which often may be delayed and gradual.', 'Antagonism', 'Bethanechol', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39395/', '[1] Patten BM, Oliver KL, Engel WK "Adverse interaction between steroid hormones and anticholinesterase drugs." Neurology 24 (1974): 442-9[2] Brunner NG, Namba T, Grob D "Corticosteroids in management of severe, generalized myasthenia gravis." Neurology 22 (1972): 603-10[3] Namba T "Corticotropin therapy in patients with myasthenia gravis." Arch Neurol 26 (1972): 144-50[4] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[5] Millikan CH, Eaton LM "Clinical evaluation of ACTH and cortisone in myasthenia gravis." Neurology 1 (1951): 145-52', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39340, 'Dexamethasone', 'Quetiapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.', NULL, 'Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary.', NULL, 'Pharmacologic response to quetiapine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the quetiapine dosage adjusted as necessary. Patients should be advised to notify their physician if their symptoms worsen or their condition changes.', 'Metabolism', 'Mesoridazine, Methotrimeprazine, Asenapine, Promazine, Thiothixene, Thioridazine, Pimozide, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More', 'Mupirocin, Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Olopatadine, Cromoglicic acid, Hyaluronic acid, Betamethasone, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39396/', '[1] "Quetiapine for schizophrenia." Med Lett Drugs Ther 39 (1997): 117-8[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Wong YWJ, Yeh C, Thyrum PT "The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine." J Clin Psychopharmacol 21 (2001): 89-93[4] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[5] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB "Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics." Br J Clin Pharmacol 61 (2006): 58-69[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[9] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39341, 'Dexamethasone', 'Quinapril', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39397/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39342, 'Dexamethasone', 'Quinestrol', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39398/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39343, 'Dexamethasone', 'Quinine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St.', NULL, 'Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St. John''s wort. The possibility of diminished therapeutic efficacy should be considered.', 'Metabolism', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Pyrimethamine, Tafenoquine, Halofantrine, Primaquine, Proguanil, More', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39399/', '[1] Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3[2] "Product Information. Qualaquin (quinine)." AR Scientific Inc, Philadelphia, PA.[3] Twum-Barima Y, Carruthers SG "Quinidine-rifampin interaction." N Engl J Med 304 (1981): 1466-9[4] "Product Information. Rifadin (rifampin)." Hoechst Marion-Roussel Inc, Kansas City, MO.[5] Pukrittayakamee S, Prakongpan S, Wanwimolruk S, Clemens R, Looareesuwan S, White NJ "Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria." Antimicrob Agents Chemother 47 (2003): 1509-1513[6] Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S "Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man." Br J Clin Pharmacol 40 (1995): 87-91[7] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[17] "Product Information. Qualaquin (quinine)." AR Scientific Inc, Philadelphia, PA.[18] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S "Grapefruit juice has no effect on quinine pharmacokinetics." Eur J Clin Pharmacol 55 (1999): 393-8[19] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S "Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine." Br J Clin Pharmacol 43 (1997): 245-52[20] Hermans K, Stockman D, Van den Branden F "Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome." Am J Med 114 (2003): 511-2[21] Mirghani RA, Yasar U, Zheng T, et al "Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway." Drug Metab Dispos 30 (2002): 1368-71', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39344, 'Dexamethasone', 'Racepinephrine', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39400/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39345, 'Dexamethasone', 'Raltegravir', 'Minor', 'Coadministration with inducers of uridine diphosphate glucuronosyltransferase (UGT) 1A1 may reduce the plasma concentrations of raltegravir, which is primarily metabolized by UGT1A1-mediated glucuronidation. The impact of other potent inducers of drug-metabolizing enzymes such as carbamazepine, phenytoin, and phenobarbital on UGT1A1 is unknown. Other, less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, dexamethasone, St. John''s Wort, pioglitazone) may be used with the recommended dosage of raltegravir.', NULL, '-', NULL, '-', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39401/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] "Product Information. Isentress (raltegravir)." Merck & Company Inc, West Point, PA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[11] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[14] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39346, 'Dexamethasone', 'Ramelteon', 'Moderate', 'Coadministration with inducers of CYP450 isoenzymes may decrease the plasma concentrations and pharmacologic effects of ramelteon, which is metabolized by CYP450 1A2 and, to a lesser extent, by CYP450 3A4 and the 2C subfamily of isoenzymes.', NULL, 'The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The efficacy of ramelteon may be reduced when prescribed with potent inducers of CYP450 isoenzymes such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifampin, and St. John''s wort. Other known inducers include aminoglutethimide, bexarotene, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, mitotane, modafinil, nafcillin, nevirapine, rifabutin, rifapentine, barbiturates and various other anticonvulsants, although the extent to which they interact with ramelteon is unknown.', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39402/', '[1] "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America, Lincolnshire, IL.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America, Lincolnshire, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39347, 'Dexamethasone', 'Ramipril', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39403/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39348, 'Dexamethasone', 'Ranolazine', 'Major', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme.', NULL, 'The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St.', NULL, 'The manufacturer considers the use of ranolazine to be contraindicated in patients taking potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, primidone (partially metabolized to phenobarbital), rifamycins, and St. John''s wort. The extent to which other, less potent CYP450 3A4 inducers may interact with ranolazine is unknown. Caution is advised if they are used with ranolazine.', 'Metabolism', 'Adenosine, Regadenoson, Ubidecarenone', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39404/', '[1] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[2] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39349, 'Dexamethasone', 'Rapacuronium', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39405/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39350, 'Dexamethasone', 'Regorafenib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of regorafenib.', NULL, 'The use of regorafenib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The use of regorafenib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and St. John''s wort should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39406/', '[1] "Product Information. Stivarga (regorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Stivarga (regorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39351, 'Dexamethasone', 'Relugolix', 'Moderate', 'Coadministration with dual inducers of CYP450 3A4 and P-glycoprotein (P-gp) may decrease the plasma concentrations of relugolix. In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8. Relugolix is also a substrate for intestinal P-gp.', NULL, 'The potential for diminished pharmacologic effects of relugolix should be considered during coadministration with dual CYP450 3A4 and P-gp inducers.', NULL, 'The potential for diminished pharmacologic effects of relugolix should be considered during coadministration with dual CYP450 3A4 and P-gp inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Norethisterone, Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Degarelix, Abarelix, Nilutamide, Abiraterone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39407/', '[1] "Product Information. Orgovyx (relugolix)." Myovant Sciences, Inc., Brisbane, CA.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39352, 'Dexamethasone', 'Repaglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39408/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39353, 'Dexamethasone', 'Reserpine', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39409/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39354, 'Dexamethasone', 'Ribociclib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ribociclib, which is a substrate of the isoenzyme.', NULL, 'The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine.', NULL, 'The potential for diminished therapeutic effects of ribociclib should be considered when prescribed with inducers of CYP450 3A4, particularly moderate inducers including efavirenz and nevirapine. Pharmacologic effects of ribociclib should be monitored more closely whenever an inducer is added to or withdrawn from therapy. Alternative treatment may be required if an interaction is suspected.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39410/', '[1] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[5] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39355, 'Dexamethasone', 'Rifabutin', 'Moderate', 'Rifampin may induce the hepatic metabolism of corticosteroids, possibly reducing their therapeutic effect. The elimination half-life of corticosteroids has been shown to be reduced by up to 45% when rifampin is coadministered.', NULL, 'Patients should be monitored for altered corticosteroid effects.', NULL, 'Patients should be monitored for altered corticosteroid effects. Dosage increases may be necessary. Two- to threefold increases in prednisolone dosage have been recommended.', 'Metabolism', 'Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Aminosalicylic acid, Tinidazole, Bismuth subcitrate potassium, Dexlansoprazole, Esomeprazole', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39411/', '[1] Lee KH, Shin JG, Chong WS, Kim S, Lee JS, Jang IJ, Shin SG "Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin." Eur J Clin Pharmacol 45 (1993): 287-9[2] Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992): 47-65[3] Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6[4] Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8[5] Powell-Jackson PR, Gray BJ, Heaton RW, et al "Adverse effect of rifampicin administration on steroid-dependent asthma." Am Rev Respir Dis 128 (1983): 307-10[6] McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ "Rifampicin reduces effectiveness and bioavailability of prednisolone." Br Med J 286 (1983): 923-5[7] Bergrem H, Refvem OK "Altered prednisolone pharmacokinetics in patients treated with rifampicin." Acta Med Scand 213 (1983): 339-43', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39356, 'Dexamethasone', 'Rifampicin', 'Moderate', 'Rifampin may induce the hepatic metabolism of corticosteroids, possibly reducing their therapeutic effect. The elimination half-life of corticosteroids has been shown to be reduced by up to 45% when rifampin is coadministered.', NULL, 'Patients should be monitored for altered corticosteroid effects.', NULL, 'Patients should be monitored for altered corticosteroid effects. Dosage increases may be necessary. Two- to threefold increases in prednisolone dosage have been recommended.', 'Metabolism', 'Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Aminosalicylic acid', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39412/', '[1] Lee KH, Shin JG, Chong WS, Kim S, Lee JS, Jang IJ, Shin SG "Time course of the changes in prednisolone pharmacokinetics after co-administration or discontinuation of rifampin." Eur J Clin Pharmacol 45 (1993): 287-9[2] Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992): 47-65[3] Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6[4] Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8[5] Powell-Jackson PR, Gray BJ, Heaton RW, et al "Adverse effect of rifampicin administration on steroid-dependent asthma." Am Rev Respir Dis 128 (1983): 307-10[6] McAllister WA, Thompson PJ, Al-Habet SM, Rogers HJ "Rifampicin reduces effectiveness and bioavailability of prednisolone." Br Med J 286 (1983): 923-5[7] Bergrem H, Refvem OK "Altered prednisolone pharmacokinetics in patients treated with rifampicin." Acta Med Scand 213 (1983): 339-43', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39357, 'Dexamethasone', 'Rifapentine', 'Moderate', 'Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine. Enzyme activities may be induced within 4 days of the first dose and return to normal 14 days after discontinuation of rifapentine.', NULL, 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.', NULL, 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.', 'Metabolism', 'Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Aminosalicylic acid', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39413/', '[1] Thijssen HH, Flin ois JP, Beaune PH "Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes." Drug Metab Dispos 28 (2000): 1284-90[2] "Product Information. Priftin (rifapentine)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39358, 'Dexamethasone', 'Rilonacept', 'Moderate', 'The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.', NULL, 'The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.', NULL, 'The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39414/', '[1] "Product Information. Kineret (anakinra)." Amgen, Thousand Oaks, CA.[2] "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39359, 'Dexamethasone', 'Rilpivirine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of rilpivirine with potent CYP450 3A4 inducers is considered contraindicated.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of rilpivirine with potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39415/', '[1] "Product Information. Edurant (rilpivirine)." Tibotec Pharmaceuticals, Titusville, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):[4] "Product Information. Edurant (rilpivirine)." Tibotec Pharmaceuticals, Titusville, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39360, 'Dexamethasone', 'Rimegepant', 'Major', 'Coadministration with strong or moderate inducers of CYP450 3A4 may significantly reduce the plasma concentrations and therapeutic effects of rimegepant, which is primarily metabolized by the isoenzyme.', NULL, 'Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.', NULL, 'Coadministration of rimegepant with strong or moderate inducers of CYP450 3A4 should be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39416/', '[1] "Product Information. Nurtec ODT (rimegepant)." Biohaven Pharmaceuticals, New Haven, CT.[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Nurtec ODT (rimegepant)." Biohaven Pharmaceuticals, New Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39361, 'Dexamethasone', 'Riociguat', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of riociguat, which is partially metabolized by the isoenzyme.', NULL, 'The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers.', NULL, 'The potential for diminished therapeutic effects of riociguat should be considered when prescribed in combination with CYP450 3A4 inducers. Patients should be closely monitored, and the dosage of riociguat adjusted as necessary. Data are not available to guide dosing of riociguat when coadministered with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort. Alternative agents with no or minimal CYP450 3A4-inducing activity should be considered whenever possible.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Ambrisentan, Metyrosine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39417/', '[1] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.[2] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[5] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[6] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[9] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39362, 'Dexamethasone', 'Ripretinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations and anti-tumor activities of ripretinib and its active metabolite (DP-5439). The proposed mechanism is induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.', NULL, 'Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer.', NULL, 'Until more information is available, caution is advised when ripretinib is used with a CYP450 3A4 inducer. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the ripretinib dosage adjusted as necessary. Patients should be monitored for loss of anti-tumor activity.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39418/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Qinlock (ripretinib)." Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[33] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39363, 'Dexamethasone', 'Ritodrine', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Bremelanotide, Black cohosh, Cabergoline', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39419/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39364, 'Dexamethasone', 'Ritonavir', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39420/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39365, 'Dexamethasone', 'Rivaroxaban', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of rivaroxaban, which is a substrate of the isoenzyme as well as the efflux transporter.', NULL, 'Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein.', NULL, 'Caution is advised if rivaroxaban is used in combination with inducers of CYP450 3A4 and/or P-glycoprotein. Pharmacologic effects of rivaroxaban should be monitored more closely whenever the inducer is added to or withdrawn from therapy.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Betrixaban, Cilostazol, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Streptokinase, Eptifibatide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39421/', '[1] "Product Information. Xarelto (rivaroxaban)." Bayer Inc, Toronto, IA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39366, 'Dexamethasone', 'Rocuronium', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Botulinum toxin type A', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39422/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39367, 'Dexamethasone', 'Rofecoxib', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39423/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39368, 'Dexamethasone', 'Roflumilast', 'Moderate', 'The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.', NULL, 'According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.', NULL, 'According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39424/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Daxas (roflumilast)." Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Daxas (roflumilast)." Nycomed Inc, Princeton, NJ.[5] "Product Information. Daliresp (roflumilast)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39369, 'Dexamethasone', 'Rolapitant', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of rolapitant, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of rolapitant should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Nabilone, Dronabinol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39425/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Varubi (rolapitant)." Tesaro Inc., Waltham, MA.[3] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39370, 'Dexamethasone', 'Romidepsin', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may increase the plasma concentrations of romidepsin. The exact mechanism of interaction has not been established, particularly since romidepsin is a substrate of CYP450 3A4, and induction of the isoenzyme would be expected to reduce its plasma concentration.', NULL, 'The use of romidepsin in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'The use of romidepsin in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided if possible. Alternative treatment lacking CYP450 3A4-inducing activity should be considered in patients receiving romidepsin. If concomitant use is required, patients should be closely monitored for development of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39426/', '[1] "Product Information. Istodax (romidepsin)." Gloucester Pharmaceuticals, Cambridge, MA.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39371, 'Dexamethasone', 'Romosozumab', 'Moderate', 'Coadministration of romosozumab with bisphosphonates, denosumab, angiogenesis inhibitors, or corticosteroids may increase the risk of developing osteonecrosis of the jaw (ONJ). The condition can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. Other risk factors for ONJ include cancer, chemotherapy, radiotherapy to the head and neck, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy.', NULL, 'Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw.', NULL, 'Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw. A routine oral examination should be performed by the prescriber prior to initiation of romosozumab treatment. For patients requiring invasive dental procedures, clinical judgment and risk-benefit assessment should guide the management plan of each patient based on their clinical circumstances. Patients should be advised to seek medical attention if they experience signs and symptoms of ONJ, such as: pain in the mouth, teeth, or jaw; swelling or sores inside the mouth; numbness or a feeling of heaviness in the jaw; loosening of a tooth; or exposure of bone in the jaw.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tiludronic acid, Vosoritide, Etidronic acid, Cholecalciferol, Burosumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39427/', '[1] "Product Information. Evenity (romosozumab)." Amgen USA, Thousand Oaks, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39372, 'Dexamethasone', 'Rosiglitazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Mometasone, Vitamin A, Fluticasone, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Beclomethasone dipropionate, Fluorometholone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39428/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39373, 'Dexamethasone', 'Rotavirus vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39429/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39374, 'Dexamethasone', 'Rubella virus vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39430/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39375, 'Dexamethasone', 'Rucaparib', 'Moderate', 'Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.', NULL, 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39431/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39376, 'Dexamethasone', 'Ruxolitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ruxolitinib, which is primarily metabolized by the isoenzyme.', NULL, 'No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer.', NULL, 'No dosage adjustment is recommended when ruxolitinib is coadministered with a CYP450 3A4 inducer. However, patients should be closely monitored and the dose titrated based on safety and efficacy.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39432/', '[1] "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE.[2] "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39377, 'Dexamethasone', 'Salmeterol', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Olodaterol, Beclomethasone dipropionate', 'Mupirocin, Mometasone furoate, Vitamin A, Hyaluronic acid, Ipratropium, Nedocromil, Mometasone furoate, Fluorometholone, Minocycline, Vitamin A, Isotretinoin, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39433/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39378, 'Dexamethasone', 'Salsalate', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', NULL, 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', NULL, 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Excretion', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Ziconotide, Methoxyflurane', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39434/', '[1] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[2] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34[3] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L "Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis." Ther Drug Monit 9 (1987): 177-9[4] Edelman J, Potter JM, Hackett LP "The effect of intra-articular steroids on plasma salicylate concentrations." Br J Clin Pharmacol 21 (1986): 301-7[5] Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39379, 'Dexamethasone', 'Saquinavir', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39435/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39380, 'Dexamethasone', 'Pfizer-BioNTech Covid-19 Vaccine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39436/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39381, 'Dexamethasone', 'Saxagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39437/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39382, 'Dexamethasone', 'Secobarbital', 'Moderate', 'Barbiturates may decrease the plasma concentrations and systemic effects of both endogenous and exogenous corticosteroids. The mechanism is accelerated corticosteroid metabolism due to induction of the CYP450 3A4 enzymatic pathway by barbiturates.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with a barbiturate may require higher dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever a barbiturate is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39438/', '[1] Stjernholm MR, Katz FH "Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate." J Clin Endocrinol Metab 41 (1975): 887-93[2] Sehgal VN, Srivastava G "Corticosteroid-unresponsive pemphigus vulgaris following antiepileptic therapy." Int J Dermatol 27 (1988): 258[3] Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8[4] Hancock KW, Levell MJ "Primidone/dexamethasone interaction." Lancet 2 (1978): 97-8[5] Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32[6] Gambertoglio JG, Holford NH, Kapusnik JE, et al "Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants." Kidney Int 25 (1984): 119-23[7] "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.[8] Young MC, Hughes IA "Loss of therapeutic control in congenital adrenal hyperplasia due to interaction between dexamethasone and primidone." Acta Paediatr Scand 80 (1991): 120-4[9] Brooks PM, Buchanan WW, Grove M, Downie WW "Effects of enzyme induction on metabolism of prednisolone." Ann Rheum Dis 35 (1976): 339-43[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39383, 'Dexamethasone', 'Selpercatinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of selpercatinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Ipratropium, Cromoglicic acid, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39439/', '[1] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39384, 'Dexamethasone', 'Selumetinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may decrease the plasma concentrations of selumetinib, which is primarily metabolized by CYP450 3A4 and to a lesser extent by CYP450 2C19, 1A2, 2C9, 2E1, and 3A5. Selumetinib also undergoes glucuronidation by UGT1A1 and UGT1A3.', NULL, 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of selumetinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39440/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] "Multum Information Services, Inc. Expert Review Panel"[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39385, 'Dexamethasone', 'Semaglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39441/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39386, 'Dexamethasone', 'Sildenafil', 'Moderate', 'Theoretically, coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of sildenafil, which is primarily metabolized by the isoenzyme. The possibility of a diminished therapeutic response to sildenafil should be considered.', NULL, 'Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.', NULL, 'Pharmacologic response to sildenafil should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the sildenafil dosage adjusted if necessary.', 'Metabolism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39442/', '[1] "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Hyland R, Roe GH, Jones BC, Smith DA "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol 51 (2001): 239-48[3] Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ "In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions." Drug Metab Disposition 28 (2000): 392-7[4] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[5] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39387, 'Dexamethasone', 'Silodosin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of silodosin, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', NULL, 'The potential for diminished pharmacologic effects of silodosin should be considered during coadministration with CYP450 3A4 and/or P-gp inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39443/', '[1] "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals, Corona, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals, Corona, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39388, 'Dexamethasone', 'Simeprevir', 'Major', 'Coadministration with potent and some moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of simeprevir, which is primarily metabolized by the isoenzyme.', NULL, 'The use of simeprevir in combination with potent and some moderate CYP450 3A4 inducers such as carbamazepine, dexamethasone, efavirenz, enzalutamide, eslicarbazepine, etravirine, nevirapine, oxcarbazepine, phenobarbital, phenytoin, primidone, rifamycins, St.', NULL, 'The use of simeprevir in combination with potent and some moderate CYP450 3A4 inducers such as carbamazepine, dexamethasone, efavirenz, enzalutamide, eslicarbazepine, etravirine, nevirapine, oxcarbazepine, phenobarbital, phenytoin, primidone, rifamycins, St. John''s wort, and tipranavir should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39444/', '[1] "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals, Titusville, NJ.[2] "Product Information. Sustiva (efavirenz)." DuPont Pharmaceuticals, Wilmington, DE.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals, Titusville, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39389, 'Dexamethasone', 'Siponimod', 'Major', 'Coadministration with drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 may decrease the plasma concentrations of siponimod, which is primarily metabolized by these isoenzymes. This interaction includes concomitant use of siponimod with a moderate CYP450 2C9/strong CYP450 3A4 dual inducer or a moderate CYP450 2C9 inducer in combination with a separate strong CYP450 3A4 inducer.', NULL, 'Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.', NULL, 'Concomitant use of siponimod and drugs that cause moderate induction of CYP450 2C9 and strong induction of CYP450 3A4 (e.g., carbamazepine, enzalutamide, rifampin) is not recommended for all patients. Concomitant use of siponimod and moderate or strong CYP450 3A4 inducers (e.g., apalutamide, bosentan, dabrafenib, dexamethasone, efavirenz, eslicarbazepine, etravirine, fosphenytoin, lorlatinib, lumacaftor, mitotane, modafinil, nafcillin, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, St. John''s wort) is not recommended for patients with CYP450 2C9*1/*3 and *2/*3 genotypes.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39445/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39390, 'Dexamethasone', 'Sipuleucel-T', 'Moderate', 'Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.', NULL, 'Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.', NULL, 'Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39446/', '[1] "Product Information. Provenge (sipuleucel-T)." Dendreon Corporation, Seattle, WA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39391, 'Dexamethasone', 'Sirolimus', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.', NULL, 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39447/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Hooks MA "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother 28 (1994): 501-11[6] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[7] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39392, 'Dexamethasone', 'Sitagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Guar gum', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39448/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39393, 'Dexamethasone', 'Smallpox (Vaccinia) Vaccine, Live', 'Major', 'The administration of live virus smallpox vaccine during corticosteroid therapy may be associated with a risk of localized or disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients receiving high dosages of systemic corticosteroids and those who are systemically immunosuppressed due to long-term topical or aerosol use of corticosteroids may also have an increased risk of neurologic reactions to vaccines and decreased or suboptimal immunologic response due to antibody inhibition. The risk of ocular complications may be increased in patients who are using ophthalmic corticosteroids.', NULL, 'Routine nonemergency smallpox vaccination is considered a relative contraindication in patients receiving immunosuppressive corticosteroid therapy or ophthalmic corticosteroids.', NULL, 'Routine nonemergency smallpox vaccination is considered a relative contraindication in patients receiving immunosuppressive corticosteroid therapy or ophthalmic corticosteroids. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored. The interval depends on the dosage, duration, and route of corticosteroid therapy administered, but may be at least 3 months in most cases of systemic corticosteroid use. In patients who have recently been vaccinated, high-dose corticosteroid therapy should not be initiated for at least 2 weeks. Household contacts of immunosuppressed patients should also not be vaccinated. However, there are no absolute contraindications to vaccination if a high-risk exposure has occurred. In an outbreak emergency, smallpox vaccine is generally recommended for all persons, regardless of medical conditions. The risk for experiencing serious complications from the vaccine should be weighed against the risk of acquiring a potentially fatal smallpox infection. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39449/', '[1] CDC. Centers for Disease Control and Prevention "Clinical guidance for smallpox vaccine use in a postevent vaccination program. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6402a1.htm." ([2015 Feb 20]):[2] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[3] "Product Information. Dryvax (smallpox vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] CDC. Centers for Disease Control and Prevention "Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov" ([2002 Oct 16]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39394, 'Dexamethasone', 'Sodium bicarbonate', 'Minor', 'Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.', NULL, '-', NULL, '-', 'Absorption', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Sodium chloride, Sulfamethizole, Sorbitol, Sodium citrate, Sodium acetate, Arginine, Sodium glycerophosphate, Tromethamine, Sodium chloride, Potassium acetate, Ammonium chloride, Magnesium chloride', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39450/', '[1] Naggar VF, Khalil SA, Gouda MW "Effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans." J Pharm Sci 67 (1978): 1029-30[2] Tanner AR, Caffin JA, Halliday JW, Powell LW "Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone." Br J Clin Pharmacol 7 (1979): 397-400[3] Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39395, 'Iodide I-123', 'Dexamethasone', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39451/', '[1] "Product Information. Sodium Iodide I-123 (sodium iodide I-123)." GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39396, 'Iodide I-131', 'Dexamethasone', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Ibritumomab tiuxetan, Tositumomab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39452/', '[1] "Product Information. Sodium Iodide I-123 (sodium iodide I-123)." GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39397, 'Dexamethasone', 'Phenylbutyric acid', 'Moderate', 'Drugs that can increase plasma ammonia levels such as corticosteroids, haloperidol, or the anticonvulsants carbamazepine, topiramate, and phenobarbital may interfere with the therapeutic effects of phenylbutyrate therapy in the management of urea cycle disorders. Corticosteroids can cause the breakdown of body protein, which may lead to increased ammonia levels. The use of haloperidol has been associated with hyperammonemia in a young child with citrullinemia, an inherited disorder of ammonia excretion.', NULL, 'Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.', NULL, 'Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Metreleptin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39453/', '[1] "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc, South San Francisco, CA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Buphenyl (sodium phenylbutyrate)." Horizon Pharma USA Inc, Northbrook, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39398, 'Dexamethasone', 'Tolevamer', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Levoleucovorin, Arginine, Methionine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39454/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39399, 'Dexamethasone', 'Salicylic acid (sodium)', 'Moderate', 'Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.', NULL, 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs.', NULL, 'Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', 'Excretion', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39455/', '[1] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[2] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34[3] Koren G, Roifman C, Gelfand E, Lavi S, Suria D, Stein L "Corticosteroids-salicylate interaction in a case of juvenile rheumatoid arthritis." Ther Drug Monit 9 (1987): 177-9[4] Edelman J, Potter JM, Hackett LP "The effect of intra-articular steroids on plasma salicylate concentrations." Br J Clin Pharmacol 21 (1986): 301-7[5] Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39400, 'Dexamethasone', 'Solifenacin', 'Moderate', 'Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of solifenacin, which has been shown to be a substrate of the isoenzyme in vitro.', NULL, 'Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.', NULL, 'Pharmacologic response to solifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the solifenacin dosage adjusted if necessary.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Cromoglicic acid, Prednisolone, Nedocromil, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39456/', '[1] "Product Information. VESIcare (solifenacin)." GlaxoSmithKline, Research Triangle Park, NC.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39401, 'Dexamethasone', 'Somapacitan', 'Moderate', 'Human growth hormone may reduce the pharmacologic effects of corticosteroids. Growth hormone is thought to enhance the activity of CYP450 3A4, an enzyme involved in the catabolism of corticosteroids. In addition, growth hormone (GH) inhibits microsomal enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD-1), which is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Treatment with pharmacologic and supraphysiologic glucocorticoid dosages may attenuate the growth promoting effects of human growth hormone in children due to inhibition of the hypothalamic-pituitary-adrenal axis.', NULL, 'Higher dosages of corticosteroids may be required during concomitant use of human growth hormone.', NULL, 'Higher dosages of corticosteroids may be required during concomitant use of human growth hormone. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of GH treatment. In addition, glucocorticoid replacement dosing should be carefully adjusted in children receiving concomitant GH treatment to avoid both hypoadrenalism and an inhibitory effect on growth.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39457/', '[1] "Product Information. Protropin (somatrem)." Genentech, South San Francisco, CA.[2] "Product Information. Norditropin Cartridge (somatropin)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] "Product Information. Nutropin (somatropin)." Genentech, South San Francisco, CA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39402, 'Dexamethasone', 'Somatrem', 'Moderate', 'Human growth hormone may reduce the pharmacologic effects of corticosteroids. Growth hormone is thought to enhance the activity of CYP450 3A4, an enzyme involved in the catabolism of corticosteroids. In addition, growth hormone (GH) inhibits microsomal enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD-1), which is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Treatment with pharmacologic and supraphysiologic glucocorticoid dosages may attenuate the growth promoting effects of human growth hormone in children due to inhibition of the hypothalamic-pituitary-adrenal axis.', NULL, 'Higher dosages of corticosteroids may be required during concomitant use of human growth hormone.', NULL, 'Higher dosages of corticosteroids may be required during concomitant use of human growth hormone. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of GH treatment. In addition, glucocorticoid replacement dosing should be carefully adjusted in children receiving concomitant GH treatment to avoid both hypoadrenalism and an inhibitory effect on growth.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39458/', '[1] "Product Information. Protropin (somatrem)." Genentech, South San Francisco, CA.[2] "Product Information. Norditropin Cartridge (somatropin)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] "Product Information. Nutropin (somatropin)." Genentech, South San Francisco, CA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39403, 'Dexamethasone', 'Somatotropin', 'Moderate', 'Human growth hormone may reduce the pharmacologic effects of corticosteroids. Growth hormone is thought to enhance the activity of CYP450 3A4, an enzyme involved in the catabolism of corticosteroids. In addition, growth hormone (GH) inhibits microsomal enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD-1), which is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Treatment with pharmacologic and supraphysiologic glucocorticoid dosages may attenuate the growth promoting effects of human growth hormone in children due to inhibition of the hypothalamic-pituitary-adrenal axis.', NULL, 'Higher dosages of corticosteroids may be required during concomitant use of human growth hormone.', NULL, 'Higher dosages of corticosteroids may be required during concomitant use of human growth hormone. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of GH treatment. In addition, glucocorticoid replacement dosing should be carefully adjusted in children receiving concomitant GH treatment to avoid both hypoadrenalism and an inhibitory effect on growth.', 'Antagonism', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Ciclesonide, Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39459/', '[1] "Product Information. Protropin (somatrem)." Genentech, South San Francisco, CA.[2] "Product Information. Norditropin Cartridge (somatropin)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] "Product Information. Nutropin (somatropin)." Genentech, South San Francisco, CA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39404, 'Dexamethasone', 'Sonidegib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sonidegib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of sonidegib with potent and moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39460/', '[1] "Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39405, 'Dexamethasone', 'Sorafenib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of sorafenib, which is partially metabolized by the isoenzyme.', NULL, 'Concomitant use of sorafenib with potent CYP450 3A4 inducers should be avoided whenever possible.', NULL, 'Concomitant use of sorafenib with potent CYP450 3A4 inducers should be avoided whenever possible.', 'Metabolism', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39461/', '[1] "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39406, 'Dexamethasone', 'Sparfloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39462/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39407, 'Dexamethasone', 'Spironolactone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39463/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39408, 'Dexamethasone', 'Stanozolol', 'Moderate', 'Concomitant use of androgens with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and edema due to additive steroidal effects.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Prasterone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39464/', '[1] "Product Information. Oxandrin (oxandrolone)." Bio-Tech, Levittown, PA.[2] "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39409, 'Dexamethasone', 'Stiripentol', 'Moderate', 'Coadministration with inducers of CYP450 1A2, 2C19, and/or 3A4 may decrease the plasma concentrations of stiripentol, which has been shown in vitro to undergo phase I metabolism via these pathways.', NULL, 'The potential for diminished pharmacologic effects of stiripentol should be considered during coadministration with CYP450 inducers.', NULL, 'The potential for diminished pharmacologic effects of stiripentol should be considered during coadministration with CYP450 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39465/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Diacomit (stiripentol)." Biocodex Inc, Creswell, OR.[3] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[14] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[15] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[16] "Product Information. Diacomit (stiripentol)." Biocodex Inc, Creswell, OR.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39410, 'Dexamethasone', 'Sulindac', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39466/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39411, 'Dexamethasone', 'Sunitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sunitinib and its pharmacologically active metabolite, both of which are substrates of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of sunitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or dose increase for sunitinib may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39467/', '[1] "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[5] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[6] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[7] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[8] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[9] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[10] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[11] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[12] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[13] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[14] "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39412, 'Dexamethasone', 'Suvorexant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of suvorexant, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4.', NULL, 'The potential for diminished therapeutic effects of suvorexant should be considered when prescribed with inducers of CYP450 3A4. Pharmacologic effects of suvorexant should be monitored more closely whenever an inducer is added to or withdrawn from therapy, and the suvorexant dosage adjusted as necessary.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39468/', '[1] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.[2] "Product Information. Belsomra (suvorexant)." Merck & Company Inc, Whitehouse Station, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39413, 'Dexamethasone', 'Tacrolimus', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sirolimus and tacrolimus, both of which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers.', NULL, 'Given the risk of organ rejection associated with inadequate immunosuppressant drug levels, caution is advised during concomitant therapy with CYP450 3A4 inducers. Sirolimus and tacrolimus blood levels should be checked frequently and the dosage adjusted accordingly whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.', 'Metabolism', 'Deoxycholic acid, Calcium gluconate, Glycopyrronium, Aminobenzoic acid, Caffeine, Dupilumab, Tralokinumab, Povidone-iodine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, More', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39469/', '[1] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Hooks MA "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother 28 (1994): 501-11[6] "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.[7] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39414, 'Dexamethasone', 'Tadalafil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tadalafil, which is primarily metabolized by the isoenzyme.', NULL, 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers.', NULL, 'For the treatment of benign prostatic hyperplasia and erectile dysfunction, no dosage adjustment of tadalafil is warranted during coadministration with CYP450 3A4 inducers. However, the possibility of diminished pharmacologic effects of tadalafil should be considered. For the treatment of pulmonary arterial hypertension, use of tadalafil should be avoided in patients chronically taking potent inducers of CYP450 3A4.', 'Metabolism', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Vardenafil, Ammonium chloride, Dimethyl sulfoxide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Hydrocortisone, Olopatadine, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39470/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39415, 'Dexamethasone', 'Talimogene laherparepvec', 'Major', 'Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient''s immune system has sufficiently recovered.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39471/', '[1] "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA, Thousand Oaks, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39416, 'Dexamethasone', 'Tamoxifen', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tamoxifen, which is metabolized by the isoenzyme.', NULL, 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period.', NULL, 'In general, agents without CYP450 3A4-inducing activity are preferable in patients treated with tamoxifen, particularly if these agents are to be used for a prolonged period. Otherwise, pharmacologic response to tamoxifen should be monitored closely whenever an inducing agent is added to or withdrawn from therapy, and the tamoxifen dosage adjusted if necessary.', 'Metabolism', 'Degarelix, Abarelix, Nilutamide, Abiraterone', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39472/', '[1] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8[2] Lien EA, Anker G, Lonning PE, et al "Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide." Cancer Res 50 (1990): 5851-7[3] "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.[4] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[5] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[6] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[7] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[8] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[9] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39417, 'Dexamethasone', 'Tasimelteon', 'Moderate', 'Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of tasimelteon, which is primarily metabolized by these isoenzymes.', NULL, 'The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4.', NULL, 'The potential for diminished therapeutic effects of tasimelteon should be considered during coadministration with inducers of CYP450 1A2 and/or 3A4. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39473/', '[1] "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc, Rockville, MD.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39418, 'Dexamethasone', 'Tazemetostat', 'Major', 'Coadministration with moderate or potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of tazemetostat, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of tazemetostat with moderate or potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39474/', '[1] "Product Information. Tazverik (tazemetostat)." Epizyme, Inc, Cambridge, MA.[2] "Product Information. Tazverik (tazemetostat)." Epizyme, Inc, Cambridge, MA.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39419, 'Dexamethasone', 'Telaprevir', 'Moderate', 'Coadministration with dexamethasone may decrease the plasma concentrations of the hepatitis C virus NS3/4A protease inhibitors, boceprevir and telaprevir. The proposed mechanism is dexamethasone induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of these and other protease inhibitors. The interaction has not been specifically studied with dexamethasone, but has been reported with the potent CYP450 3A4 inducer, rifampin.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of boceprevir or telaprevir with dexamethasone should be avoided if possible.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic drug levels, concomitant use of boceprevir or telaprevir with dexamethasone should be avoided if possible. Otherwise, close clinical monitoring of the virologic response is advised. In addition, patients may experience increased systemic glucocorticoid effects and should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, and bone loss. Dosage reduction for dexamethasone may be required.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39475/', '[1] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.[2] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.[3] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39420, 'Dexamethasone', 'Telbivudine', 'Moderate', 'Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.', NULL, 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together.', NULL, 'Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39476/', '[1] "Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation, San Diego, CA.[2] "Product Information. Retrovir (zidovudine)." Glaxo Wellcome, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39421, 'Dexamethasone', 'Telithromycin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme.', NULL, 'The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers.', NULL, 'The potential for diminished therapeutic effects of telithromycin should be considered when prescribed with CYP450 3A4 inducers. Pharmacologic response to telithromycin should be monitored closely during coadministration, and alternative treatment given if an interaction is suspected. Whenever possible, telithromycin should preferably not be used during or within 2 weeks after discontinuation of treatment with a CYP450 3A4 inducer.', 'Metabolism', 'Lincomycin, Dirithromycin', 'Mupirocin, Mometasone furoate, Epinephrine, Ephedrine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39477/', '[1] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products "European Public Assessment Report Ketek (telithromycin) (Rev. 2) Available from: URL: http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm." ([2001]):[2] "Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals, Bridgewater, NJ.[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39422, 'Dexamethasone', 'Telmisartan', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Sacubitril', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39478/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39423, 'Dexamethasone', 'Telotristat ethyl', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39479/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39424, 'Dexamethasone', 'Temsirolimus', 'Major', 'Coadministration of temsirolimus with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of sirolimus, a major active metabolite of temsirolimus and known substrate of CYP450 3A4.', NULL, 'Concomitant use of temsirolimus with potent CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of temsirolimus with potent CYP450 3A4 inducers should generally be avoided. If coadministration is required in patients treated with temsirolimus for renal cell carcinoma, the manufacturer recommends increasing the temsirolimus dosage from 25 mg to 50 mg once a week depending on patient tolerability. Based on pharmacokinetic studies, this dosage is predicted to adjust the sirolimus systemic exposure (AUC) to the range observed without inducers. However, clinical data are lacking. The dosage should be reduced to the normally recommended dosage (i.e., 25 mg once a week) following discontinuation of the potent CYP450 3A4 inducer.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39480/', '[1] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39425, 'Dexamethasone', 'Terazosin', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39481/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39426, 'Dexamethasone', 'Terbutaline', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Glycopyrronium, Ipratropium, Olodaterol, Beclomethasone dipropionate', 'Mupirocin, Mometasone furoate, Vitamin A, Olopatadine, Cromoglicic acid, Ipratropium, Hyaluronic acid, Nedocromil, Azelastine, Mometasone furoate, Fluorometholone, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39482/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39427, 'Dexamethasone', 'Teriflunomide', 'Major', 'The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide''s active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.', NULL, 'Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.', NULL, 'Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39483/', '[1] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[2] "Product Information. Aubagio (teriflunomide)." Genzyme Corporation, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39428, 'Dexamethasone', 'Testosterone (topical)', 'Moderate', 'Concomitant use of androgens with adrenocorticotropic hormone (ACTH) or corticosteroids may result in increased fluid retention and edema due to additive steroidal effects.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', NULL, 'Caution is advised if androgens are used in combination with ACTH or corticosteroids, particularly in patients with conditions that may be aggravated by fluid retention such as cardiovascular, renal, or hepatic diseases.', 'Synergism', 'Prasterone', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39484/', '[1] "Product Information. Oxandrin (oxandrolone)." Bio-Tech, Levittown, PA.[2] "Product Information. AndroGel (testosterone)." Unimed Pharmaceuticals, Buffalo Grove, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39429, 'Dexamethasone', 'Thalidomide', 'Major', 'Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism. The exact mechanism is unknown but likely multifactorial.', NULL, 'Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents.', NULL, 'Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.', 'Synergism', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39485/', '[1] Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304[2] Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71[3] Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6[4] Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM "A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma." Cancer 95 (2002): 1629-36[5] Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J "Thromboembolic events during treatment with thalidomide." Blood 99 (2002): 4247-8[6] Lee CK, Barlogie B, Munshi N, et al "DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma." J Clin Oncol 21 (2003): 2732-9[7] Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma." J Clin Oncol 21 (2003): 16-9[8] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[9] Cavo M, Zamagni E, Cellini C, et al. "Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy." Blood 100 (2002): 2272-3[10] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40[11] Zangari M, Anaissie E, Barlogie B, et al "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy." Blood 98 (2001): 1614-5[12] Rajkumar SV, Hayman S, Gertz MA, et al. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." J Clin Oncol 20 (2002): 4319-23[13] Osman K, Comenzo R, Rajkumar SV "Deep venous thrombosis and thalidomide therapy for multiple myeloma." N Engl J Med 344 (2001): 1951-2[14] Zangari M, Barlogie B, Anaissie E, et al "Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation." Br J Haematol 126 (2004): 715-21[15] Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A "Thalidomide and venous thrombosis." Ann Intern Med 136 (2002): 711[16] Bennett CL, Schumock GT, Desai AA, et al "Thalidomide-associated deep vein thrombosis and pulmonary embolism." Am J Med 113 (2002): 603-6[17] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[18] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[20] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39430, 'Dexamethasone', 'Thallous Chloride', 'Moderate', 'Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', 'Others', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39486/', '[1] "Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201)." GE Healthcare, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy "Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl." ([cited Feb2015]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39431, 'Dexamethasone', 'Theophylline', 'Moderate', 'The concomitant use of theophylline and corticosteroids may theoretically increase the risk of hypokalemia due to additive potassium-lowering effects. Additionally, theophylline serum concentrations may be altered.', NULL, 'Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered.', NULL, 'Monitoring for altered efficacy and safety of theophylline and altered serum potassium and theophylline concentrations is advisable when these drugs are coadministered. Patients should be advised to notify their physician if they experience signs of hypokalemia (e.g., weakness, lethargy, and muscle pains or cramps), worsening respiratory symptoms, or signs of theophylline toxicity (e.g., nausea, vomiting, diarrhea, headache, restlessness, insomnia, or irregular heartbeat).', 'Synergism', 'Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, Oxtriphylline, Mepolizumab, Zafirlukast, Bromotheophylline', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39487/', '[1] Fergusson RJ, Scott CM, Rafferty P, Gaddie J "Effect of prednisolone on theophylline pharmacokinetics in patients with chronic airflow obstruction." Thorax 42 (1987): 195-8[2] Buchanan N, Hurwitz S, Butler P "Asthma - a possible interaction between hydrocortisone and theophylline." S Afr Med J 56 (1979): 1147-8[3] Leavengood DC, Bunker-Soler AL, Nelson HS "The effect of corticosteroids on theophylline metabolism." Ann Allergy 50 (1983): 249-51[4] Elvey SM, Saccar CL, Rocci ML, Mansmann HC, Martynec DM, Kester MB "The effect of corticosteroids on theophylline metabolim in asthmatic children." Ann Allergy 56 (1986): 520[5] Tatsis G, Orphanidou D, Douratsos D, et al "The effect of steroids on theophylline absorption." J Int Med Res 19 (1991): 326-9[6] Anderson JL, Ayres JW, Hall CA "Potential pharmacokinetic interaction between theophylline and prednisone." Clin Pharm 3 (1984): 187-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39432, 'Dexamethasone', 'Ticagrelor', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided. Otherwise, caution is advised, and patients should be closely monitored for diminished clinical response to ticagrelor therapy. Alternative treatment may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Betrixaban, Cilostazol, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Streptokinase, Eptifibatide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39488/', '[1] "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Weeks P, Sieg A, Vahdat K, Raissi F, Nathan S "Improved ticagrelor antiplatelet effect on discontinuation of phenytoin." Ann Pharmacother 48 (2014): 644-7[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Teng R, Mitchell P, Butler K "Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects." Eur J Clin Pharmacol 69 (2013): 877-83[5] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39433, 'Dexamethasone', 'Ticlopidine', 'Minor', 'Limited data have shown that corticosteroids may significantly decrease ticlopidine-induced prolongations in bleeding times. The mechanism may be related to corticosteroid induced peripheral vasoconstriction as limited data have shown that corticosteroids do not affect ADP-mediated platelet aggregation in patients who are taking therapeutic doses of ticlopidine. The clinical relevance of this interaction is unknown, although it is suggested by some experts that systemic corticosteroids could be used prior to emergency surgery in patients who are taking ticlopidine. It is unknown whether the risk of thrombosis is increased in patients who are taking both drugs. More data are needed.', NULL, '-', NULL, '-', 'Others', 'Betrixaban, Cilostazol, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Streptokinase, Eptifibatide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39489/', '[1] Thebault J, Blatrix C, Blanchard J, Panak E "A possible method to control prolongations of bleeding time under antiplatelet therapy with ticlopidine." Thromb Haemost 48 (1982): 6-8[2] "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39434, 'Dexamethasone', 'Timolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Esmolol, Acetylcholine, Physostigmine, Apraclonidine, Levobunolol', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39490/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39435, 'Dexamethasone', 'Tipranavir', 'Moderate', 'Coadministration with protease inhibitors may increase the plasma concentration and pharmacologic effects of dexamethasone. The proposed mechanism is protease inhibitor-mediated inhibition of CYP450 3A4, the isoenzyme involved in the metabolic clearance of dexamethasone. Corticosteroids such as dexamethasone may cause hypokalemia and potentiate the risk of QT and/or PR interval prolongation associated with the use of certain protease inhibitors such as atazanavir, lopinavir-ritonavir, and saquinavir-ritonavir. The risk of torsade de pointes arrhythmia, bradycardia, and heart block may be increased.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat.', NULL, 'Caution is advised if dexamethasone must be used concomitantly with protease inhibitors or cobicistat. Some authorities advise against concomitant use unless the potential benefit outweighs the risk. Adrenal function should be monitored regularly during chronic use of these agents, and dexamethasone dosage adjusted as necessary. Patients should be monitored for symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, glucose intolerance, and irregular menstruations), immunosuppression, and osteoporosis. In addition, it may be appropriate to monitor patients for potentially reduced antiretroviral response following initiation or any dosage increase of dexamethasone. Serum potassium and ECG monitoring should also be considered during coadministration of dexamethasone with certain protease inhibitors in accordance with the product labeling.', 'Metabolism', 'Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39491/', '[1] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[7] "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39436, 'Dexamethasone', 'Tofacitinib', 'Major', 'Coadministration of baricitinib or tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving baricitinib and tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Baricitinib and tofacitinib, both Janus kinase (JAK) inhibitors, have been associated with an increased risk of diverticulitis (DV) and gastrointestinal (GI) perforation, particularly in patients with risk factors (e.g., history of diverticulosis or diverticulitis, concomitant use of other agents associated with DV). Baricitinib and tofacitinib, both Janus kinase (JAK) inhibitors, have been associated with an increased risk of diverticulitis (DV) and gastrointestinal (GI) perforation, particularly in patients with risk factors.', NULL, 'Close monitoring for the development of infection is recommended if baricitinib or tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.', NULL, 'Close monitoring for the development of infection is recommended if baricitinib or tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and the baricitinib or tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, baricitinib should be interrupted until the infection is controlled. Caution is recommended when using baricitinib or tofacitinib in patients with a history of diverticular disease and in patients receiving long-term concomitant treatment with drugs associated with an increased risk of DV and/or GI perforation, such as aspirin, NSAIDs, corticosteroids, and opioids. Patients should be advised to contact their healthcare provider if they experience signs of DV or GI perforation, such as severe abdominal pain, fever, nausea, or vomiting.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39492/', '[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT "Use of Aspirin or Nonsteroidal Anti-inflammatory Drugs Increases Risk for Diverticulitis and Diverticular Bleeding." Gastroenterology 140 (2011): 1427-33[2] "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[3] "Product Information. Olumiant (baricitinib)." Lilly, Eli and Company, Indianapolis, IN.[4] Medicines and Healthcare products Regulatory Agency "Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors. Available from: URL: https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-fac" ([2020, Aug 26]):[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39437, 'Dexamethasone', 'Tolazamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Guar gum', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39493/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39438, 'Dexamethasone', 'Tolbutamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Vitamin A, Caffeine, Metyrapone, Histamine, Indocyanine green, More', 'Ciclesonide, Mupirocin, Budesonide, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39494/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39439, 'Dexamethasone', 'Tolmetin', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39495/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39440, 'Dexamethasone', 'Tolvaptan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tolvaptan, which is primarily metabolized by the isoenzyme. When tolvaptan was administered with the potent CYP450 3A4 inducer rifampin, tolvaptan peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 85%.', NULL, 'The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of tolvaptan should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39496/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Samsca (tolvaptan)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39441, 'Dexamethasone', 'Toremifene', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of toremifene.', NULL, 'Concomitant use of toremifene with potent CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of toremifene with potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible during treatment with toremifene. If coadministration is required, a doubling of the toremifene dosage may be necessary depending on patient tolerability. Close monitoring for toxicities (e.g., QT prolongation, hepatotoxicity, hypercalcemia and tumor flare) is recommended if the dosage of toremifene is increased. The dosage should be reduced to the indicated dosage following discontinuation of the potent CYP450 3A4 inducer.', 'Metabolism', 'Degarelix, Abarelix, Nilutamide, Abiraterone', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39497/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[5] Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ "Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin." Clin Pharmacol Ther 64 (1998): 648-54[6] "Product Information. Fareston (toremifene)." Schering Laboratories, Kenilworth, NJ.[7] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):[8] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39442, 'Dexamethasone', 'Torasemide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39498/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39443, 'Dexamethasone', 'Trabectedin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers.', NULL, 'The possibility of diminished therapeutic effects should be considered when trabectedin is prescribed with CYP450 3A4 inducers. Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inducer is added to or withdrawn from trabectedin therapy, and the dosage adjusted if necessary.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Teniposide, Cabazitaxel', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39499/', '[1] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Machiels JP, Staddon A, Herremans C, et al. "Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies." Cancer Chemother Pharmacol 74 (2014): 729-37[4] "Product Information. Yondelis (trabectedin)." Janssen Pharmaceuticals, Titusville, NJ.[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39444, 'Dexamethasone', 'Trandolapril', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39500/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39445, 'Dexamethasone', 'Triamterene', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39501/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39446, 'Dexamethasone', 'Triazolam', 'Minor', 'Certain corticosteroids may decrease the plasma concentration of some benzodiazepines. The mechanism is related to induction of hepatic cytochrome P450 enzymes responsible for benzodiazepine metabolism. The clinical significance may depend on the dosage and duration of corticosteroid therapy and be of greater importance with oral administration of benzodiazepines.', NULL, '-', NULL, '-', 'Others', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39502/', '[1] Villikka K, Kivisto KT, Neuvonen PJ "The effect of dexamethasone on the pharmacokinetics of triazolam." Pharmacol Toxicol 83 (1998): 135-8[2] Nakajima M, Suzuki T, Sasaki T, Yokoi T, Hosoyamada A, Yamamoto T, Kuroiwa Y "Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans." Ther Drug Monit 21 (1999): 507-13[3] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[4] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[7] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[8] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[9] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39447, 'Dexamethasone', 'Trichlormethiazide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39503/', '[1] Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves'' disease." Aust N Z J Med 22 (1992): 312[2] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[3] "Product Information. Hydeltrasol (prednisolone)." Merck & Co, Inc, West Point, PA.[4] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7[5] Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32[6] Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81[7] Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42[8] Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39448, 'Dexamethasone', 'Trichophyton mentagrophytes', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39504/', '[1] "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc, Wallingford, CT.[2] "Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative)." Connaught Laboratories Ltd, Toronto, ON.[3] "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc, San Diego, CA.[4] "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals, Swiftwater, PA.[6] "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc, Wallingford, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39449, 'Dexamethasone', 'Trimethaphan', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Mecamylamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39505/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39450, 'Dexamethasone', 'Troglitazone', 'Moderate', 'Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.', NULL, 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.', 'Metabolism', 'Guar gum', 'Ciclesonide, Mupirocin, Mometasone, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39506/', '[1] "Product Information. Rezulin (troglitazone)." Parke-Davis, Morris Plains, NJ.[2] Fraser CG, Fierro L "Comment: troglitazone." Ann Pharmacother 32 (1998): 1111-2[3] Park MH, Pelegrin D, Haug MT, Young JB "Troglitazone, a new antidiabetic agent, decreases cyclosporine level." J Heart Lung Transplant 17 (1998): 1139-40[4] Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP "Potential interaction of troglitazone and cyclosporine." Transplantation 65 (1998): 1399-400[5] Frantz RP, Nguyen TT "Rezulin (troglitazone) greatly increases cyclosporine metabolism." J Heart Lung Transplant 17 (1998): 1037-8[6] Burgess SJ, Singer GG, Brennan DC "Effect of troglitazone on cyclosporine whole blood levels." Transplantation 66 (1998): 272[7] Terra SG, Washam JB, May DB "Comment: troglitazone drug interactions." Ann Pharmacother 32 (1998): 1111[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[15] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[16] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[17] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39451, 'Dexamethasone', 'Troleandomycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Lincomycin, Dirithromycin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39507/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39452, 'Dexamethasone', 'Trovafloxacin', 'Major', 'Concomitant administration of corticosteroids may potentiate the risk of tendinitis and tendon rupture associated with fluoroquinolone treatment. The mechanism is unknown. Tendinitis and tendon rupture have most frequently involved the Achilles tendon, although cases involving the rotator cuff (the shoulder), the hand, the biceps, and the thumb have also been reported. Some have required surgical repair or resulted in prolonged disability. Tendon rupture can occur during or up to several months after completion of fluoroquinolone therapy.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.', NULL, 'Caution is recommended if fluoroquinolones are prescribed in combination with corticosteroids, particularly in patients with other concomitant risk factors (e.g., age over 60 years; recipient of kidney, heart, and/or lung transplant). Patients should be advised to stop taking the fluoroquinolone, avoid exercise and use of the affected area, and promptly contact their physician if they experience pain, swelling, or inflammation of a tendon.', 'Synergism', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39508/', '[1] Khaliq Y, Zhanel GG "Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature." Clin Infect Dis 36 (2003): 1404-1410[2] "Product Information. Cipro (ciprofloxacin)." Bayer, West Haven, CT.[3] van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH "Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids." Arch Intern Med 163 (2003): 1801-7[4] "Product Information. Levaquin (levofloxacin)." Ortho Pharmaceutical Corporation, Raritan, NJ.[5] "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Lincolnshire, IL.[6] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008]. Available from: URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/fluoroquinolonesHCP.htm." ([7/8/2008]):[7] "Product Information. Avelox (moxifloxacin)" Bayer, West Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39453, 'Dexamethasone', 'Tuberculin purified protein derivative', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39509/', '[1] "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc, Wallingford, CT.[2] "Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative)." Connaught Laboratories Ltd, Toronto, ON.[3] "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc, San Diego, CA.[4] "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals, Swiftwater, PA.[6] "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc, Wallingford, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39454, 'Dexamethasone', 'Tubocurarine', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Botulinum toxin type A', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39510/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39455, 'Dexamethasone', 'Tucatinib', 'Moderate', 'Coadministration with CYP450 3A4 inducers may decrease the plasma concentrations of tucatinib, which is primarily metabolized by CYP450 2C8 and to a lesser extent by CYP450 3A4.', NULL, 'The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of tucatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39511/', '[1] "Product Information. Tukysa (tucatinib)." Seattle Genetics Inc, Bothell, WA.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39456, 'Dexamethasone', 'Typhoid vaccine (inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39512/', '[1] "Product Information. Imovax Rabies (rabies vaccine)." sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service "Immunisation Against Infectious Disease - "The Green Book". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.[5] "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention "General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf." ([2017, Apr 17]):[7] "Product Information. Biothrax (anthrax vaccine adsorbed)." Emergent BioSolutions Inc., Lansing, MI.[8] "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] "Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39457, 'Dexamethasone', 'Typhoid vaccine (live)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39513/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39458, 'Dexamethasone', 'Ubrogepant', 'Moderate', 'Coadministration with moderate or weak inducers of CYP450 3A4 may decrease the plasma concentrations of ubrogepant, which is primarily metabolized by the isoenzyme. Dedicated drug interaction studies have not been conducted to assess concomitant use of ubrogepant with moderate or weak CYP450 3A4 inducers.', NULL, 'The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers.', NULL, 'The manufacturer recommends an initial ubrogepant dose of 100 mg when coadministered with moderate or weak CYP450 3A4 inducers. If needed, a second 100 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Frovatriptan, Eptinezumab, Lasmiditan, Eletriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39514/', '[1] "Product Information. Ubrelvy (ubrogepant)." Allergan Inc, Irvine, CA.[2] "Product Information. Ubrelvy (ubrogepant)." Allergan Inc, Irvine, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39459, 'Dexamethasone', 'Upadacitinib', 'Major', 'Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.', NULL, 'Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.', NULL, 'Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39515/', '[1] "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39460, 'Dexamethasone', 'Ustekinumab', 'Moderate', 'The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', NULL, 'Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.', NULL, 'Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Abatacept, Inebilizumab, Ozanimod, Belimumab, Emapalumab, Sutimlimab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39516/', '[1] "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39461, 'Dexamethasone', 'Valdecoxib', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', 'Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39517/', '[1] Wilcox CM, Shalek KA, Cotsonis G "Striking prevalence of over-the-counter nonsteroidal anti- inflammatory drug use in patients with upper gastrointestinal hemorrhage." Arch Intern Med 154 (1994): 42-6[2] Stewart JT, Pennington CR, Pringle R "Anti-inflammatory drugs and bowel perforations and haemorrhage." Br Med J 290 (1985): 787-8[3] Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4[4] Kaufman DW, Kelly JP, Sheehan JE, Laszlo A, Wiholm BE, Alfredsson L, Koff RS, Shapiro S "Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding." Clin Pharmacol Ther 53 (1993): 485-94[5] Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6[6] Sacanella E, Munoz F, Cardellach F, Estruch R, Miro O, Urbanomarquez A "Massive haemorrhage due to colitis secondary to nonsteroidal anti-inflammatory drugs." Postgrad Med J 72 (1996): 57-8[7] Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S "Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics." Arch Intern Med 148 (1988): 281-5[8] Cantu TG, Lipani JA "Gastrointestinal ulceration with NSAIDs." Am J Med 99 (1995): 440-1[9] Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5[10] Piper JM, Ray WA, Daugherty JR, Griffin MR "Corticosteroid use and peptic ulcer disease: role of nonsteroidal ani-inflammatory drugs." Ann Intern Med 114 (1991): 735-40[11] ReMine SG, McIlrath DC "Bowel perforation in steroid-treated patients." Ann Surg 192 (1980): 581-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39462, 'Dexamethasone', 'Valsartan', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Sacubitril', 'Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39518/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39463, 'Dexamethasone', 'Vandetanib', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations of vandetanib, which is a substrate of the isoenzyme.', NULL, 'Concomitant use of vandetanib with potent CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of vandetanib with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39519/', '[1] Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51[2] "Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39464, 'Dexamethasone', 'Varicella Zoster Vaccine (Recombinant)', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39520/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39465, 'Dexamethasone', 'Vecuronium', 'Moderate', 'Corticosteroids may inhibit or enhance the action of nondepolarizing skeletal muscle relaxants. The mechanism is unknown. In addition, the risk of myopathy may be increased after long-term use of neuromuscular blocking agents and corticosteroids.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy.', NULL, 'Patients should be closely monitored for altered neuromuscular blockade and signs of myopathy. Dose adjustments of the muscle relaxant may be required. The benefit-to-risk ratio should be considered and the duration of administration of the neuromuscular blocking agent should be limited as much as clinically feasible.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Botulinum toxin type A', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39521/', '[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[2] "Product Information. Norcuron (vecuronium)." Organon, West Orange, NJ.[3] Laflin MJ "Interaction of pancuronium and corticosteroids." Anesthesiology 47 (1977): 471-2[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Parr SM, Galletly DC, Robinson BJ "Betamethasone-induced resistance to vercuronium: a potential problem in neurosurgery." Anaesth Intensive Care 19 (1991): 103-5[6] "Product Information. Zemuron (rocuronium)." Organon, West Orange, NJ.[7] Meyers EF "Partial recovery from pancuronium neuromuscular blockade following hydrocortosone administration." Anesthesiology 46 (1977): 148-50', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39466, 'Dexamethasone', 'Vemurafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of vemurafenib, which has been shown in vitro to be a substrate of the isoenzyme.', NULL, 'The potential for diminished pharmacologic effects of vemurafenib should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The potential for diminished pharmacologic effects of vemurafenib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments or a dose adjustment of vemurafenib may be required if an interaction is suspected.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Tinidazole, Ascorbic acid, Miconazole, Sulfamethoxazole, Sulfamethizole, Povidone-iodine, Sulfisoxazole, Mafenide, Tioconazole, Furazolidone, Lactic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39522/', '[1] "Product Information. Zelboraf (vemurafenib)." Genentech, South San Francisco, CA.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39467, 'Dexamethasone', 'Venetoclax', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of venetoclax, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of venetoclax with potent and moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of venetoclax with potent and moderate CYP450 3A4 inducers should generally be avoided. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39523/', '[1] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[2] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[3] Cronk GA, Wheatley WB, Fellers GF, Albright H "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci 240 (1960): 219-25[4] Neuvonen PJ, Elonen E, Pentikainen PJ "Comparative effect of food on absorption of ampicillin and pivampicillin." J Int Med Res 5 (1977): 71-6[5] Klein JO, Sabath LD, Finland M "Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young." Am J Med Sci 245 (1963): 399-411[6] Welling PG, Huang H, Koch PA, Madsen PO "Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects." J Pharm Sci 66 (1977): 549-52[7] McCarthy CG, Finland M "Absorption and excretion of four penicillins." N Engl J Med 263 (1960): 315-26[8] Neu HC "Antimicrobial activity and human pharmacology of amoxicillin." J Infect Dis 129 (1974): s123-31', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39468, 'Dexamethasone', 'Verapamil', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Azelastine, Beclomethasone dipropionate, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39524/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39469, 'Dexamethasone', 'Vigabatrin', 'Major', 'Theoretical concerns exist that oculotoxic effects of vigabatrin may be additive with those of other drugs that are associated with serious adverse ophthalmic effects. Vigabatrin causes permanent bilateral concentric visual field constriction in 30% or more of patients, with severity ranging from mild to severe. Vigabatrin can also damage the central retina and decrease visual acuity. The onset of vision loss is unpredictable, occurring within weeks of starting treatment to months or even years later. The risk of vision loss increases with increasing dose and cumulative exposure, although there is no dose or exposure known to be risk-free. It is possible that vision loss can worsen even after discontinuation of vigabatrin.', NULL, 'Vigabatrin should generally not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks.', NULL, 'Vigabatrin should generally not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks. These drugs may include amiodarone, deferoxamine, ethambutol, quinine derivatives, tamoxifen, and long-term corticosteroids. Vision testing at baseline (no later than 4 weeks after starting vigabatrin) and at least every 3 months during therapy is required for adults. Vision testing is also required about 3 to 6 months after the discontinuation of vigabatrin therapy. Due to the risk of irreversible vision loss, vigabatrin should be withdrawn from patients who fail to show substantial clinical benefit within 3 months of initiation, or sooner if treatment failure becomes obvious. The patient''s response and continued need for vigabatrin should be periodically reassessed. The lowest dosage and shortest duration of treatment consistent with clinical objectives should be employed.', 'Synergism', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39525/', '[1] "Product Information. Sabril (vigabatrin)." Lundbeck Inc, Deerfield, IL.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39470, 'Dexamethasone', 'Vilazodone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of vilazodone, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of a diminished therapeutic response to vilazodone should be considered during coadministration with CYP450 3A4 inducers.', NULL, 'The possibility of a diminished therapeutic response to vilazodone should be considered during coadministration with CYP450 3A4 inducers. Pharmacologic effects of vilazodone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Phenelzine, Desipramine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John''s Wort, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39526/', '[1] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39471, 'Dexamethasone', 'Vinblastine', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John''s wort should generally be avoided.', 'Metabolism', 'Teniposide, Cabazitaxel', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Nedocromil, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39527/', '[1] "Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc, South San Francisco,, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39472, 'Dexamethasone', 'Vincristine', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John''s wort should generally be avoided.', 'Metabolism', 'Teniposide, Cabazitaxel', 'Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39528/', '[1] "Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc, South San Francisco,, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39473, 'Dexamethasone', 'Vincristine (liposome)', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John''s wort should generally be avoided.', 'Metabolism', 'Teniposide, Cabazitaxel', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39529/', '[1] "Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc, South San Francisco,, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39474, 'Dexamethasone', 'Vinorelbine', 'Moderate', 'Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein may significantly decrease the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St.', NULL, 'The use of vinca alkaloids in combination with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, and St. John''s wort should generally be avoided.', 'Metabolism', 'Teniposide, Cabazitaxel', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Ipratropium, Cromoglicic acid, Nedocromil, Beclomethasone dipropionate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39530/', '[1] "Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc, South San Francisco,, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39475, 'Dexamethasone', 'Vitamin E', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', NULL, '-', NULL, '-', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39531/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[3] Pepping J "Echinacea." Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39476, 'Dexamethasone', 'Voriconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39532/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39477, 'Dexamethasone', 'Vortioxetine', 'Moderate', 'Coadministration with potent inducers of CYP450 isoenzymes may significantly decrease the plasma concentrations of vortioxetine, which is primarily metabolized by CYP450 2D6.', NULL, 'An increase in the dosage of vortioxetine should be considered when used in combination with potent CYP450 inducers (e.', NULL, 'An increase in the dosage of vortioxetine should be considered when used in combination with potent CYP450 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifamycins) for greater than 14 days, up to a maximum of three times the original dosage depending on clinical response. Following discontinuation of the potent CYP450 inducer, vortioxetine dosage should be returned to the original level within 14 days. Other known CYP450 inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, enzalutamide, efavirenz, etravirine, nevirapine, somatrem, somatropin, and various other anticonvulsants, although the extent to which they interact with vortioxetine is unknown.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Phenelzine, Desipramine, Tranylcypromine, Desvenlafaxine, Maprotiline, St. John''s Wort, Isocarboxazid, Oxitriptan, Tryptophan, Milnacipran, Levomilnacipran, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39533/', '[1] "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America, Lincolnshire, IL.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[13] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[14] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[15] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39478, 'Dexamethasone', 'Voxelotor', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations and pharmacologic effects of voxelotor. The proposed mechanism is accelerated clearance of voxelotor due to induction of the CYP450 3A4 isoenzyme, which is the primary route of elimination of voxelotor.', NULL, 'The use of voxelotor with moderate to potent CYP450 3A4 inducers should generally be avoided.', NULL, 'The use of voxelotor with moderate to potent CYP450 3A4 inducers should generally be avoided. Alternative therapeutic agents with less enzyme induction potential should be considered whenever possible. If coadministration is required, the manufacturer recommends increasing the voxelotor dose to 2500 mg once daily. Pharmacologic response to voxelotor should also be monitored more closely.', 'Metabolism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39534/', '[1] "Product Information. Oxbryta (voxelotor)." Global Blood Therapeutics, Inc., South San Francisco, CA.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[33] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39479, 'Dexamethasone', 'Warfarin', 'Moderate', 'Corticosteroids and adrenocorticotropic agents may alter the pharmacologic effects of oral anticoagulants. Both increased anticoagulant dosage requirements as well as bleeding and increased anticoagulant sensitivity have been reported during concomitant corticosteroid therapy. Proposed mechanisms include blood hypercoagulability or diminished vascular integrity induced by corticosteroids.', NULL, 'Close monitoring for clinical and laboratory evidence of altered anticoagulant response is recommended during concurrent treatment with corticosteroids or adrenocorticotropic agents.', NULL, 'Close monitoring for clinical and laboratory evidence of altered anticoagulant response is recommended during concurrent treatment with corticosteroids or adrenocorticotropic agents. Patients should be advised to promptly report any signs and symptoms of bleeding or blood clots.', 'Others', 'Betrixaban, Cilostazol, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Streptokinase, Eptifibatide, More', 'Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, Ipratropium, Hyaluronic acid, Nedocromil, Phenylephrine, Beclomethasone dipropionate, Mometasone furoate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39535/', '[1] Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970): 300-6[2] Stading JA "Effects of prednisone on the International Normalized Ratio." Am J Health Syst Pharm 63 (2006): 2354-2356[3] Brozovic M, Gurd LJ "Prothrombin during warfarin treatment." Br J Haematol 24 (1973): 579-88[4] Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34[5] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58[6] Wadman B, Werner I "Thromboembolic complications during corticosteroid treatment of temporal arteritis." Lancet 1 (1972): 907[7] Hamblin TJ "Interaction between warfarin and phenformin." Lancet 2 (1971): 1323[8] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (first of two parts)." N Engl J Med 285 (1971): 487-98[9] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[10] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[11] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[12] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[13] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[14] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[15] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[16] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[17] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[18] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[19] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[20] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[21] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[22] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[23] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[24] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[25] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[26] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[27] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[28] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[30] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[31] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70[32] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[33] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[34] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[36] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[37] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[38] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[39] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[40] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[41] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[42] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[43] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[44] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[45] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39480, 'Dexamethasone', 'Yellow Fever Vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39536/', '[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison''s Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):[2] "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.[3] "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR "Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012." MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] "Product Information. M-M-R II (measles/mumps/rubella virus vaccine)." Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK "Acute retinal necrosis after herpes zoster vaccination." Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39481, 'Dexamethasone', 'Zaleplon', 'Minor', 'Inducers of hepatic microsomal enzyme CYP450 3A4 may increase the plasma clearance of zaleplon, which is partially metabolized by this enzyme. Be aware of the possibility of reduced efficacy associated with zaleplon if these drugs are given together.', NULL, '-', NULL, '-', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Hydrocortisone, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39537/', '[1] "Product Information. Sonata (zaleplon)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[3] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[4] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[5] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[6] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[7] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[8] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[11] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[12] "Product Information. Sonata (zaleplon)" Wyeth-Ayerst Laboratories, Philadelphia, PA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39482, 'Dexamethasone', 'Zanubrutinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of zanubrutinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of zanubrutinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, 'Concomitant use of zanubrutinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More', 'Lenvatinib, Trametinib, Dacomitinib, Tivozanib, Alectinib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39538/', '[1] "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.[2] "Product Information. Brukinsa (zanubrutinib)." BeiGene USA, Inc, San Mateo, CA.[3] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39483, 'Dexamethasone', 'Zinc acetate', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', NULL, '-', NULL, '-', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tetracaine, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39539/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[3] Pepping J "Echinacea." Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39484, 'Dexamethasone', 'Zinc chloride', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', NULL, '-', NULL, '-', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tetracaine, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Sodium acetate, Arginine, Sodium glycerophosphate, Tromethamine, Sodium chloride, Potassium acetate, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39540/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[3] Pepping J "Echinacea." Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39485, 'Dexamethasone', 'Zinc gluconate', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', NULL, '-', NULL, '-', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tetracaine, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Magnesium gluconate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Sodium sulfate, Magnesium chloride', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39541/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[3] Pepping J "Echinacea." Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39486, 'Dexamethasone', 'Zinc sulfate', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', NULL, '-', NULL, '-', 'Antagonism', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Tetracaine, Procaine, Betamethasone, Fluorometholone, Dexamethasone, Magnesium gluconate, Magnesium aspartate, Magnesium lactate, Sodium chloride, Sodium sulfate, Magnesium chloride, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39542/', '[1] Izzo AA, Ernst E "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs 61 (2001): 2163-75[2] Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11[3] Pepping J "Echinacea." Am J Health Syst Pharm 56 (1999): 121-2[4] Therapeutic Research Faculty "Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com." ([1995-2008...]):', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39487, 'Dexamethasone', 'Ziprasidone', 'Minor', 'Coadministration with drugs that are inducers of the CYP450 3A4 isoenzyme may only modestly decrease the plasma concentrations of ziprasidone, as less than 1/3 of ziprasidone metabolic clearance occurs via oxidation mediated by CYP450 3A4.', NULL, '-', NULL, '-', 'Metabolism', 'Mesoridazine, Methotrimeprazine, Asenapine, Promazine, Thiothixene, Thioridazine, Pimozide, Trifluoperazine, Amisulpride, Triflupromazine, Loxapine, More', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Vitamin A, Ipratropium, Cromoglicic acid, Hyaluronic acid, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39543/', '[1] Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A "The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers." Br J Clin Pharmacol 49(suppl 1) (2000): s65-70[2] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[13] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[14] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[15] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39488, 'Dexamethasone', 'Zolpidem', 'Moderate', 'Coadministration with CYP450 inducers may decrease the plasma concentrations of zolpidem, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 1A2.', NULL, 'The potential for diminished pharmacologic effects of zolpidem should be considered during coadministration with CYP450 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, 'The potential for diminished pharmacologic effects of zolpidem should be considered during coadministration with CYP450 inducers, particularly potent ones like carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort. Alternative treatments or a dosage adjustment for zolpidem may be required if an interaction is suspected.', 'Metabolism', 'Remimazolam, Chloral hydrate, Thiopental, Paraldehyde, Propiomazine, Dexmedetomidine, Methohexital, Ethchlorvynol, Melatonin, Dichloralphenazone, Valerian', 'Ciclesonide, Mometasone furoate, Mometasone, Flunisolide, Ephedrine, Olopatadine, Ipratropium, Hyaluronic acid, Betamethasone, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39544/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Villikka K, Kivisto KT, Luurila H, Neuvonen PJ "Rifampin reduces plasma concentrations and effects of zolpidem." Clin Pharmacol Ther 62 (1997): 629-34[3] Vlase L, Popa A, Neag M, Muntean D, Baldea I, Leucuta SE "Pharmacokinetic Interaction Between Zolpidem and Carbamazepine in Healthy Volunteers." J Clin Pharmacol (2010):[4] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[5] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[6] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[7] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[8] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[9] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[10] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[11] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[12] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[13] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[14] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[15] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[16] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39489, 'Dexamethasone', 'Zonisamide', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of zonisamide, which is primarily metabolized by the isoenzyme.', NULL, 'Pharmacologic response to zonisamide should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the zonisamide dosage adjusted as necessary.', NULL, 'Pharmacologic response to zonisamide should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the zonisamide dosage adjusted as necessary. Patients should be advised to notify their physician if they experience loss of seizure control.', 'Metabolism', 'Tiagabine, Brivaracetam, Rufinamide, Cannabidiol, Methsuximide, Ezogabine, Paramethadione, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 'Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Ipratropium, Cromoglicic acid, Nedocromil, Beclomethasone dipropionate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39545/', '[1] "Product Information. Zonegran (zonisamide)" Elan Pharmaceuticals, S. San Francisco, CA.[2] Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[13] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[14] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[15] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[16] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39490, 'Conjugated estrogens', 'Acetohexamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Chlorotrianisene, Estrone, Diethylstilbestrol, Bazedoxifene', 'Simvastatin, Guar gum, Rosuvastatin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39546/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39491, 'Aminoglutethimide', 'Conjugated estrogens', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Diethylstilbestrol, Bazedoxifene', 'Darolutamide, Tamoxifen, Fulvestrant, Toremifene, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Abiraterone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39547/', '[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML "Drug interactions between oral contraceptives and antibiotics." Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP "Possible interaction between oxcarbazepine and an oral contraceptive." Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K "St John''s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. "The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women." Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F "Use of oral contraceptives by women with epilepsy." JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H "Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man." Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD "Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974): 1113[11] Cote J "Interaction of griseofulvin and oral contraceptives." J Am Acad Dermatol 22 (1990): 124-5[12] D''Arcy PF "Drug interactions with oral contraceptives." Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA "Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate." Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974): 1113[15] Weaver K, Glasier A "Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review." Contraception 59 (1999): 71-8[16] Michalets EL "Update: clinically significant cytochrome P-450 drug interactions." Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF "Do anticonvulsants reduce the efficacy of oral contraceptives?" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK "Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone." J Clin Pharmacol 38 (1998): 1042-50[19] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6[21] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD "The effect of St. John''s wort on the efficacy of oral contraception." Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH "Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants." Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA "Drug interactions with the pill." Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE "Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer." Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35[29] Dossetor J "Drug interactions with oral contraceptives." Br Med J 4 (1975): 467-8[30] Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J 288 (1984): 1125-6[31] "Unwanted pregnancy on self-medication with St John''s wort despite hormonal contraception." Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD "Oral contraceptives and griseofulvin interaction." Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. "The interaction between St John''s wort and an oral contraceptive." Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W "Failure of oral contraceptives because of St. John''s wort." Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH "Rifampin drug interactions." Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA "Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database." Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al "The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive." Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP "Letter: Drugs affecting oral contraceptives." Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J "Interaction of St John''s wort with low-dose oral contraceptive therapy: a randomized controlled trial." Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M "Interaction between estrogen and dilantin in a menopausal woman." N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH "Rifampin, oral contraceptives, and pregnancy." JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf." ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al "The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy." Contraception 22 (1980): 495-503[44] Zachariassen RD "Loss of oral contraceptive efficacy by concurrent antibiotic administration." Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al "The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids." Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML "Pharmacokinetic drug interactions with oral contraceptives." Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L "Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives." JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39492, 'Amoxapine', 'Conjugated estrogens', 'Minor', 'The effects of tricyclic antidepressants (TCAs) may be altered in women receiving estrogen-containing therapy. Simultaneous TCA toxicity and reduced effects have been reported. Akathisia has also been reported in some women taking this combination. The mechanism of interaction is unknown but may be related to increased TCA bioavailability or inhibition of hepatic TCA metabolism.', NULL, 'The clinical significance of this interaction has not been established.', NULL, 'The clinical significance of this interaction has not been established. Monitoring for altered effects may be advisable during concomitant therapy. Dose adjustments of the TCA may be required if an interaction is suspected.', 'Others', 'Bazedoxifene', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39548/', '[1] Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973): 560[2] Prange AJ, Wilson IC, Alltop LB "Estrogen may well affect response to antidepressant." JAMA 219 (1972): 143-4[3] Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87[4] Krishnan KR, France RD, Ellinwood EH, Jr "Tricyclic-induced akathisia in patients taking conjugated estrogens." Am J Psychiatry 141 (1984): 696-7[5] Abernethy DR, Greenblatt DJ, Shader RI "Imipramine disposition in users of oral contraceptive steroids." Clin Pharmacol Ther 35 (1984): 792-7[6] Khurana RC "Estrogen-imipramine interaction." JAMA 222 (1972): 702-3[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39493, 'Anisindione', 'Conjugated estrogens', 'Moderate', 'Concomitant therapy with estrogen-containing drugs may diminish the therapeutic effects of oral anticoagulants. Estrogens can increase the plasma levels of certain clotting factors such as fibrinogen, prothrombin, and factors VII and VIII in a dose-dependent manner, resulting in increased risk of thromboembolism, stroke, and/or myocardial infarction. The risk may be further increased by lifestyle choices such as smoking and lack of exercise.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks.', NULL, 'Use of estrogen-containing drugs should be avoided in patients receiving anticoagulant therapy unless benefits are anticipated to outweigh the risks. Close clinical and laboratory monitoring are recommended if the combination is prescribed. Patients should be advised to promptly notify their physician if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity.', 'Antagonism', 'Chlorotrianisene, Estrone, Diethylstilbestrol, Bazedoxifene', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39549/', '[1] von Kaulla E, Droegemueller W, von Kaulla KN "Conjugated estrogens and hypercoagulability." Am J Obstet Gynecol 122 (1975): 688-92[2] Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83[3] Stangel JJ, Innerfield I, Reyniak JV, Stone ML "The effect of conjugated estrogens on coagulability in menopausal women." Obstet Gynecol 49 (1977): 314-6[4] Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58[5] Schrogie JJ, Solomon HM, Zieve PD "Effect of oral contraceptives on vitamin K-dependent clotting activity." Clin Pharmacol Ther 8 (1967): 670-5[6] Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970): 300-6[7] Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982): 758-61[8] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[9] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[10] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[11] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[12] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[13] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[14] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[15] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[16] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[17] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[18] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[19] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[20] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[21] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[22] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[25] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[26] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[27] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[28] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[29] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[30] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[31] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[32] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[33] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[34] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[35] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[36] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[37] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[38] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[39] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[40] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[41] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[42] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[43] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[44] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39494, 'Conjugated estrogens', 'Berotralstat', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Metabolism', 'Chlorotrianisene, Diethylstilbestrol, Bazedoxifene', 'Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39550/', '[1] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc, Durham, NC.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39495, 'Conjugated estrogens', 'Betamethasone', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Bazedoxifene', 'Ciclesonide, Mupirocin, Mometasone furoate, Mometasone, Epinephrine, Flunisolide, Ephedrine, Olopatadine, Fluticasone, Vitamin A, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39551/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39496, 'Conjugated estrogens', 'Bexarotene', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Bazedoxifene', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39552/', '[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML "Drug interactions between oral contraceptives and antibiotics." Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP "Possible interaction between oxcarbazepine and an oral contraceptive." Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K "St John''s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. "The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women." Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F "Use of oral contraceptives by women with epilepsy." JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H "Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man." Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD "Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974): 1113[11] Cote J "Interaction of griseofulvin and oral contraceptives." J Am Acad Dermatol 22 (1990): 124-5[12] D''Arcy PF "Drug interactions with oral contraceptives." Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA "Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate." Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974): 1113[15] Weaver K, Glasier A "Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review." Contraception 59 (1999): 71-8[16] Michalets EL "Update: clinically significant cytochrome P-450 drug interactions." Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF "Do anticonvulsants reduce the efficacy of oral contraceptives?" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK "Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone." J Clin Pharmacol 38 (1998): 1042-50[19] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6[21] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD "The effect of St. John''s wort on the efficacy of oral contraception." Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH "Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants." Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA "Drug interactions with the pill." Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE "Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer." Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35[29] Dossetor J "Drug interactions with oral contraceptives." Br Med J 4 (1975): 467-8[30] Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J 288 (1984): 1125-6[31] "Unwanted pregnancy on self-medication with St John''s wort despite hormonal contraception." Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD "Oral contraceptives and griseofulvin interaction." Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. "The interaction between St John''s wort and an oral contraceptive." Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W "Failure of oral contraceptives because of St. John''s wort." Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH "Rifampin drug interactions." Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA "Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database." Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al "The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive." Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP "Letter: Drugs affecting oral contraceptives." Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J "Interaction of St John''s wort with low-dose oral contraceptive therapy: a randomized controlled trial." Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M "Interaction between estrogen and dilantin in a menopausal woman." N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH "Rifampin, oral contraceptives, and pregnancy." JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf." ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al "The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy." Contraception 22 (1980): 495-503[44] Zachariassen RD "Loss of oral contraceptive efficacy by concurrent antibiotic administration." Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al "The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids." Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML "Pharmacokinetic drug interactions with oral contraceptives." Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L "Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives." JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39497, 'Conjugated estrogens', 'Boceprevir', 'Moderate', 'Coadministration with boceprevir may increase the plasma concentrations of drugs that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by boceprevir.', NULL, 'Caution is advised if boceprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if boceprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever boceprevir is added to or withdrawn from therapy.', 'Metabolism', 'Diethylstilbestrol, Bazedoxifene', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Rilpivirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39553/', '[1] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.[2] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39498, 'Conjugated estrogens', 'Bosentan', 'Moderate', 'RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.', NULL, 'Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary. For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers. Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).', 'Metabolism', 'Diethylstilbestrol, Bazedoxifene', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39554/', '[1] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61[2] van Dijke CP, Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J (Clin Res Ed) 288 (1984): 1125-6[3] Dickinson BD, Altman RD, Nielsen NH, Sterling ML "Drug interactions between oral contraceptives and antibiotics." Obstet Gynecol 98(5 Pt 1) (2001): 853-60[4] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP "Possible interaction between oxcarbazepine and an oral contraceptive." Epilepsia 33 (1992): 1149-52[5] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K "St John''s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther 68 (2000): 598-604[6] Back DJ, Breckenridge AM, Crawford FE, et al. "The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women." Contraception 21 (1980): 135-43[7] Mattson RH, Cramer JA, Darney PD, Naftolin F "Use of oral contraceptives by women with epilepsy." JAMA 256 (1986): 238-40[8] Bolt HM, Bolt M, Kappus H "Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man." Acta Endocrinol (Copenh) 85 (1977): 189-97[9] Laengner H, Detering K "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 2 (1974): 600[10] Furlan AJ, Rothner AD "Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974): 1113[11] Cote J "Interaction of griseofulvin and oral contraceptives." J Am Acad Dermatol 22 (1990): 124-5[12] D''Arcy PF "Drug interactions with oral contraceptives." Drug Intell Clin Pharm 20 (1986): 353-62[13] Halpenny O, Bye A, Cranny A, Feely J, Daly PA "Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate." Med Oncol Tumor Pharmacother 7 (1990): 241-7[14] Janz D, Schmidt D "Letter: Anti-epileptic drugs and failure of oral contraceptives." Lancet 1 (1974): 1113[15] Weaver K, Glasier A "Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review." Contraception 59 (1999): 71-8[16] Michalets EL "Update: clinically significant cytochrome P-450 drug interactions." Pharmacotherapy 18 (1998): 84-112[17] Coulam CB, Annegers JF "Do anticonvulsants reduce the efficacy of oral contraceptives?" Epilepsia 20 (1979): 519-26[18] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK "Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone." J Clin Pharmacol 38 (1998): 1042-50[19] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[20] Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6[21] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[22] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD "The effect of St. John''s wort on the efficacy of oral contraception." Clin Pharmacol Ther 71 (2002): P25[23] Wilbur K, Ensom MHH "Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants." Clin Pharmacokinet 38 (2000): 355-65[24] Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8[25] Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992): 47-65[26] Curran MA "Drug interactions with the pill." Med J Aust 144 (1986): 670-1[27] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE "Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer." Cancer Chemother Pharmacol 27 (1990): 101-5[28] Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35[29] Dossetor J "Drug interactions with oral contraceptives." Br Med J 4 (1975): 467-8[30] Weber JC "Interaction between oral contraceptives and griseofulvin." Br Med J 288 (1984): 1125-6[31] "Unwanted pregnancy on self-medication with St John''s wort despite hormonal contraception." Br J Clin Pharmacol 55 (2003): 112-113[32] McDaniel PA, Caldroney RD "Oral contraceptives and griseofulvin interaction." Drug Intell Clin Pharm 20 (1986): 384[33] Hall SD, Wang Z, Huang SM, et al. "The interaction between St John''s wort and an oral contraceptive." Clin Pharmacol Ther 74 (2003): 525-35[34] Schwarz UI, Buschel B, Kirch W "Failure of oral contraceptives because of St. John''s wort." Eur J Clin Pharmacol 57 (2001): A25[35] Baciewicz AM, Self TH "Rifampin drug interactions." Arch Intern Med 144 (1984): 1667-71[36] Szoka PR, Edgren RA "Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database." Fertil Steril 49 (1988): s31-8[37] Barditch-Crovo P, Trapnell CB, Ette E, et al "The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive." Clin Pharmacol Ther 65 (1999): 428-38[38] Mumford JP "Letter: Drugs affecting oral contraceptives." Br Med J 2 (1974): 333-4[39] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J "Interaction of St John''s wort with low-dose oral contraceptive therapy: a randomized controlled trial." Br J Clin Pharmacol 56 (2003): 683-90[40] Notelovitz M, Tjapkes J, Ware M "Interaction between estrogen and dilantin in a menopausal woman." N Engl J Med 304 (1981): 788-9[41] Skolnick JL, Stoler BS, Katz DB, Anderson WH "Rifampin, oral contraceptives, and pregnancy." JAMA 236 (1976): 1382[42] Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf." ([2012, Jan 1]):[43] Back DJ, Bates M, Bowden A, et al "The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy." Contraception 22 (1980): 495-503[44] Zachariassen RD "Loss of oral contraceptive efficacy by concurrent antibiotic administration." Women Health 22 (1994): 17-26[45] Crawford P, Chadwick DJ, Martin C, et al "The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids." Br J Clin Pharmacol 30 (1990): 892-6[46] Back DJ, Orme ML "Pharmacokinetic drug interactions with oral contraceptives." Clin Pharmacokinet 18 (1990): 472-84[47] Nocke-finck L "Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives." JAMA 226 (1973): 378[48] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[49] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[50] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39499, 'Conjugated estrogens', 'Brigatinib', 'Moderate', 'Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.', NULL, 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever brigatinib is added to or withdrawn from therapy.', 'Metabolism', 'Diethylstilbestrol, Bazedoxifene', 'Entrectinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Selumetinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39555/', '[1] "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Alunbrig (brigatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (39500, 'Conjugated estrogens', 'Budesonide', 'Moderate', 'Estrogens may enhance the systemic effects of both endogenous and exogenous corticosteroids. The proposed mechanism is an increase in serum cortisol-binding globulin (transcortin) induced by estrogens, resulting in a decreased rate of corticosteroid metabolic clearance. The interaction has been reported with estrogens or estrogen-containing oral contraceptives (OCs) and hydrocortisone, prednisone, and prednisolone.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents.', NULL, 'Patients treated concomitantly with an estrogen-containing drug may require lower dosages of corticosteroids or adrenocorticotropic agents. Pharmacologic response to these agents should be monitored more closely whenever an estrogen is added to or withdrawn from therapy in patients stabilized on their existing corticosteroid or adrenocorticotropic regimen, and the dosage(s) adjusted as necessary.', 'Synergism', 'Bazedoxifene', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/39556/', '[1] Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64[2] Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9[3] Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11[4] "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] Olivesi A "Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives." Biomed Pharmacother 40 (1986): 301-8[6] "Product Information. Ortho-Novum (oral contraceptive combination pill)." Ortho Pharmaceutical Corporation, Raritan, NJ.[7] Boekenoogen SJ, Szefler SJ, Jusko WJ "Prednisolone disposition and protein binding in oral contraceptive users." J Clin Endocrinol Metab 56 (1983): 702-8[8] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[9] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
